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Feline oral squamous cell carcinomas (FOSCCs) are locally aggressive 
tumours and a common cause of mortality and morbidity. Current treatment 
options are rarely successful and animals are frequently euthanised upon 
diagnosis due to their grave prognosis. Epidermal Growth Factor Receptor 
(EGFR) is a tyrosine kinase receptor which is frequently dysregulated in SCC 
of the head and neck (HNSCC) in man. Recent advances in human medicine 
have identified EGFR as a therapeutic target in HNSCC.  
In this study the role of EGFR in FOSCC was investigated. Sixty seven 
biopsy samples were immunohistochemically labelled for EGFR and Ki67, a 
proliferation marker. The tyrosine kinase region of feline EGFR was cloned 
and sequenced, and six small interfering RNAs (siRNAs) targeting the 
tyrosine kinase region were developed. The most effective siRNA as well as 
an EGFR specific tyrosine kinase inhibitor, gefitinib, was then used on a 
feline SCC cell line (SCCF1), and the effect of EGFR targeting alone, or in 
combination with irradiation, on the cell line was determined.  
The majority of the biopsy samples were labelled positively for EGFR 
and Ki67, and high proliferation corresponded with poor prognosis. The 
siRNA caused reduction in EGFR mRNA by Real-Time Polymerase Chain 
Reaction and protein levels as assessed by western blot analysis. Reduced 
cell proliferation and migration were also observed by proliferation assays 
and scratch assays respectively. Combining EGFR knockdown with 
irradiation caused an additive effect on the ability of the cell line to form 
colonies. These results support the role of EGFR as a potential therapeutic 
target in FOSCCs.   
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1.1 Feline squamous cell carcinoma  
Squamous cell carcinoma (SCC) is an important feline tumour of 
epithelial cell origin, affecting a wide range of sites. Feline SCC has been 
reported to affect (in descending order of occurrence) the oropharynx 
(including the pharynx and tonsils), skin (including head, neck, trunk and 
digits), nasal cavity and paranasal sinuses, and rarely, the trachea and larynx 
(Stebbins et al., 1989, Miller et al., 1991, Mukaratirwa et al., 2001, Jakubiak et 
al., 2005). SCCs are frequently locally aggressive and only rarely metastasise 
to local lymph nodes and even less frequently to distant sites (Stebbins et al., 
1989, Hayes et al., 2007). 
Oral neoplasia accounts for up to 10% of all tumours diagnosed in the 
cat (Stebbins et al., 1989, Mauldin, 2001), and SCC is the most common 
tumour type at this site (Stebbins et al., 1989, Postorino-Reeves et al., 1993, 
Jones et al., 2003) accounting for 61.2% (Stebbins et al., 1989) to 75% 
(Kapatkin et al., 1991) of oral malignancies diagnosed. 
Tonsillar tumours are quite rare, but when diagnosed, the majority are 
SCC (Morris and Dobson, 2001). Similarly, neoplastic laryngeal and tracheal 
masses are seen infrequently in cats (Saik et al., 1986, Jakubiak et al., 2005). 
Nevertheless, seven out of 19 cases with laryngeal masses reported in one 
study were confirmed as SCC (Jakubiak et al., 2005).  
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Cutaneous SCC is reported to be one of the most commonly diagnosed 
malignant skin tumours in the cat accounting for 7-50% of tumours (Dorn et 
al., 1971, Bostock, 1972, Priester, 1973, Macy and Reynolds, 1981, Miller et al., 
1991, Sabattini et al., 2010), depending on geographical location (Sabattini et 
al., 2010).  
1.1.1 Oropharyngeal, laryngeal and tracheal squamous cell 
carcinomas  
1.1.1.1 Signalment and risk factors 
Commonly, oral SCC affects older cats (Stebbins et al., 1989, Postorino-
Reeves et al., 1993, Northrup et al., 2006, Hayes et al., 2007), although cats as 
young as three years of age have been reported in the literature (Stebbins et 
al., 1989). The mean ages of cases reported range from 11 to 15.4 years (Table 
1.1). Apart from an increasing incidence with age, (Dorn et al., 1971, Bertone 
et al., 2003), no apparent sex or breed predilections were reported (Dorn et 
al., 1971, Postorino-Reeves et al., 1993, Morris and Dobson, 2001).  
A variety of risk factors have been identified for the development of the 
disease in man including smoking, exposure to environmental tobacco 
smoke (ETS, i.e. passive smoking) and air pollution (Zhang et al., 2000b, 
Dobrossy, 2005). Other risk factors include human papillomavirus (HPV) 
infection, dietary deficiencies or imbalances and poor dental hygiene, (Zhang 
et al., 2000b, Dobrossy, 2005, Hashibe et al., 2007). A similar study in cats 
identified a trend for feline oral SCC to also be associated with ETS (Snyder 
et al., 2004). The study investigated the relationship between exposure to ETS 
and overexpression of the tumour suppression protein p53 in cats with SCC, 
and reported an association between p53 overexpression in the oral mucosa 
of cats and the development of oral SCCs (Snyder et al., 2004). This 
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association did not, however, reach statistical significance (Snyder et al., 
2004). p53 has been found to be overexpressed in human tumours linked to 
carcinogens found in tobacco products (Snyder et al., 2004). These types of 
causal relationships frequently necessitate large sample sizes in order to 
reach statistical significance (Petrie and Watson, 2006a). Until larger scale 
studies can be undertaken, these relationships may well remain unproven.   
 
Cat oral cavities are potentially exposed to high levels of environmental 
toxins due to their meticulous grooming behaviour (Ogilvie and Moore, 
1996a, Bertone et al., 2003, Snyder et al., 2004).  Bertone et al. (2003) 
investigated the relationship between oral SCC and environmental and 
lifestyle risk factors. They found that the use of flea collars and the feeding of 
wet food were statistically significantly associated with an increased risk of 
developing oral SCC. 
Recently, the presence of papilloma virus DNA was identified in a 
small number of oral SCC biopsy samples (three out of 64 samples in total) 
using polymerase chain reaction (PCR) to detect viral DNA (Munday et al., 











Bregazzi et al. 2001 7  15  
Fox et al. 2000 18 13.2  3.7-20 
Postorino-Reeves et 
al. 1993 
52 11.6 12 2.5-18 
Hutson et al. 1992 7 11 10 8-16 
Northrup et al. 2006 42  13.8 5-17.5 
Hayes et al. 2007 54  13.3 7-20 
Stebbins et al. 1989 227 12.5  3-21 
Jones et al. 2003 8 15.4  13-19 
Table 1.1: Summary of reported ages of cats affected by oral SCC.  ♦ Age in years 
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2009, O'Neill et al., 2010). The low occurrence of papillomavirus DNA in 
these oral tumours suggests this to be only a minor risk factor in cats.  
1.1.1.2 Affected areas 
Oral SCC most commonly affects the sublingual region and tongue, 
commonly near the frenulum (Dorn and Priester, 1976, Dubielzieg, 1982, 
Stebbins et al., 1989). Oral SCC also affects the gingiva and these tumours 
frequently invade the underlying bone (Dubielzieg, 1982). Despite being 
locally very aggressive tumours, they are slow to metastasise (Dubielzieg, 
1982, Stebbins et al., 1989). Tonsillar SCC metastasises to regional lymph 
nodes and distant organs more readily than oral SCC (Stebbins et al., 1989). 
Occasionally, SCC may arise in the epithelium of the mucosal surfaces of the 
cheek or lip. These neoplastic lesions are often more ulcerative than 
proliferative in nature (Morris and Dobson, 2001). 
The majority of feline laryngeal tumours are either SCC or lymphomas 
(Saik et al., 1986, Jakubiak et al., 2005). They carry a very poor prognosis, 
with a median survival of five days following diagnosis, partly because they 
frequently present with signs of airway obstruction (Jakubiak et al., 2005). 
1.1.1.3 Clinical and presenting signs 
The most commonly reported clinical signs of feline oral SCC were 
facial asymmetry or facial mass, ptyalism (sometimes with haemorrhage), 
anorexia, inappetence, dysphagia and weight loss, behavioural changes (for 
example cessation of grooming), pawing at mouth, and other signs of oral 
pain (Fox et al., 2000, Bertone et al., 2003, Snyder et al., 2004, Northrup et al., 
2006). Gagging was sometimes the presenting sign with tonsillar, laryngeal 
and tracheal SCC, as well as respiratory signs including dyspnoea, voice 
changes, coughing, wheezing and tachypnoea (Saik et al., 1986, Jakubiak et 
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al., 2005). Occasionally, teeth were noted to be loose or to fall out (Postorino-
Reeves et al., 1993). If the tumours invaded the nasal cavity, a nasal 
discharge was sometimes apparent (Mauldin, 2001). Fifteen percent of the 
cases in one study were detected incidentally by a veterinary surgeon during 
routine clinical examinations or dental treatments (Hayes et al., 2007), so a 
proportion of cats did not exhibit clinical signs appreciable to the owners.  
1.1.1.4 Treatment options, prognosis and survival times 
Historically, the only treatment option available for oral SCC was 
surgery. Hence, only tumours amenable to surgical excision were treatable. 
Early studies reported oral SCCs to carry a poor prognosis with a mean 
survival of seven weeks following diagnosis, and found no correlation 
between the degree of differentiation of the tumours and survival (Bostock, 
1972). Although this study consisted of a very small study population, 
subsequent reports have supported these conclusions. Overall, oral SCCs still 
only have around 10% one year survival rates with median survival between 
one and five months (Evans et al., 1991, Postorino-Reeves et al., 1993, Hayes 
et al., 2007).  
Surgery remains the main stem of treatment, but is now often 
combined with other therapies. Successful surgery is likely to involve radical 
resection by mandibulectomy or maxillectomy (Birchard, 1996). One study 
with 21 cases treated by radical surgical excision reported a one year survival 
rate of 43% (Northrup et al., 2006). The surgeries caused considerable post-
operative morbidity with half of the cats that had more than 50% of their 
mandible resected never regaining the ability to eat (Northrup et al., 2006). 
The authors reported overall high owner satisfaction, but many owners 
would find this level of morbidity unacceptable. Another small study of five 
cats achieved a median survival of six months following mandibular 
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resections (Bradley et al., 1984). Even better results were achieved when 
surgery was combined with radiotherapy giving a one year survival rate of 
57% and a median survival of 14 months (Hutson et al., 1992). In this small 
study of only seven cases all cases with sublingual involvement had been 
excluded, as this tumour site has been associated with a poorer prognosis 
(Evans et al., 1991). The small number of cases and restrictive inclusion 
criteria of these studies means that the survival rates reported are not 
directly comparable to the earlier reports in the literature that estimated 
overall survival regardless of tumour site and treatment. Exclusions of 
certain tumours from survival analysis may skew data and may produce 
artificially high survival rates.   
Table 1.2: Summary of remission and survival rates achieved for combination therapies 
reported in oral SCCs, N/A: not applicable.  
 
Radiation therapy has been used alone and in combination with other 
therapies, but has not increased survival times considerably. The main 
benefits of radiation therapy include the ability to treat a large area without 





Remission rates Survival rates 
Bregazzi et 
al. 2001 
2 Radiation and 
mitoxantrone 
N/A, palliative study 60 days (42-97) 
Evans et 
al. 1991 
11 Radiation and 
intratumoural 
etanidazole 
Partial remission 100% 
Days to progression 
ranged from 55-331 days 
Median survival 
116 days (19-389) 
Jones et al. 
2003 
8 Radiation and 
gemcitabine 
CR 2  PR 4 
Median remission 42.5 






8 Radiation and 
gemcitabine 






11 Radiation and 
cisplatin 




the radiation field (Postorino-Reeves et al., 1993). Side effects of radiation 
therapy may occur even at palliative doses (Bregazzi et al., 2001), and  
include osteonecrosis, permanent alopecia, stomatitis, halitosis, mucositis, 
anorexia and depression (Evans et al., 1991, Hutson et al., 1992, Ogilvie et al., 
1993, Postorino-Reeves et al., 1993, LeBlanc et al., 2004).  
In one study, radiotherapy alone produced median survival of three 
months (Postorino-Reeves et al., 1993) and when used in combination with 
mitoxantrone chemotherapy it produced complete remission in eight out of 
eleven cats with a median remission time of five and a half months (Ogilvie 
et al., 1993). Other combination therapies reported have been summarised in 
Table 1.2.  
In human chemotherapy, cisplatin analogues are sometimes used as 
single agents in the treatment of head and neck cancers (Fox et al., 2000). In 
cats, one study used mitoxantrone as a single agent, but reported 
disappointing results with only one of 32 cats achieving complete remission 
before relapsing after two months (Ogilvie et al., 1993). Similar results were 
achieved using a cisplatin analogue as the single agent (Fox et al., 2000).  
A more recent study evaluated the survival times of cats with oral SCC 
managed in non-specialist settings and given palliative care only. The one 
year survival rate was 9.5% and median survival time from presentation was 
44 days (Hayes et al., 2007). The author concluded that if aggressive 
therapies for feline oral SCC are to be considered they must exceed the 
survival rates achieved with palliative therapy alone (Hayes et al., 2007). So 
far, no single treatment modality has convincingly improved survival times 
far beyond those reported with palliative therapy alone.  
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1.1.2 Cutaneous squamous cell carcinomas 
The classification of cutaneous SCC in man is subject to a continual 
debate and is under constant review. There are inconsistencies in the 
literature in the naming of the different classes of tumours, causing some 
confusion when comparing results from different studies (Anwar et al., 
2004). It follows that similar confusion exists in the veterinary literature, and 
different authors classify actinic keratosis, SCC in situ and feline Bowenoid in 
situ carcinomas (BISC) differently. For the purpose of this review, the 
cutaneous form of feline squamous cell carcinomas will be divided into three 
groups depending on the depth of invasion and their aetiology. SCC in situ 
will be divided into two separate groups, solar or actinic keratosis (AK) and 
feline BISC (Baer and Helton, 1993, Fox, 1995, Nespeca et al., 2006, Munday 
et al., 2007). Both of these types are generally confined to the epidermis (Baer 
and Helton, 1993, Munday et al., 2007) and are often considered to be pre-
malignant lesions (O'Neill et al., 2010). Comparative studies of these two 
early lesions showed that BISC could reliably be diagnosed histologically, 
while the histologic diagnosis of lesions clinically suggestive of AK is more 
difficult (Favrot et al., 2009). 
The last group is made up of the invasive SCC, which is characterised 
by invasion of the basement membrane, and is often considered an extension 
or progression from SCC in situ of the AK type, although invasive SCC can 
also develop from normal skin (Anwar et al., 2004). It is generally accepted 
that BISC differs from the others in its aetiology and prevalence (Favrot et al., 
2009) and this entity will therefore be discussed separately.   
1.1.2.1 Signalment and risk factors 
As with most tumours, cutaneous SCCs have an increasing incidence 
with age (Priester, 1973, Miller et al., 1991). The reported ages of the affected 
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animals from the eight largest studies are summarised in Table 1.3. The 
mean age of affected animals ranged from 8.5 to 14 years and the median 
ages reported were 12 to 13 years. Cats as young as nine months were 
reported in some studies (Evans et al., 1985, Miller et al., 1991, Favrot et al., 
2009). The youngest cats in some of these studies had AK, which is known to 
have a significantly earlier onset than BISC (Favrot et al., 2009). No increase 
in risk has been reported in relation to gender or neutering status (Dorn et 
al., 1971). 
Table 1.3: Summary of reported ages of cats affected by cutaneous SCC.  ♦ Age in years, 
AK: actinic keratosis, BISC: Bowenoid in situ carcinoma 
 
A clear predisposition for cutaneous SCC is reported in white cats, 
which are 13.4 times more likely to develop this neoplasm compared to non-
white cats (Dorn et al., 1971). An overview of the proportion of cats 
diagnosed with cutaneous SCC with lack of pigment in affected areas is 
given in Table 1.4.   
The combination of lack of pigment in sparsely haired areas 
predisposes these cats to repeated sunburn, which in turn predisposes them 
to develop actinic or solar keratosis (Dorn et al., 1971, Favrot et al., 2009). AK 
Study 
 









Theon et al. 1995 90  11.1 3-20 
Carlisle and Gould 
1982 
88  8.5 1-17 
O’Neill et al. 2010 84 13  0.75-25 
Lana et al. 1997 61 12  5-17 
Miller et al. 1991 52 12 11.6 1-19 
Favrot et al. 2009 AK 22 
BISC 23 
 AK 9.5 
BISC 13.1 
2-17 
Theon et al. 1996 23  14 8-17 
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is thought to be a potential precursor to invasive SCC (Anwar et al., 2004). 
Siamese cats are less likely to develop AK, presumably because of their 
pigmented extremities (ears, eyelids, lips and nose) where these tumours 
commonly occur (Dorn et al., 1971, Priester, 1973). Access to the outdoors 
increases risk of sunlight exposure and hence tumour risk (Dorn et al., 1971, 
Macy and Reynolds, 1981, Lana et al., 1997), and in one study (Lana et al., 
1997), 95% of all cats with cutaneous SCCs had outdoor access. It has been 
proposed that the reduced incidence of SCC reported in Siamese cats could 
be partly due to the fact that pedigree cats are often more likely to be kept 
indoors (Goodfellow et al., 2006).  
Table 1.4: Proportion of cats diagnosed with cutaneous SCC reported to have a white coat 
colour or unpigmented affected areas. 
 
In man, immunocompromised patients are reported to be more prone 
to developing metastasis from invasive SCC compared to healthy 
individuals (Anwar et al., 2004) but no similar trend has been reported to 
date in the cat. No relationship has been found between Feline Leukaemia 
Virus (FeLV) and Feline Immunodeficiency Virus (FIV) infections and the 
development of cutaneous SCC (Lana et al., 1997). One study did identify an 
increased incidence of chronic lip ulceration following radiotherapy in FIV 
Study Total  Cats white/part 
white 
% Notes 
Carlisle and Gould 
1982 
97 97 100 All cats had white areas to 
their nose (only nasal SCC 
reported) 
Theon et al.1995 90 66 73.3 Proportion reported in article  
Lana et al. 1997 61 58 95.1 Proportion reported in article 
Nespeca et al. 
2006 
22 22 100 Number of samples taken 
from sun exposed or white 
areas 
Favrot et al. 2009 22 22 100 Proportion reported in article  
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positive cats with SCC of the nasal planum (Theon et al., 1995). However, 
these authors reported that treatment response rates were not influenced by 
FIV status and concluded that FIV status alone should not be used as a 
criterion to deny radiotherapy (Theon et al., 1995).  
1.1.2.2 Affected areas 
The largest study published reviewed 340 cases diagnosed with 
cutaneous neoplasia by biopsy or necropsy over a three-year period. This 
study found that 82% of SCC affected the head, 11% affected the limbs, 2 % 
affected the neck and another 2% affected the trunk while 3% affected other 
areas (Miller et al., 1991). Another study reported that 96% of 149 cases of 
histologically confirmed cutaneous SCC originated on the head or neck 
(Dorn et al., 1971).  
The commonly affected areas on the head in order of prevalence are the 
pinnae, nasal planum, eyelids, chin and lips. These are the areas of sparser 
hair growth so they are more at risk of sunburn (Nespeca et al., 2006).  
1.1.2.3 Clinical and presenting signs 
Cutaneous SCC lesions tend to be slowly progressing, and this was 
reflected in the time interval reported between when the lesions were first 
noted by the owners and when the animals were first presented for 
treatment, ranging from a few days to two years, with an overall median 
time of three to six months (Lana et al., 1997, Goodfellow et al., 2006). On 
first presentation the owners often ascribed the lesions to a traumatic injury 
such as a cat scratch that never healed (Goodfellow et al., 2006). Early lesions 
seen with AK often appear as non-healing wounds, plaque-like to papillated 
in nature, often with scaling or crust formation (Favrot et al., 2009). These 
lesions progress over time and often become erosive and ulcerative (Lana et 
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al., 1997), appearing as shallow ulcers surrounded by elevated, indurated 
borders (Fox, 1995). Left untreated, the neoplastic lesion may remain the 
same size or spread and become larger in size and depth, sometimes 
invading underlying cartilage (Carlisle and Gould, 1982). The lesions may 
also become secondarily infected, which may lead to a sudden deterioration 
in appearance, prompting the owner to bring the animal to the veterinarian.  
1.1.2.4 Treatment options, prognosis and survival  
Several treatments are available for the treatment of cutaneous SCCs, 
and the preferred options depend on the area affected. Tumour staging 
influences the treatment options available, as does cost, owner preference, 
general health of the patient (which may, for example, limit the 
administration of multiple anaesthetics) and what treatments are available at 
the treatment centre (Lana et al., 1997, Thomson, 2007).  
An overview of treatment options is summarised in Figure 1.1. In order 
to assess more accurately how different treatment options compare to each 
other a common assessment of tumour behaviour and invasiveness was 
required, and the Tumour Node Metastasis (TNM) staging protocol is most 
commonly used (Owen, 1980). Clinical stages of feline tumours of epidermal 
origin according to the World Health Organisation (WHO) classification are 
summarised in Table 1.5.  
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Figure 1.1: Diagram showing an overview of the treatment options available for cutaneous 
SCC. Adapted from Ogilvie & Moore (1996b). 
 
Historically, surgery was the only treatment option available. Bostock 
reported in 1972 that cats with well differentiated cutaneous SCC had a good 
prognosis and in some cases were cured by surgical intervention, while cats 
with poorly differentiated tumours only survived on average for twelve 
weeks (Bostock, 1972).  
For some tumours, surgery offers a relatively simple procedure with 
potentially low complication rates (Withrow and Straw, 1990). It is a widely 
available treatment which is cost effective and involves overall less total 
treatment time (Lana et al., 1997). Depending on area affected, surgery 
produces cosmetically acceptable results (Lana et al., 1997).  Surgical excision 
of lesions allows for the histopathological examination of the surgical margin 
contributing to the prediction of the long term prognosis of the animal 






Table 1.5: Clinical staging (TNM) of feline tumours of epidermal or dermal origin (Owen 
1980). 
 
Prognosis improves if a complete excision of tumour with a wide 
surgical margin is achieved, but depending on the tumour site this is not 
always possible (Fox, 1995). Excisions of the pinnae can give mean (Fox, 
1995) or median (Lana et al., 1997) disease free intervals of two years. This is 
probably the most straightforward surgery to perform and it allows for 
potentially larger areas of tissue to be removed without interfering overtly 
with function (Lana et al., 1997). Regardless of treatment used, animals with 
Site Stage Definition 
Primary tumour Tis Pre-invasive carcinoma (carcinoma in situ) 
T0 No evidence of tumour 
T1 Tumour < 2 cm maximum diameter, superficial or 
exophytic 
T2 Tumour 2-5 cm maximum diameter, or with 
minimal invasion irrespective of size 
T3 Tumour >5 cm maximum diameter, or with 
invasion of subcutis, irrespective of size 
T4 Tumour invading other structures such as fascia 
muscle, bone or cartilage 
Regional lymph nodes N0 No evidence of RLN involvement 
N1 Moveable ipsilateral nodes 
  N1a Nodes not considered to contain growth 
  N1b Nodes considered to contain growth 
N2 Moveable contralateral or bilateral nodes 
  N2a Nodes not considered to contain growth 
  N2b Nodes considered to contain growth 
N3 Fixed nodes 
Distant metastasis M0 No evidence of distant metastasis 
M1 Distant metastasis detected 
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lesions confined to the pinnae had the greatest disease free intervals and the 
longest survival times (Lana et al., 1997).  
Nasal planum resections caused more morbidity compared to pinnae 
resections (Withrow and Straw, 1990, Thomson, 2007), but the median 
disease free intervals and median survival times compared favourably to 
other treatment modalities (Lana et al., 1997). Surgery remains the most 
effective treatment for invasive SCC of stage T3 and T4 (Stell et al., 2001). In 
one study eight cats with highly invasive SCCs of the nasal planum were 
treated with surgery alone and three died within five months due to 
recurrence of tumours (Withrow and Straw, 1990). One died of unrelated 
causes with no recurrence after eight months; the remaining four cats were 
disease free with a mean follow up of 17.2 months (Withrow and Straw, 
1990).  
The lack of staging of the tumours in some of the studies (Withrow and 
Straw, 1990, Lana et al., 1997) makes a true comparison with other treatment 
modalities difficult.  For example, in the study performed by Lana et al. 
(1997), surgery and cryosurgery had median survival rates twice that of the 
radiotherapy treated group, but details of the clinical stage of the tumours 
were not given. Cryosurgery is widely reported not to be effective in lesions 
larger than one centimetre (Ogilvie and Moore, 1996b), or four millimetres 
(Thomson, 2007) due to high recurrence rate. Some authors recommend that 
cryosurgery is never performed as it produces poor results (Fox, 1995) and 
may delay more effective treatments (Ogilvie and Moore, 1996b). The long 
median survival reported in the Lana study could be due to only low grade 
lesions (TIS and T1) being treated, compared to the lesions treated with 
irradiation and surgery. Without the clinical stages of the tumours in the 
different groups no meaningful comparison could be made.  
16 
 
Despite conflicting reports in the literature, cryosurgery is still being 
used to treat SCC. Cryosurgery was described as the destruction of tissues 
by the controlled use of freezing and thawing using liquid nitrogen or 
nitrous oxide (Thomson, 2007). The advantages of the technique reported 
were cost effectiveness and availability (Thomson, 2007), while the 
disadvantages were lack of surgical margins, protracted period required for 
the eschar detachment, and high and relatively rapid recurrence rate 
(Withrow and Straw, 1990, Lana et al., 1997, Thomson, 2007). 
Table 1.6: Summary of reported survival times and disease free intervals for different 
radiation treatment protocols. CR: complete response, MS: median survival, MPFS: median 
progression free survival, MPFI: mean progression free interval, MDFI: median disease free 
interval.  
 
Radiotherapy offers an alternative to surgery that produces excellent 
cosmetic outcomes (Thomson, 2007). The reported disadvantages of 
radiotherapy were availability (as it can only be offered in specialist 
settings), cost and the requirement for repeat general anaesthetics (Lana et 











Cox et al.1991 
  Mix  
Not given All had initial 
regression 
MS 12 months Not given 
Fidel et al. 
2001 
  Proton 
irradiation 
T1a to T2b CR 60% 
T1a 100%  
T2b 33% 
MS 31 months 
MPFS 14.4 
months 




Tis to T2 CR 87% MS 25.6 months MDFI 21.4 
months 
Lana et al. 
1997 
  Mix 
Not given Not given MS 12.5 months MDFI 12 months 
Theon et al. 
1995 
  Orthovoltage 





efficacy of radiation therapy investigated two treatment regimens; 
irradiation at monthly intervals, and a schedule that consisted of three 
irradiations in one week (Carlisle and Gould, 1982). They reported superior 
results with weekly treatment schedules and poor response rates in larger 
and more invasive T3 lesions (Carlisle and Gould, 1982). Later studies 
confirmed these findings, and also reported tumour stage to be a statistically 
significant prognostic indicator (Theon et al., 1995). A summary of reported 
survival times and response rates is presented in Table 1.6.  
Recent advances in the field of photodynamic therapy (PDT) have 
produced some favourable results (Fox, 1995). PDT works by utilising two 
components, a photosensitizer and a light source of a specific wavelength to 
maximally activate the tumour localising photosensitizer (Frimberger et al., 
1998, Stell et al., 2001, Buchholz et al., 2005). The photosensitizer is usually 
injected intravenously and has tumour seeking properties (Peaston et al., 
1993), although topical photosensitizers are also available (Stell et al., 2001). 
Light at wavelengths of 600-900 nm of the red and infrared spectrum 
penetrates tissues best, so photosensitizers should ideally be activated in this 
range (Frimberger et al., 1998). Tumour destruction is achieved through 
three principal mechanisms: direct tumour kill via the release of free oxygen 
radicals and other cytotoxic substances, destruction of tumour-associated 
vasculature, and activation of the host’s immune system against tumour cells 
(Peaston et al., 1993, Stell et al., 2001, Buchholz et al., 2005).  
PDT is reserved for lower grade tumours, where it achieves acceptable 
response rates ranging from a 57% to 100% (Peaston et al., 1993, Magne et al., 
1997, Frimberger et al., 1998, Stell et al., 2001, Buchholz et al., 2005). Response 
rates for T3 and T4 tumours are much lower (Peaston et al., 1993, Magne et 
al., 1997) . In one study, increasing the fluence from 100 Jcm-2 to 200 Jcm-2 
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resulted in an improved overall response rate of 70% (Hahn et al., 1998). 
There was a statistically significant increase in median remission duration 
for the tumours treated at the higher fluence, achieving median remission 
times that compared favourably with other available treatments options for 
late stage tumours (Hahn et al., 1998).  
Adverse effects of PDT treatments are mild and well tolerated, and 
include vomiting during injection of the photosensitizer, sneezing, reversible 
facial swelling, local infection, permanent alopecia, and variable length (from 
a few days to up to two weeks) of photosensitization (Roberts et al., 1991, 
Peaston et al., 1993, Magne et al., 1997, Frimberger et al., 1998, Hahn et al., 
1998, Stell et al., 2001, Buchholz et al., 2005). 
In summary, a range of therapies are available for the management of 
feline cutaneous SCC.  Good results are achieved with complete surgical 
excision, but this is not always possible. A range of other therapies have also 
been evaluated, but local recurrence remains a common reason for treatment 
failure.   
1.1.2.5 Prevention 
Education of clients and veterinarians to identify and treat early lesions 
could improve response rates as early lesions have a better prognosis 
following treatment (Thomson, 2007). Other suggested preventative 
measures include tattooing (Withrow and Straw, 1990, Fox, 1995), henna 
tattooing (Thomson, 2007), applying sunscreen (Macy and Reynolds, 1981, 
Carlisle and Gould, 1982, Fox, 1995), and keeping cats indoors during 
maximum sunlight hours (Macy and Reynolds, 1981, Withrow and Straw, 
1990) to limit sunlight exposure to the extremities. The main obstacle to 
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successful enforcement of these latter two measures may well be cat 
compliance (Fox, 1995). 
1.1.2.6 Feline Bowenoid in situ carcinoma (BISC) 
Feline BISC is morphologically similar to Bowen’s disease in man; 
however, it is not identical and should therefore be referred to as Bowenoid 
or Bowen’s-like disease (Favrot et al., 2009). It is a rare skin disease, 
predominantly affecting older cats. The lesions are usually multicentric and 
may occur at any site and are not associated with sun exposure (Baer and 
Helton, 1993, Favrot et al., 2009).  The lesions usually occur as hyper-
pigmented plaques (Wilhelm et al., 2006, Munday et al., 2007) that are often 
alopecic, slightly elevated and covered by crusts (Baer and Helton, 1993).  
The lesions are distinguished from actinic keratosis on the basis of a 
history of no or little sun exposure and on the basis of distribution of lesions, 
as histologically the two lesions are very similar (Favrot et al., 2009). The 
aetiology of BISC is predominantly unknown, but papillomaviruses have 
been identified in a proportion of these tumours (Wilhelm et al., 2006, 
Munday et al., 2007, Favrot et al., 2009). 
Treatment consists of surgical removal of the lesions, which do not tend 
to recur locally, although de novo lesions may develop. A proportion of these 
lesions may progress to invasive SCC if left untreated (Baer and Helton, 
1993). 
 
1.1.3 Squamous cell carcinomas of the nose and paranasal 
sinuses 
Tumours of the nose and paranasal sinuses accounts for up to 4% of all 
neoplasms in the cat (Cox et al., 1991). These figures do not include tumours 
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of the nasal planum (Mukaratirwa et al., 2001). SCCs are the third most 
common nasal tumour in the cat, accounting for about ten percent of all 
nasal and paranasal tumours (Mukaratirwa et al., 2001, Tromblee et al., 
2006). In one study, however, none of the sixteen tumours diagnosed in the 
nasal passages and sinuses were SCC (Cox et al., 1991). 
These tumours are of unknown aetiology with no breed predisposition, 
but a male predisposition has been reported as well as an increased 
incidence with age (Cox et al., 1991, Mukaratirwa et al., 2001).   Most 
commonly reported clinical signs include nasal and ocular discharge, 
epistaxis, upper respiratory signs such as stridor and stertor, seizures, 
sneezing, facial swelling, exophthalmos, and enophthalmos (Cox et al., 1991, 
Mukaratirwa et al., 2001, Malinowski, 2006).   
Treatment modalities include surgery, irradiation, chemotherapy or 
combination therapies (Cox et al., 1991, Malinowski, 2006). Supportive care is 
important as affected cats have reduced ability to smell their food often 
leading to anorexia (Malinowski, 2006). The best treatment responses were 
achieved with a combination of surgery and orthovoltage therapy, but no 
large scale studies comparing different treatments have been performed 
(Malinowski, 2006). 
1.2 Squamous cell carcinomas of the head and neck in man 
Squamous cell carcinoma of the head and neck (HNSCC) accounts for 
more than 90% of upper aerodigestive tract malignancies in man (Dobrossy, 
2005, Rogers et al., 2005, Reuter et al., 2007). The disease is locally aggressive 
with rapid spread to regional lymph nodes, and with high incidences of 
recurrence and de novo primary tumour formation (Reuter et al., 2007). The 
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most commonly affected sites are the larynx, followed by the oropharynx, 
hypopharynx and the oral cavity (Bentzen et al., 2005).  
1.2.1 Risk factors  
The aetiology of HNSCC is not fully understood, but epidemiological 
studies have identified several factors that independently or in combination 
are associated with an increased risk of disease (Dobrossy, 2005, Hashibe et 
al., 2007). The two major predisposing factors were tobacco use and alcohol 
consumption. Individually they account for a two- or three-fold increase in 
disease, but in combination they increase risk 15-fold (Dobrossy, 2005). 
When investigated as independent entities, smoking was shown to be the 
main contributor to risk (Hashibe et al., 2007). In addition, ETS exposure 
caused a dose dependant increase in risk (Zhang et al., 2000b). Up to three 
quarters of all HNSCCs diagnosed were attributable to a combination of 
smoking and alcohol drinking (Hashibe et al., 2007), rendering them per se 
preventable (Dobrossy, 2005).  
Other reported risk factors for the development of HNSSC were human 
papillomavirus infection, oral leukoplakia, dietary deficiencies, poor dental 
hygiene and, atmospheric pollution (Dobrossy, 2005). 
1.2.2 Current treatments and outcome 
The management of HNSCC has improved over the past decades 
(Kramer et al., 2005, Rogers et al., 2005), resulting in better response rates to 
new treatment protocols (Reuter et al., 2007). There is little evidence, 
however, that this has significantly enhanced outcome (Ford and Grandis, 
2003). A summary of the reported outcomes to different treatments of 






1.3 Epidermal Growth Factor Receptor (EGFR) 
1.3.1 Epidermal growth factor receptor family 
The epidermal growth factor (EGF) receptor family makes up the first 
of six subfamilies of the receptor tyrosine kinases (RTK) superfamily of 
proteins (Graus-Porta et al., 1997, Holbro and Hynes, 2004). It compromises 
four members: the EGF receptor (EGFR) also known as ErbB1/HER1 (Ullrich 
et al., 1984), ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4, collectively termed 
the ErbB receptors due to their homology with the avian erythroblastosis 
viral gene product (v-erbB) (Holbro and Hynes, 2004). These receptors share 
a similar structure consisting of a single-pass transmembrane protein of 
approximately 1200 amino acids (Figure 1.2) (Alberts et al., 1994, Jimeno and 
Hidalgo, 2005), with the EGFR protein being approximately 170kDa in size 
(Milano et al., 2008). The receptor extracellular domain consists of four 
subdomains: ligand binding domains L1 and L2, and two cysteine-rich 
domains C1 and C2. A single alpha-helix hydrophobic domain spans the cell 
membrane and intracellularly a region with tyrosine kinase function is 
Stage of disease & treatment Expected outcome 
Early stage disease  
Surgery and/or radiotherapy 
/chemotherapy 
Approximately 80% cure rate 
Resectable, advanced disease 
Surgery and radiotherapy/chemotherapy 
50-60% develop local/regional recurrence 
20% develop metastatic disease or 
secondary primaries 
Unresectable, advanced disease   5 year survival of < 10% 
Recurrent/metastatic disease Median survival 4 months 
1 year survival < 30% 
Table 1.7: Summary of reported expected outcome for patients with HNSCC. Modified 
from Kirby et al. (2006) and Reuter et al. (2007) 
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flanked by a carboxy-terminus with tyrosine phosphorylation sites (Yarden 
and Sliwkowski, 2001, Holbro and Hynes, 2004). A schematic diagram of the 
receptors with their phosphotyrosine residues and associated docking 
molecules is shown in Figure 1.3.  The juxtamembrane region of EGFR 
exhibits a distinct set of sorting sequences that are involved in regulatory 
events such as internalisation and recycling of the receptor–ligand complex 
(Yarden and Sliwkowski, 2001, Jorissen et al., 2003, Wiley, 2003).   
 
Figure 1.2: Schematic diagram of the structure of EGFR. All the members of the ErbB family 
have a similar structure of two ligand-binding domains and two cysteine-rich regions in the 
extracellular part of the receptor complex. ErbB2 has substitutions in the L1 and L2 domains, 
rendering it unable to bind ligand and ErbB3 has a substitution of a critical residue in the 






Figure 1.3: Schematic diagram showing ErbB receptor phosphorylation sites and their 
respective docking molecules. Cytosolic Src (c-Src) is able to phosphorylate EGFR in 
absence of ligand, while Cbl, an ubiquitin ligase is involved in receptor downregulation. Grb2 
is an important molecule in the activation of the MAPK pathway, but often binds the 
receptors via the scaffolding molecule Shc. SHP phosphatases are important in RTK 
regulation, while p85 is the RTK interacting PI3K subunit.  Modified from Prigent (2006) and 
Chaturvedi (2009), see text for more detail.  
 
ErbB2 differs structurally in its extracellular domain from the other 
receptors, and so far, no exogenous ligand has been identified interacting 
with this receptor (Graus-Porta et al., 1997, Hynes and Lane, 2005). Graus-
Porta (1997) demonstrated in a series of experiments that ligand-induced 
ErbB receptor heterodimerization follows a strict hierarchy, with ErbB2 
being the preferred partner for all the other ErbB receptors. However, if 
ErbB2 is downregulated the other receptors are able to dimerize with each 
other (Graus-Porta et al., 1997). This has led to the hypothesis that the 
primary function of ErbB2 is as a co-receptor (Olayioye et al., 2000).   
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ErbB3 differs structurally from the other family members in the 
catalytic domain, rendering it devoid of intrinsic kinase activity (Holbro and 
Hynes, 2004). It is therefore dependent upon its heterodimerization partner 
to be transphosphorylated for downstream signalling to occur (Rogers et al., 
2005).  
1.3.2 EGFR function in normal development 
EGFR and other members of the gene family are expressed in a wide 
range of epithelial and neuronal tissues during normal development and 
throughout life (Henson and Gibson, 2006, Sibilia et al., 2007). Gene 
knockout studies demonstrated that the gene family is crucial for normal 
embryonic development (Sibilia et al., 2007). EGFR receptor knockout mice 
die from day 11.5 of gestation to the early postnatal period due to multiple 
defects in epithelial organ development (Henson and Gibson, 2006, Sibilia et 
al., 2007). ErbB2, ErbB3, and ErbB4 gene knockout mice die during early to 
mid-gestation due to defects in cardiac, glial and neuronal development 
(Citri et al., 2003, Henson and Gibson, 2006, Sibilia et al., 2007). 
 
1.3.3 ErbB receptor family ligands 
To date, ten cognate ligands have been identified interacting with the 
receptor family, each containing an EGF-like domain (Nicholson et al., 2001, 
Prigent, 2006). They can broadly be divided into three groups depending on 
their receptor specificity (Table 1.8).  
The members of this family of peptides are initially synthesised as large 
glycosylated membrane-associated precursors consisting of a hydrophobic 
signal peptide and a transmembrane domain (Salomon et al., 1995). Some 
ligands can act in a juxtacrine fashion when still tethered to the cell 
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membrane, but most require further processing (Rogers et al., 2005). The low 
molecular weight EGF peptide is found in the amino-terminus of the 
precursor from which it is proteolytically cleaved by matrix 
metalloproteinases (MMPs) and adamalysins (ADAMs), leading to shedding 
of soluble growth factors (Salomon et al., 1995). ErbB ligands generally act 
over short distances as autocrine or paracrine growth factors, except EGF 
which can also be found in many body fluids (Olayioye et al., 2000).  
 
Table 1.8: Binding specificity of the different ligands that interact with the ErbB family of 
receptors. Compiled from Hynes & Lane (2005) and Graus-Porta et al. 1997. 
 
ErbB ligands exhibit distinct expression patterns that are specific to 
tissue type and developmental stage, providing additional control of the 
signalling pathways (Olayioye et al., 2000). Their biochemical properties also 
influence signalling diversity. ErbB ligands are bivalent and upon receptor 
binding, the ligand will influence the dimerization partner interaction 
(Lenferink et al., 1998, Olayioye et al., 2000). The ligands also exhibit 
Group of ligands Receptor binding specificity 
Group 1  
Ligands that binds specifically to 
EGFR 
Epidermal Growth Factor (EGF) 





Ligands that have dual specificity to 
EGFR and ErbB4 
Betacellulin (BTC)  
Heparin-binding EGF (HB-EGF)  
Epiregulin (EPI) 
Group 3 
Ligands that bind to ErbB3 and 







Neuregulin (NRG) 2 
ErbB 4 only Neuregulin (NRG) 3 
Neuregulin (NRG) 4 
♦ Some authors suggests that AR also activates ErbB4, Rogers et al. (2005) 
♣ NRG-1 is also known as neu differentiation factor, heregulin, acetylcholine receptor 
inducing activity and glial growth factor, Olayioye et al. (2000) 
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differential receptor binding affinities which influence signal duration and 
strength (Olayioye et al., 2000). In addition, ligands influence signalling 
through their differential pH stability (Lenferink et al., 1998, Wiley, 2003). 
Ligand-receptor complexes dissociate at ligand-dependent pH values, and 
this influences downstream trafficking of the receptor (Wiley, 2003) by, for 
example, targeting the receptor for recycling rather than degradation and 
contributing to receptor upregulation (Lenferink et al., 1998, Olayioye et al., 
2000, Wiley, 2003).  
1.3.4 ErbB receptor interactions and signalling and expression 
and their role in the pathogenesis of cancer 
ErbB receptor signalling is induced by ligand binding to their 
extracellular domain causing conformational changes to the receptor 
(Prigent, 2006), which promote formation of homo- or heterodimers between 
receptor family members (Holbro and Hynes, 2004, Jimeno and Hidalgo, 
2005). Dimerization is dictated by the nature of the ligands and the cell’s 
complement of ErbB receptors (Olayioye et al., 2000) and follows a strict 
hierarchal pattern (Graus-Porta et al., 1997, Olayioye et al., 2000). 
Dimerization in turn activates the intracellular tyrosine kinase and leads to 
autophosphorylation of one or more of the tyrosine residues in the 
intracellular carboxy-terminus. These phosphorylated residues act as 
docking sites for several adaptor and docking molecules which in turn 
activate downstream pathways (Holbro and Hynes, 2004, Jimeno and 
Hidalgo, 2005).   
Each ErbB receptor displays distinct specificities for different adaptor 
proteins or enzymes determined by the amino acids surrounding the 
autophosphorylation sites (Olayioye et al., 2000, Holbro and Hynes, 2004). 
The cytoplasmic mediators bind via their Src-homology 2 (SH2)-domains or 
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their phosphotyrosine-binding (PTB)-domains. The recruitment of these 
adaptor proteins and enzymes leads to activation of a variety of intracellular 
downstream signalling pathways (Rogers et al., 2005, Holbro and Hynes, 
2004). The major EGFR downstream pathways include the mitogen-activated 
protein-kinase (MAPK) pathway, the phosphatidylinositol 3-kinase (PI3K) 
pathway, the signal transducers and activators of transcription (STAT) 
pathway and the phospholipase Cγ (PLCγ) pathway (Yarden and 
Sliwkowski, 2001, Jorissen et al., 2003, Rogers et al., 2005) (Figure 1.4). In 
addition, abundant cross talk exists between different receptor pathways 
both at the intracellular and the extracellular level (Rogers et al., 2005). 
Activation of these pathways leads to increased cell proliferation, 
angiogenesis, cell survival and invasive and migratory potential (Eriksen et 
al., 2004). 
Figure 1.4: EGFR downstream pathways. Activation of PI3-K pathway leads to conversion of 
PIP2 to PIP3, the first step in a phosphorylation cascade ending in activation of Akt. It in turn 
activates anti-apoptotic proteins bcl, IKK and NFκβ and inhibits pro-apoptotic proteins FOXO 
and Caspase 9. Activation of mTOR and inhibition of cell cycle inhibitors GSK3β and p27 
drives cell proliferation. MAPK pathway stimulates cell proliferation and STAT pathways 
inhibit apoptosis and stimulate angiogenesis and cell proliferation. The PLCγ pathway is 
implicated in cell survival and migration, and the MMP pathway is involved in processing of 
growth factors potentially causing an autocrine signalling loop and in the hydrolysis of 
basement membrane and extracellular matrix which may play a role in invasion. 
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Dysregulation of EGFR function and the overexpression of EGFR and 
its ligands were commonly reported features of epithelial malignancies. The 
major pathways, their role in cancer and other important mechanisms in the 
pathogenesis of EGFR are discussed further below. 
1.3.4.1 The MAPK pathway promotes proliferation 
All four ErbB receptors activate the MAPK pathway, but EGFR is the 
most important activator (Jorissen et al., 2003, Rogers et al., 2005). The 
pathway is a potent inducer of proliferation in cancer while its contributions 
towards invasive capability are thought to be limited (Thomas et al., 2003, 
Sharma et al., 2007). The pathway has also been implicated in transactivation 
of vascular endothelial growth factor (VEGF) receptors contributing to 
neoangiogenesis (Rogers et al., 2005). 
Upon ligand activation and tyrosine kinase phosphorylation of tyrosine 
residues, the adaptor molecules growth factor receptor-bound protein 2 
(Grb2) and Shc are recruited to the receptor. Grb2 interacts with EGFR either 
directly at tyrosine residues Y1068 or Y1086 via its SH2 domain, or indirectly 
by binding Shc which binds EGFR at Y1148 or Y1173 via its PTB domain 
(Jorissen et al., 2003, Prigent, 2006). It has been suggested that the Shc-Grb2 
complex interaction is the major activation step (Sasaoka et al., 1994), but 
regardless of interaction involved, the Grb2 protein associates constitutively 
with the Son of Sevenless (SOS) protein, which regulates the activity of Ras 
(Sasaoka et al., 1994, Prigent, 2006). Ras is a guanosine triphosphate (GTP) 
binding protein, which, in its inactive state, is bound to guanosine 
diphosphate (GDP) and localised to the plasma membrane by a fatty acid 
chain modification (Egan and Weinberg, 1993, Prigent, 2006, Roberts and 
Der, 2007). The recruitment of the Grb2–SOS complex to the plasma 
membrane promotes their interaction.  SOS catalyses the exchange of GTP to 
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GDP converting Ras into its active form (Roberts and Der, 2007).  Ras 
remains active until its GTP is converted back to GDP by GTPase activating 
protein (GAP) (Roberts and Der, 2007). There are three mutated forms of Ras 
commonly found in cancer, and these proteins are GAP insensitive, 
rendering them constitutively activated (Prigent, 2006, Roberts and Der, 
2007).  
Ras-GTP activates the serine/threonine kinase raf-1, which in turn via a 
series of intermediate kinases phosphorylates the dual specificity kinases 
MEK1 and MEK2.  The next step is the phosphorylation of extracellular 
signal–regulated kinase 1 (ERK1) and ERK2, which translocate to the nucleus 
where they regulate various transcription factors including cyclin D1, jun, 
fos and myc (Jorissen et al., 2003, Roberts and Der, 2007). Cyclin D1 is 
important in cell cycle progression and jun, fos and myc are proto-
oncogenes. The pathway is further regulated by a negative feedback loop 
where the Grb2-Sos complex dissociates following ERK phosphorylation 
(Jorissen et al., 2003).  
1.3.4.2 The PI3K pathway is the pro-survival arm downstream of 
EGFR 
Phosphatidylinositol 3-kinase (PI3K) is one of the most important 
phospholipid modifying enzymes downstream of the RTKs (Jorissen et al., 
2003). PI3K contains two subunits, the p85 units which carry a SH2 binding 
domain and the catalytic subunit p110 (Jorissen et al., 2003, Prigent, 2006).  
The PI3K pathway is often termed the pro-survival pathway, as this is 
one of the main mechanisms tumour cells use to circumvent apoptosis 
(Rogers et al., 2005, Sharma et al., 2007). It is also thought to be the main 
mechanism conferring radiation resistance in HNSCC cells (Thomas et al., 
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2003, Sharma et al., 2007), and it has been implicated as the main inducer of 
neoangiogenesis during tumour growth (Rogers et al., 2005). 
The main activator of the PI3K pathway is ErbB3 (Olayioye et al., 2000), 
which has several binding sites for the p85 subunit (Prigent, 2006). EGFR has 
to date no reported direct binding sites for this subunit (Prigent, 2006), but 
EGFR specific ligands are still strong initiators of this pathway through three 
mechanisms (Jorissen et al., 2003, Prigent, 2006). Firstly, following ligand-
induced heterodimerization between EGFR and ErbB3, the p85 subunit binds 
to the transphosphorylated ErbB3 tail (Prigent, 2006). Secondly, EGFR can 
interact with the p85 subunit via a scaffold protein, Grb2 associated-binding 
protein 1 (GAB1), and the adaptor protein Grb2 which binds EGFR via Y1068 
and Y1086 (Prigent, 2006). Thirdly, the pathway can also be activated by Src, 
a cytosolic tyrosine kinase that phosphorylates novel sites within the kinase 
domain of the EGFR,  providing a docking site for the p85 subunit (Jorissen 
et al., 2003, Prigent, 2006). 
Upon activation, PI3K catalyses the conversion of phosphatidylinositol 
(4,5) biphosphate (PIP2) to phosphatidylinositol (3,4,5) triphosphate (PIP3) 
(Gupta et al., 2002, Jorissen et al., 2003, Prigent, 2006).  PIP3 is a second 
messenger which targets the serine/threonine kinase Akt (also referred to as 
protein kinase B [PKB]) (Jorissen et al., 2003, Rogers et al., 2005). PIP3 
localises Akt to the membrane where phosphoinositide-dependent kinases 
(PDKs) phosphorylate it at two sites, causing full activation of Akt (Gupta et 
al., 2002, Rogers et al., 2005). Downstream of Akt a multitude of proteins are 
substrates for Akt phosphorylation (Gupta et al., 2002, Jorissen et al., 2003, 
Rogers et al., 2005), including the forkhead box protein O (FOXO) family of 
transcription factors, which are implicated in promoting cell cycle 
progression by promoting cyclin D1 expression and repressing cell cycle 
32 
 
inhibitors like p27 (Jorissen et al., 2003, Prigent, 2006). Akt also inhibits bcl-2-
associated death promoter (BAD), a pro-apoptotic protein (Rogers et al., 
2005), activates mammalian target of rapamycin (mTOR), which induces 
protein synthesis (Sharma et al., 2007) and the pro-survival transcriptional 
regulator protein nuclear factor-κB (NFκB) (Rogers et al., 2005).  
In normal tissues the pathway is regulated by the phosphatase and 
tensin homologue (PTEN), a tumour suppression protein that 
dephosphorylates PIP3. In some tumours, PTEN is found to be mutated, 
which removes the negative regulator of the pathway causing continuous 
activation of the pathway (Rogers et al., 2005, Negri et al., 2010).  
1.3.4.3 The STAT3 and STAT5b pathways drive cell survival and 
migration 
STAT proteins were first identified as signal transducers downstream 
of cytokine receptors and they were dependent on the Janus kinase (JAK) 
family for activation (Jorissen et al., 2003). Later, it was shown that EGFR 
also mediates STAT phosphorylation in a JAK-independent manner (Song 
and Grandis, 2000).   
Seven STAT proteins have been identified in mammals: STAT 1 to 4, 5a, 
5b, and STAT 6 (Grandis et al., 2000). STAT 1 demonstrates a tumour 
suppression function, whereas STAT 3 and 5b behave as oncogenes and 
contribute to cell proliferation, survival and invasion (Xi et al., 2003, Rogers 
et al., 2005, Wheeler et al., 2010b). 
Activation of the STAT3 pathway involves the binding of STAT SH2 
domains to EGFR phosphorylation sites Y1068 and Y1086 (Grandis et al., 
2000, Song and Grandis, 2000, Xi et al., 2003). This interaction leads to 
phosphorylation, dimerization and nuclear translocation of STAT (Grandis 
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et al., 2000, Song and Grandis, 2000).  STAT 5b is activated in a similar 
manner (Xi et al., 2003), and combined they contribute to inhibition of 
apoptosis and progression of tumour cell growth in HNSCC (Song and 
Grandis, 2000, Xi et al., 2003). The downstream targets of STAT includes 
hypoxia induced factor (HIF-1α) (Wheeler et al., 2010b), the anti-apoptotic 
protein Bcl-xL (Xi et al., 2003) and cyclin D1, which is important in 
permitting cell cycle progression from checkpoint G1 to S-phase and 
consequent cell growth (Rogers et al., 2005).  
1.3.4.4 The PLCγ pathway is implicated in tumour migration and 
invasion  
PLCγ is capable of binding both EGFR and ErbB2 receptors (Rogers et 
al., 2005). It interacts directly with EGFR by binding phosphorylated tyrosine 
residues Y992 and Y1173 (Jorissen et al., 2003, Reuter et al., 2007). The 
activation of this pathway has been implicated in migration and invasion in 
HNSCC (Thomas et al., 2003, Rogers et al., 2005, Kalyankrishna and Grandis, 
2006).  
Once activated by associating with EGFR, PLCγ hydrolyses PIP2 to 
inositol triphosphate (IP3) and 1,2-diacylglycerol (DAG) (Jorissen et al., 2003, 
Thomas et al., 2003, Rogers et al., 2005). IP3 induces calcium release from 
intracellular stores stimulating a number of calcium dependent enzymes. 
DAG activates the serine/threonine kinase Protein Kinase C (PKC) which in 
turn induces a number of signalling pathways including the MAPK 
pathways (Rogers et al., 2005).  
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1.3.4.5 Receptor crosstalk and minor signalling pathways also 
play important roles in cancer pathogenesis  
There is an abundance of signalling pathways downstream of the ErbB 
family members (Olayioye et al., 2000). The complexity increases further as 
other RTK families are capable of transactivation and crosstalk with the ErbB 
receptors (Yarden and Sliwkowski, 2001, Holbro and Hynes, 2004). For 
example, EGFR may be activated by gastrin-releasing peptide receptor (Lui 
et al., 2003), insulin-like growth factor 1 receptor (IGF1-R), cell adhesion 
molecules and G protein coupled receptor (GPCR) (Rogers et al., 2005). 
In the latter case, ligand bound GPCRs activate MMPs through a poorly 
understood mechanism. The MMPs proteolytically cleave ligand precursors 
which in turn cause EGFR activation and downstream signalling (Yarden 
and Sliwkowski, 2001, Holbro and Hynes, 2004, Rogers et al., 2005). The 
release of MMPs can also be stimulated via the MAPK pathway following 
binding of ligands (in descending order of potency) BTC, EGF and NRG to 
ErbB receptors (Rogers et al., 2005). This creates a positive feedback loop 
where the MAPK pathway activates the transcription of genes encoding 
ErbB ligands (Yarden and Sliwkowski, 2001, Rogers et al., 2005). MMPs are 
often overexpressed in HNSCC, and the degree of upregulation correlates 
with invasive potential of the tumour (Rogers et al., 2005). 
GPCRs also transactivate EGFR through the activation of Src, a 
cytosolic tyrosine kinase (Rogers et al., 2005). Src phosphorylates tyrosine 
residues in the EGFR tyrosine kinase domain, treating the receptor as a 
passive scaffold not utilising its tyrosine kinase function, creating a ligand 
independent process (Rogers et al., 2005). 
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1.3.4.6 Switching off the response  
An important level of cell signalling control is the ability to switch off a 
signal following activation. In comparison to the process of EGFR 
stimulation, the inactivation of signalling is poorly understood (Lenferink et 
al., 1998, Sorkin and Goh, 2009). Downregulation is the net result of receptor 
degradation and recycling (Levkowitz et al., 1998, Sorkin and Goh, 2009), 
and downregulation of receptor-ligand complexes is the main mechanism of 
receptor inactivation (Sorkin and Goh, 2009). The downregulation of EGFR 
differs from the other receptors in its family (Lenferink et al., 1998, Wiley, 
2003), and it has been suggested that this is mediated through differential 
binding affinities at their carboxy tails (Olayioye et al., 2000, Sorkin and Goh, 
2009). For example, cbl (Lenferink et al., 1998, Levkowitz et al., 1998, 
Olayioye et al., 2000) and epidermal growth factor receptor substrate 15 
(Eps15) (Olayioye et al., 2000) only bind to activated EGFR. Cbl has been 
identified as an ubiquitin protein ligase responsible for receptor 
ubiquitination causing subsequent degradation (Olayioye et al., 2000, Wiley, 
2003) while Eps15 (Olayioye et al., 2000) are thought to be important in the 
internalization of activated receptor-ligand complexes.  
In normal cells, EGFR cluster over clathrin-coated regions of the plasma 
membrane, which rapidly internalize receptor-ligand complexes forming 
endocytic vesicles upon activation (Lenferink et al., 1998, Sigismund et al., 
2008). The majority of EGFR signalling occurs within these endosomal 
compartments (Wiley, 2003). The route the receptor then follows is 
dependent on its ligand and dimerization partner (Lenferink et al., 1998) and 
the level of receptor ubiquitination (Sigismund et al., 2008). EGFR 
homodimers are targeted to the lysosome for degradation, while 
heterodimerization with ErbB2 will increase recycling of EGFR (Yarden and 
36 
 
Sliwkowski, 2001). ErbB2 has a slower rate of internalization compared to 
EGFR due to a lack of internalization signals in its carboxy terminal (Sorkin 
and Goh, 2009). Expression levels of ErbB2 also influence EGFR 
internalization with decreased EGFR degradation in cells overexpressing 
ErbB2 (Sorkin and Goh, 2009).  
TGFα, in contrast to EGF, readily dissociates from EGFR inside the 
endosome even at moderately acidic pH, and thus directs the receptor 
preferentially to recycling regardless of its heterodimerization partner 
(Lenferink et al., 1998). In contrast, EGF dissociates poorly from EGFR at the 
same pH, causing ligand receptor complex to be sorted to the lysosome 
(Sorkin and Goh, 2009). 
In HNSCC, EGFR, TGFα and Erb2 receptor are often all overexpressed 
(Grandis et al., 1998, Cavalot et al., 2007). As the concentration of ligands or 
expression levels of the receptor increase, the clathrin-independent pathways 
internalize activated EGFR which preferentially targets the receptor to 
degradation (Sigismund et al., 2008). However, saturation of endocytosis and 
the lysosomal sorting machinery will occur, further reducing receptor 
degradation rates (Levkowitz et al., 1998, Wiley, 2003).  
1.3.5 Mechanisms of aberrant EGFR activation in cancer 
1.3.5.1 EGFR overexpression is a major mechanism in 
oncogenesis 
EGFR overexpression and dysregulation is an important feature in the 
pathogenesis of HNSCC in man. Grandis and Tweardy (1993) compared the 
levels of messenger RNA (mRNA) encoding EGFR and TGFα between 
biopsy samples of tumours and the adjacent histologically normal mucosa 
from cancer patients. Normal oral mucosae from non-cancer patients were 
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used as controls. The tumour tissues had a 69-fold increase of EGFR mRNA 
compared to controls, and the histologically normal mucosa adjacent to the 
tumour samples had a 29-fold increase in mRNA levels compared to 
controls. Levels of mRNA encoding TGFα showed similar trends and 
elevated levels of mRNA encoding both molecules were associated with 
increased protein expression (Grandis and Tweardy, 1993). These findings 
led to the concept of “field cancerization”, where the changes in the levels of 
EGFR and its ligand were thought to be an early carcinogenic event in the 
development of HNSCC (Grandis and Tweardy, 1993). A dramatic 
upregulation of EGFR expression has also been observed during 
transformation from dysplasia to SCC (Shin et al., 1994). This field 
cancerization has been suggested as an explanation of why HNSCC patients 
are susceptible to developing de novo tumours following successful treatment 
of earlier lesions (Grandis and Tweardy, 1993, Baselga et al., 2005). 
Overexpression of EGFR is frequently reported in HNSCC, and has 
been reported in 38-98% of tumours (Baselga et al., 2005, Kalyankrishna and 
Grandis, 2006). The great variation reported is likely due to the lack of 
standardised scoring methods. Most studies use different labelling 
techniques and antibodies, and often use arbitrary cut off points to define 
overexpression (Dei Tos and Ellis, 2005). A consensus on a standardised 
EGFR scoring system that could be widely used with high repeatability 
would greatly enhance our understanding of what constitutes EGFR 
overexpression.  
Other ErbB family members have also been reported to be 
overexpressed in HNSCC (Lango et al., 2001, Kalyankrishna and Grandis, 
2006). Increased ErbB2 and ErbB3 expression have been associated with 
decreased survival and increased nodal metastasis (Shintani et al., 1995, 
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Cavalot et al., 2007). The role of ErbB4 is still unclear, but it has also been 
reported to be overexpressed in HNSCC (Lango et al., 2001). 
1.3.5.2 Autocrine ligand activation may be an early step in 
malignant transformation 
Uncontrolled cell growth may be the result of a cell developing the 
ability to produce growth factors that stimulate its own proliferation 
(Grandis and Tweardy, 1993). This is thought to be an important early event 
in the pathogenesis of HNSCC (Jimeno and Hidalgo, 2005, Kalyankrishna 
and Grandis, 2006). This was supported by the findings that in normal 
mucosa from non-cancer patients, TGFα and EGFR were produced by 
adjacent cells, implying a paracrine stimulation pathway (Grandis et al., 
1996). In contrast, in histologically normal mucosa from HNSCC patients, 
TGFα and EGFR were co-expressed in cells, suggesting a switch to an 
autocrine pathway (Grandis et al., 1996, Lui et al., 2003), rendering the cell 
self-sufficient in growth signals, one of the hallmarks of cancer (Hanahan 
and Weinberg, 2000).  
1.3.5.3 EGFR gene amplification in HNSCC  
One of the reported causes of EGFR overexpression is gene 
amplification (Salomon et al., 1995, Nicholson et al., 2001, Arteaga, 2003). 
Although EGFR overexpression commonly occurs in HNSCC, gene 
amplification does not seem to be the main mechanism behind this 
phenotype. In a small study of 33 HNSCC patients, 30 tumours 
overexpressed EGFR but only seven patients exhibited gene amplification, 
and that was only of a moderate degree (Mrhalova et al., 2005). Similarly, 
Grandis and Tweardy (1993) showed that ten HNSCC cell lines which 
overexpressed EGFR and TGFα mRNA did not show a significant increase in 
EGFR or TGFα gene dosage or any evidence of rearrangements of these 
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genes. They suggested the increases in mRNA in these tumours were due to 
an elevated transcription rate and possibly enhanced mRNA stability rather 
than gene amplification (Grandis and Tweardy, 1993). 
 
1.4 EGFR as a therapeutic target 
The role of EGFR as a potent driver of oncogenesis is well established, 
but there are several reasons why it has become a favoured therapeutic 
target (Arteaga, 2003, Kalyankrishna and Grandis, 2006). EGFR and its 
ligands are overexpressed in a range of tumours (Lurje and Lenz, 2009), and 
EGFR expressing tumours can be identified in diagnostic biopsies from 
patients, aiding in the selection of potentially responsive tumours (Arteaga, 
2003). EGFR expression relative to normal tissues has been extensively 
studied in ten major solid cancers in man, namely ovarian, breast, bladder, 
cervical, HNSCC, oesophageal, colorectal, gastric, endometrial and non-
small cell lung cancer (NSCLC) (Nicholson et al., 2001, Dei Tos and Ellis, 
2005). In these tumours EGFR overexpression is associated with worse 
overall survival (Dei Tos and Ellis, 2005), although EGFR overexpression is 
only considered a strong prognostic indicator in HNSCC, ovarian, cervical, 
bladder and oesophageal cancers (Dei Tos and Ellis, 2005, Lurje and Lenz, 
2009).  
The lack of an obvious physiological role of EGFR in the adult further 
indicates that it is a potentially good drug target (Arteaga, 2003). Inhibition 
of EGFR signalling can be achieved through three main approaches: 
monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs) and 
inhibition of EGFR synthesis through antisense oligonucleotides or RNA 
interference (RNAi) (discussed separately in chapter 1.6.1) (Nozawa et al., 
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2006, Reuter et al., 2007, Lai et al., 2009, Lurje and Lenz, 2009). Drugs used to 
target EGFR for the treatment of cancer in preclinical and clinical 
development are summarised in Table 1.9.  
 
Table 1.9: Examples of EGFR targeting cancer drugs at different stages of development. 
Compiled from (NCI, 2010). 
 
1.4.1 Monoclonal Antibodies 
Monoclonal antibody-based drugs compete with the EGFR ligands and 
bind to the extracellular domain of the receptor (Lurje and Lenz, 2009), 
where drug binding blocks dimerization and subsequent activation (Roberts 
and Der, 2007). The antibodies may also recruit Fc receptor-expressing 
immune effector cells leading to antibody-dependent cell-mediated 
cytotoxicity (Roberts and Der, 2007, Reuter et al., 2007, Lurje and Lenz, 2009). 
A number of EGFR mAbs have been developed, and each recognises distinct 
Drug (trade name) Type Current status 
Gefitinib (Iressa)  TKI Approved NSCLC.  
Phase II for breast, nasopharyngeal 
carcinoma, SCC of skin and oesophageal 
cancer.  
Erlotinib (Tarceva) TKI Approved NSCLC, pancreatic cancer. 
Phase II for CRC, HCC, GBM, and 
oesophageal cancer. 
Cetuximab (Erbitux) Chimeric mAb Approved HNSCC, CRC 
Phase III NSCLC, oesophageal cancer 
Phase II GBM, breast cancer 
Panitumumab (Vectibix) Humanised mAb Approved CRC 
Phase III HNSCC, oesophageal cancer 




Phase III HNSCC 
TKI = Tyrosine Kinase Inhibitors, NSCLC = non-small cell lung cancer, SCC = 
squamous cell carcinoma, CRC = colorectal cancer, HCC = hepatocellular carcinoma, 
GBM = glioblastoma multiforme. 
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sequences on the receptors and has different binding affinities, resulting in a 
range of biological activities (Roberts and Der, 2007).  
The most important mAb in HNSCC to date is cetuximab, which was 
the first new treatment approved for HNSCC in over 30 years when it came 
on the market (Baselga, 2006). Cetuximab is a chimeric mouse-human IgG 
mAb that binds the EGFR extracellular domain blocking 
autophosphorylation and inducing downregulation of receptor from the cell 
surface. It may also block dimerization (Jimeno and Hidalgo, 2005, Bonner et 
al., 2006). Cetuximab induces cell cycle G1 arrest, inhibiting cell proliferation 
and tumour induced angiogenesis (Jimeno and Hidalgo, 2005, Bernier and 
Schneider, 2007). It has been used clinically in combination with 
radiotherapy, where it significantly prolonged locoregional control and 
survival (Bonner et al., 2006, Bernier and Schneider, 2007), or in conjunction 
with chemotherapy, where it was shown to increase overall survival and 
response rates as a second line therapy in patients refractory to platinum-
based drug therapies (Baselga et al., 2005). The use of mAbs did not seem to 
increase the adverse effects of radiotherapy (Bonner et al., 2006) or 
chemotherapy (Baselga et al., 2005).  
There are no reports of use of EGFR mAbs in veterinary patients or of 
the development of specific antibodies targeting EGFR for veterinary use. 
The available human monoclonal antibody based therapies may be 
ineffective for use in animal patients. These antibodies have been raised 
against the human EGFR receptor and may have reduced affinities for the 
corresponding receptor in animals. However, low affinity binding may still 
be effective or even superior to high affinity binding as high affinity binding 
can reduce tissue penetration or cause increased binding to normal tissues 
(Nissim and Chernajovsky, 2008). Perhaps more critically, the use of the 
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currently available monoclonal antibodies may be limited by host immune 
responses to the drugs. Currently in man, murine antibodies are used that 
have been modified to avoid these host responses, either by producing 
human-mouse chimeric antibodies or humanised murine antibodies (Nissim 
and Chernajovsky, 2008).  If used in animals they are likely to cause anti-
human antibody responses similar to the human anti-mouse antibody 
responses seen in man to murine antibodies (Nissim and Chernajovsky, 
2008). Specific development of monoclonal antibodies targeting the EGF 
receptor in each individual species may be required to implement these 
therapies in veterinary oncology.  
1.4.2 Tyrosine Kinase Inhibitors 
These drugs were developed based on the observation that mutations 
in the ATP-binding pocket of the EGFR severely affected its tyrosine kinase 
function (Arteaga, 2003). The TKIs can be classified according to their 
selectivity for receptors (mono-, bi- or tri-functional) and their reversibility 
(reversible versus irreversible inhibitors) (Fry, 2003, Jimeno and Hidalgo, 
2005, Reuter et al., 2007). 
The mechanism of action of TKIs is predominantly by inhibiting the 
catalytic activity of the tyrosine kinase by blocking the ATP binding site 
(Roberts and Der, 2007, Lurje and Lenz, 2009). Two further mechanisms of 
action have also been proposed although these mechanisms are not fully 
understood (Fry, 2003). TKIs are thought to induce an inhibitor-mediated 
degradation of receptor and to cause interference with the signalling process 
by disrupting receptor dimerization (Fry, 2003). Advantages of TKIs include 
the ability to target ligand-independent signalling (necessary if EGFR 
activity has become dysregulated from ligand binding) and good oral 
bioavailability (Arteaga, 2003, Baselga and Swain, 2009). 
43 
 
Three TKIs are currently undergoing clinical trials for therapy of 
HNSCC, either as a monotherapy or in combination with radiation or 
chemotherapy (NCI, 2010, Reuter et al., 2007). Gefitinib (Iressa®, Astra 
Zeneca Pharmaceuticals, UK) is an EGFR selective and reversible TKI 
(Jimeno and Hidalgo, 2005) currently undergoing stage III clinical trials for 
the treatment of HNSCC (Reuter et al., 2007). It has been shown to exhibit 
additive and synergistic properties in combination with chemotherapy or 
irradiation (Huang et al., 2002, Reuter et al., 2007).  
Although the TKI-based therapies may be more directly transferable 
between species, the efficacy and safety of these drugs has not been 
established in veterinary species and no specific TKIs targeting EGFR in 
animals have been marketed to date. However, there is a tri-functional TKI 
licenced for use in cutaneous mast cell tumours in dogs, toceranib sulphate 
(Palladia™, Pfizer), which inhibits KIT, VEGF receptor 2 and platelet derived 
growth factor receptor β (PDGFRβ) (London et al., 2009).  
1.4.3 Side effects of EGFR targeting therapies 
The main side effects of both of these groups of drugs are skin reactions 
and acne-like rash, fever, chills, asthenia, infusion reactions (mAbs only) and 
nausea (Baselga et al., 2005, Bonner et al., 2006). Patients that develop these 
reactions seem to respond more favourably to therapy, and the severity of 
the reaction corresponds with the response rate observed (Jimeno and 
Hidalgo, 2005, Lurje and Lenz, 2009).  
1.4.4 Current use of EGFR targeting strategies 
EGFR targeting drugs have been evaluated as single agent therapies, 
but may also have roles as part of multimodality therapy and in overcoming 
resistance to other therapies. Cancer cells surviving fractionated 
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radiotherapy have been shown to upregulate both EGFR and its ligand 
TGFα, indicating that EGFR upregulation may be an important mechanism 
used by cancer cells to circumvent the cytotoxic effects of radiotherapy 
(Thariat et al., 2007). The resistance of tumour cells to radiotherapy has also 
been shown to increase proportionally with EGFR expression in HNSCC 
(Bernier and Schneider, 2007, Thariat et al., 2007). In HNSCC, increased 
locoregional control and reduced mortality was reported when cetuximab 
was used in combination with radiotherapy compared to treatment with 
radiotherapy alone (Bonner et al., 2006). EGFR inhibitors have also been used 
in combination with chemotherapy in HNSCC (Baselga et al., 2005) and 
NSCLC (Mok et al., 2009). Some trials found no benefit from combination 
therapy of EGFR-TKI and chemotherapy in NSCLC, but others demonstrated 
that a subset of NSCLC with specific EGFR mutations respond favourably to 
EGFR inhibition (Pircher et al., 2010). Efforts are now focusing on finding 
reliable predictors of response to EGFR targeted therapies when used as both 
single agents and in multimodal therapies (Mok et al., 2009, Pircher et al., 
2010).  
1.4.5 Predictors of response to therapy 
Initially the expectation was that there would be a straightforward 
relationship between level of EGFR expression and response to targeted 
therapies, mirroring the relationship in HER2 positive breast carcinomas 
where high HER2 expression is predictive of response to trastuzumab (an 
HER2-specific mAb) (Wheeler et al., 2010a). The relatively modest response 
rates of only 5-15% reported for EGFR targeted therapy in early trials were 
therefore disappointing (Lai et al., 2009), and patient selection based on 
immunohistochemical assessment of EGFR expression did not seem to 
predict response to therapy (Pircher et al., 2010, Wheeler et al., 2010a). In 
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some circumstances, EGFR expression levels were predictive, for example 
when an accelerated fractionation scheme (a fixed total dose is delivered in a 
fixed number of fractions during a shorter overall treatment time) was used 
to treat HNSCC the authors reported that patients with high EGFR 
expression received a significant benefit from this treatment type compared 
to patients with low or no EGFR expression (Eriksen et al., 2004, Bentzen et 
al., 2005). Further studies proved the benefit of cetuximab in combination 
with radiotherapy for HNSCC (Bonner et al., 2006), which then led to FDA 
approval for cetuximab in combination with radiotherapy the same year 
(Wheeler et al., 2010a).   
As our understanding of the complex relationships governing EGFR 
signalling in different tumour types has evolved, the requirement for reliable 
molecular markers capable of predicting response to therapy has become 
apparent. A good example of this is the improvement seen in response rates 
to gefitinib treatment in NSCLC following the detection of EGFR activating 
mutations in a cohort of patients (Pircher et al., 2010, Wheeler et al., 2010a). 
This cohort had been identified based on their distinct clinical profile 
(patients that were female, of Asian origin who had never smoked and 
whose tumours were adenocarcinomas) (Pircher et al., 2010). The definitive 
role of two mutations in exons 19 and 21 affecting the receptor ATP binding 
pocket, which led to ligand-independent constitutive activation was finally 
determined in 2004 (Ratushny et al., 2009, Pircher et al., 2010). Due to the 
gain of function associated with these mutations, the tumours become EGFR-
dependant, rendering them sensitive to TKI treatment (Ratushny et al., 2009), 
resulting in trials using these selection criteria achieving 50-70% response 
rates (Wheeler et al., 2010a). 
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Other predictive markers showing promise in solid tumours include 
markers of epithelial to mesenchymal transition (EMT) like E-cadherin and 
vimentin for HNSCC, pancreatic and colorectal cancers among others 
(Eyzaguirre et al., 2008, Haddad et al., 2009), EGFR copy number and K-ras 
mutations in colorectal cancer (Chen et al., 2010, Wheeler et al., 2010a) and 
H-ras mutations in HNSCC (Chen et al., 2010). 
Interestingly, in a phase I trial of intratumoural antisense DNA therapy 
against EGFR in HNSCC, a response rate of 30% was achieved in patients 
already refractory to two standard therapies and in this study, response was 
correlated to high EGFR expression (Lai et al., 2009). The authors urged 
caution against over interpretation of these results, but this might suggest 
that targeting transcriptional regulation and downregulating protein levels 
may be more effective than blockade of EGFR-ligand binding or tyrosine 
phosphorylation (Lai et al., 2009).  
1.4.6 Resistance to EGFR targeting therapies 
Response to EGFR targeted therapies is limited by two mechanisms of 
resistance. Firstly, some cancer subsets have intrinsic resistance to EGFR 
targeted therapy despite expressing high levels of EGFR and show no 
response to treatment (Li et al., 2009). It is for this group of patients that the 
development of reliable predictive markers is crucial. Secondly, in the 
subgroups of cases that do show major clinical response to EGFR targeted 
therapy many develop an acquired resistance over time (Li et al., 2009).  
Several mechanisms cause intrinsic resistance to EGFR targeted 
therapies, and they vary depending on tumour type. A relatively recent 
discovery is the presence of the mutant EGFR variant III (EGFRvIII) in up to 
40% of HNSCC (Wheeler et al., 2010b). This mutation produces a 
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constitutively active truncated receptor lacking the extracellular ligand 
binding region, and has been associated with a proportion of glioblastoma 
multiforme (GBM) tumours in man (Gan et al., 2009).  It has now been 
implicated in conferring resistance to cetuximab (Wheeler et al., 2010b) and 
radiotherapy (Ratushny et al., 2009) in HNSCC. Other mechanisms of 
intrinsic cellular resistance are mediated through inactivating mutations in 
PTEN in colorectal cancer (Negri et al., 2010, Mao et al., 2010), germ line 
polymorphisms in EGFR gene introns (Ratushny et al., 2009, Chen et al., 
2010) and a more mesenchymal phenotype tumour (Haddad et al., 2009, 
Wheeler et al., 2010a). 
Acquired resistance is mediated through a range of mechanisms, but 
most commonly through some form of oncogenic shift where the tumour 
compensates for EGFR blockade by shifting its reliance from the EGFR 
pathway to other pathways (Wheeler et al., 2010a). This could be through 
upregulation of other EGFR family members like ErbB2 (Erjala et al., 2006) 
and ErbB3 (Erjala et al., 2006, Wheeler et al., 2008, Chen et al., 2010) or 
through the activation of other RTK pathways. The main pathways 
implicated in circumventing EGFR targeting are altered VEGF receptor 
(VEGFR) expression conferring resistance to mAbs (Ratushny et al., 2009, 
Wheeler et al., 2010a), MET RTK amplification and its ligand hepatocyte 
growth factor (HGF) overexpression (Ratushny et al., 2009, Wheeler et al., 
2010a), and transactivation of GPCR (Ratushny et al., 2009, Chen et al., 2010) 
and cytosolic Src (Chaturvedi et al., 2009). Transactivation of IGF1-R has 
been implicated in conferring intrinsic resistance to EGFR targeting therapies 
in NSCLC, but the phosphorylation and activation of IGF1-R has also been 
shown to increase in response to gefitinib in tumour models including 
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HNSCC, breast, prostate and colorectal cancer (Eyzaguirre et al., 2008), 
playing a role in acquired resistance in these tumours.  
The occurrence of secondary mutations causing a methionine for 
threonine substitution in the kinase domain (T790M) has also been reported 
in acquired resistance to TKIs (Wheeler et al., 2010a). This mutation is found 
in NSCLC tumours containing the activating mutations associated with 
increased sensitivity to TKIs, but it is still not entirely clear whether this 
mutation arises in the population following treatment (Eyzaguirre et al., 
2008) or whether this mutation was already present in a small subpopulation 
and was enriched for through positive selection during treatment 
(Eyzaguirre et al., 2008, Wheeler et al., 2010a). The latter option is currently 
the favoured explanation (Wheeler et al., 2010a). 
Other mechanisms implicated in the occurrence of acquired resistance 
include impairment of receptor downregulation and deregulation of receptor 
ubiquitination (Wheeler et al., 2008, Li et al., 2009), cells undergoing EMT 
(Haddad et al., 2009, Chen et al., 2010) and EGFR nuclear translocation (Li et 
al., 2009). Further work is required to elucidate the main mechanisms of 
resistance by tumour cells to EGFR targeting therapies in order to target the 
tumour cells more strategically.  
1.5 EGFR in veterinary medicine 
Veterinary interest in EGFR as a potential prognostic indicator and 
possible therapeutic target is increasing, and a number of veterinary studies 
have been undertaken to investigate the role of EGFR in solid tumours. In 
man, EGFR has been implicated as an oncogenic driver in subsets of many 
tumours, including HNSCC (Grandis and Tweardy, 1993), NSCLC (Sharma 
et al., 2007), GBM (Gan et al., 2009), renal SCC, hepatocellular carcinoma 
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(Sibilia et al., 2007), ovarian, bladder, breast, pancreatic and colon cancers 
(Dei Tos and Ellis, 2005). Veterinary medicine is building on these advances 
in human medicine and several animal tumours have been investigated for 
EGFR expression. However, to date, there have been few studies that have 
directly evaluated if EGFR dysregulation is a key oncogenic driver and no 
studies that have evaluated EGFR targeted therapy in animals.  
1.5.1 Squamous cell carcinomas  
The expression of EGFR in feline oral SCC was investigated in an 
immunohistochemical study on archived biopsy samples and this 
demonstrated that 9 out of 13 samples had increased EGFR labelling (Looper 
et al., 2006).  Recently, the expression of EGFR was evaluated in feline 
cutaneous SCC biopsy samples (Sabattini et al., 2010), and 14 out of 19 
tumours had EGFR expression, but with great variation in intensity and 
proportion of positively labelled cells. The authors reported however, that 
cats with EGFR positive tumours had a significantly worse outcome with 
decreased disease-free intervals and survival (Sabattini et al., 2010). 
Canine nasal carcinomas have also been evaluated for EGFR and 
VEGFR expression and both have been considered as potential therapeutic 
targets for the treatment of nasal tumours in the dog (Shiomitsu et al., 2009).  
EGFR was expressed in just over half of the tumour samples (Shiomitsu et 
al., 2009), and the authors speculated that EGFR and VEGFR targeted 
therapies in canine nasal tumours may be of value. Targeted therapies could 
potentially be used concurrently with standard therapies, for example by 
augmenting radiosensitivity of the tumours (Shiomitsu et al., 2009), but this 
hypothesis has not yet been tested.  
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Although these veterinary studies demonstrate that there is merit in 
evaluating EGFR-mediated signalling in SCCs, no studies have directly 
established if EGFR expression can be used as a marker of response to 
therapy or as a therapeutic target.   
1.5.2 Mammary Tumours 
EGFR is widely expressed in human breast cancers (Normanno et al., 
2008), and feline and canine mammary carcinomas share many key features 
with the disease in man and have been cited as comparative models (Minke 
et al., 1991, De Maria et al., 2005, Gama et al., 2009, Queiroga et al., 2009). 
Both feline and canine mammary carcinomas have been reported to express 
EGFR (Minke et al., 1991, Rutteman et al., 1994, Donnay et al., 1996), but 
some authors report no correlation between EGFR expression and tumour 
aggressiveness (Rutteman et al., 1994, Donnay et al., 1996). A more recent 
study found that malignant tumours showed a significantly higher 
proportion of EGFR-expressing cells than benign tumours and that there 
were significant associations between EGFR expression and patient age and 
tumour size (Gama et al., 2009). Although not statistically significant, there 
appeared to be trends for reduced disease free survival and reduced overall 
survival in patients with malignant tumours that overexpressed EGFR 
compared to those with tumours which did not (Gama et al., 2009).  
EGFR expression has also been evaluated in a xenotransplantation 
study of feline mammary carcinoma cell lines (Minke et al., 1991). This study 
demonstrated that a subpopulation of feline mammary carcinoma cells had 
increased tumourigenicity that correlated with high expression of 
functionally active EGFR associated with amplification of the EGFR gene 
(Minke et al., 1991).  This study provides the clearest evidence that EGFR 
dysregulation may be a key oncogenic driver in some solid tumours in 
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animals, but dysregulation of EGFR has not been demonstrated in material 
from clinical cases of feline mammary carcinoma. 
1.5.3 Brain tumours 
In the dog, glial cell tumours account for 20% of CNS tumours (Thomas 
et al., 2009) and canine GBM shares many gross, microscopic and 
immunocytochemical features with the disease in human patients who often 
have EGFR gene mutations (Lipsitz et al., 2003, Stoica et al., 2004, Dickinson 
et al., 2006, Thomas et al., 2009, Higgins et al., 2010).  EGFR expression in 
canine GBM has been reported in a subset of canine GBMs (Lipsitz et al., 
2003, Stoica et al., 2004, Higgins et al., 2010), but no studies have evaluated 
the potential prognostic significance of EGFR expression in these tumours.  
1.5.4 Lung cancer 
One study has evaluated EGFR expression in a range of spontaneously 
arising and plutonium-induced lung tumours in dogs which may be 
comparable to human NSCLC (Gillett et al., 1992). In the canine study, EGFR 
was not expressed in unaffected lung, but was identified in 47% of tumours 
(spontaneously arising and plutonium-induced) of which the epidermoid 
carcinomas predominated (Gillett et al., 1992).  This study demonstrated that 
EGFR may be a suitable biological marker for distinguishing 
bronchioalveolar carcinoma from other canine lung adenocarcinomas (Gillett 
et al., 1992). It also raised the possibility that EGFR overexpression may be a 
late event in the development of lung tumours in dogs and that EGFR may 
be a potential therapeutic target for subsets of canine lung cancer. 
1.6 Nucleic acid-based gene silencing 
The three major nucleic acid-based gene silencing molecules currently 
in use are antisense oligodeoxyribonucleic acids (ODNs), ribozymes and 
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small interfering RNAs (Dorsett and Tuschl, 2004). ODNs are single stranded 
DNA molecules of approximately 20 nucleotides in length which cause gene 
silencing through hybridization to mRNA to produce a substrate for 
ribonuclease H (RNase H) which specifically degrades RNA strands of 
DNA-RNA duplexes (Dorsett and Tuschl, 2004). Ribozymes bind to RNA 
and act to degrade target RNA by catalysing the hydrolysis of the 
phosphodiester backbone (Dorsett and Tuschl, 2004). Both these technologies 
are used in current drug developments, but RNAi-based gene silencing 
using small interfering RNAs (siRNAs) have in most instances superseded 
these technologies mainly because RNAi requires much lower nucleic acid 
concentrations and produces more specific gene silencing (Dorsett and 
Tuschl, 2004, Kurreck, 2006, Pai et al., 2006). 
1.6.1 RNA interference 
RNAi is a relatively new technology first described in the nematode 
Caenorhabditis elegans in 1998 (Fire et al., 1998). Three years later RNAi was 
described in mammalian cells by Dr. Tuschl and colleagues (Elbashir et al., 
2001a). RNAi induces gene silencing at the post-transcriptional level by 
targeting mRNA for degradation (Hannon, 2002, Dorsett and Tuschl, 2004, 
Pai et al., 2006), through chromatin remodelling and by inhibition of protein 
translation (Pai et al., 2006).  
1.6.1.1 Mechanisms of RNA interference  
RNAi is a ubiquitous regulatory process found in all eukaryotic cells 
and is thought to be important in normal regulation of genes (Dorsett and 
Tuschl, 2004, Pai et al., 2006). When it was first described the mechanisms of 
action were still unknown, but Fire et al. (1998) reported two important 
observations. Firstly, the technique did not work if the sequence used 
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corresponded to intron or promoter regions of the gene in question. 
Secondly, they noted decreased mRNA levels following application, both 
suggesting interference at a post-transcriptional level (Fire et al., 1998). Later 
it was confirmed that siRNAs work by post transcriptional gene silencing 
(Scherer and Rossi, 2003, Dorsett and Tuschl, 2004). In plants and 
invertebrates, long double stranded RNA (dsRNA) are recognised by Dicer, 
an RNase III like endoribonucleotide, and cleaved into shorter 20-25 
nucleotides siRNAs (Kittler and Buchholz, 2003) (Figure 1.5). The siRNA 
double helix is then unwound in an ATP-dependent manner, one strand is 
incorporated into the RNA-induced silencing complex (RISC), and the 
complementary siRNA sense strand is degraded (Hannon, 2002, Scherer and 
Rossi, 2003). The antisense siRNA-RISC complex then binds to 
complementary mRNA sequences. The mRNA is either cleaved by Argonaut 
family proteins (Dorsett and Tuschl, 2004) or the complex promotes 
translational inhibition effectively blocking subsequent gene expression 
(Hannon, 2002, Dorsett and Tuschl, 2004). The siRNA may be recycled to 
interact with further mRNA molecules (Kurreck, 2006). In invertebrates and 
plants siRNA molecules can function as primers for RNA-dependent RNA 
polymerase that synthesises additional dsRNA which in turn are processed 
into siRNA (Yu et al., 2002). It is not known whether this occurs in 
mammalian cells (Yu et al., 2002). In plants, siRNA also induces genomic 
methylation, but this has not been reported in mammalian cells (Dorsett and 
Tuschl, 2004). The net effect of the siRNA is a reduction in specific mRNA 
levels and the protein it encodes, inducing gene silencing (Scherer and Rossi, 
2003). 
Although the same mechanism exists in mammalian cells, initially it 
proved difficult to induce gene silencing experimentally due to apparent 
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non-selective cell death in response to long dsRNA (Dorsett and Tuschl, 
2004). It has subsequently been established that dsRNA over 30 nucleotides 
in length trigger a strong interferon response in mammalian cells (Elbashir et 
al., 2001a). The interferon response activates Protein Kinase R (PKR) 
autophosphorylation and subsequent activation. PKR inhibits cell growth by 
phosphorylation of the essential protein-synthesis initiation factor eIF-2 and 
will often result in cell death (Williams, 1999, Yang et al., 2002). When 
dsRNA molecules of less than 30 nucleotides were used, gene silencing was 
achieved effectively without the concurrent non-selective interferon response 




Figure 1.5: Schematic diagram to show the RNA interference pathway. Long dsRNA 
molecules are recognised and processed into shorter siRNAs by Dicer, and the antisense 
strand is then incorporated into RISC. The antisense siRNA-RISC complex binds 
complementary mRNA sequences, facilitating cleavage of the mRNA by Argonaut family 
proteins or the complex promotes translational inhibition effectively blocking subsequent 
gene expression.The siRNA may be recycled to interact with further mRNA molecules 




1.6.1.2 Synthesis of siRNA 
The siRNA molecules used in mammalian cells usually consist of two 
complementary annealed single strands of 21-28 nucleotides in length with 
3’ ends containing two nucleotide overhangs with hydroxyl termini (Scherer 
and Rossi, 2003, Dorsett and Tuschl, 2004). Alternatively, the siRNA may be 
in the form of a single stem-loop of 19-27 nucleotides in the stem, often 
referred to as hairpin RNA (shRNA) (Scherer and Rossi, 2003). Both types of 
molecules become incorporated into RISC in a similar manner.  
Identifying an optimal target sequence is a crucial step in RNAi. 
Different siRNAs targeting different parts of the target mRNA sequence 
have sometimes vast differences in their silencing efficiency (Kurreck, 2006). 
So far it has not been possible to predict the optimal siRNA sequence for a 
target, so multiple siRNAs will usually have to be screened for their 
efficiency (Kittler and Buchholz, 2003). However, three factors have been 
identified that aid in the design of efficient siRNA (Kurreck, 2006). As 
discussed previously, low thermodynamic stability of the antisense strand 5’ 
end helps to preferentially incorporate the antisense strand into the RISC 
complex (Dorsett and Tuschl, 2004, Patzel et al., 2005, Kurreck, 2006). 
Secondly, the accessibility of the target site on the mRNA influences 
silencing efficiency. Some mRNA molecules have a very tight secondary 
structure leading to the inability of the RISC-siRNA complex to interact with 
its mRNA target site (Patzel et al., 2005, Kurreck, 2006). The third suggested 
factor is the potential for the siRNA antisense strand to form secondary 
structures (Patzel et al., 2005). It was found that antisense strands with base–
paired termini were inactive, even when the first two criteria were fulfilled 
(Patzel et al., 2005, Kurreck, 2006). Active structures were comprised of free 
terminal nucleotides especially at the 3’end (Patzel et al., 2005). 
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Several methods have been used to produce siRNAs, each of which has 
its drawbacks (Kittler and Buchholz, 2003). The first publications used 
chemically synthesised RNA, and this method is still one of the most 
commonly used techniques (Elbashir et al., 2001a, Kittler and Buchholz, 
2003). The main advantages of this technique are that large quantities can be 
made and base modifications are possible. They are, however, expensive to 
produce and require screening for an effective molecule (Kittler and 
Buchholz, 2003). In vitro transcription of siRNA and shRNA is cheaper, but 
screening of molecules is still required (Yu et al., 2002, Kittler and Buchholz, 
2003).  
SiRNA can also be produced in cells by transfection of an expression 
vector containing the hairpin sequence and a promoter (Yu et al., 2002, 
Kittler and Buchholz, 2003). This approach was found to be highly effective 
in gene silencing, but again the molecules require screening (Yu et al., 2002). 
Finally, a method of producing siRNA by enzymatic digestion of long 
dsRNA by Escherichia coli RNase III has been described (Yang et al., 2002). 
This technique produces several endoribonuclease-prepared siRNA 
(esiRNA) molecules with complementary sequences to the target mRNA, 
removing the need for screening (Yang et al., 2002, Kittler and Buchholz, 
2003).  
Despite these recent advances both in the design and the synthesis of 
siRNA, the potency of individual siRNA molecules can still not be accurately 
predicted. Additional research is required in this rapidly moving area. 
1.6.1.3 Applications for RNA interference 
RNAi is a powerful research tool as it is capable of specific gene 
silencing, and is extensively used in gene function analysis and genetic 
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screening (Kittler and Buchholz, 2003, Dorsett and Tuschl, 2004). Long term 
RNAi has been predicted to contribute extensively in drug development 
(Scherer and Rossi, 2003, Dorsett and Tuschl, 2004, Pai et al., 2006). Recently 
the first phase one trial using RNAi based systemically administered 
therapeutics was reported (Davis et al., 2010), marking another milestone in 
RNAi development. 
The main challenges for the effective application of these technologies 
include overcoming problems with delivery, stability in tissues, 
minimisation of off-target effects and identification of effective siRNAs 
(Kittler and Buchholz, 2003, Scherer and Rossi, 2003, Dorsett and Tuschl, 
2004, Pai et al., 2006). 
Their stability in tissues may be overcome by chemical modifications 
rendering them more resistant to RNases (Dorsett and Tuschl, 2004, Pai et al., 
2006). One potential way of making them more stable and aiding their 
delivery into tissues would be to link them to antibodies targeted towards 
cell surface receptors (Pai et al., 2006). This could be a feasible approach for 
targeting tumour cells in HNSCC known to overexpress EGFR.  
A second approach used for delivery is using viral vector delivery 
systems. Viral vectors that have been used to date include retroviral, 
lentiviral, adenoviral and adeno-associated viral vectors (Pai et al., 2006).  
Major drawbacks of the viral vectors are lack of specificity, low efficiency of 
gene delivery as well as potential concerns regarding safety of the use of the 
vectors themselves (Pai et al., 2006).  
Off target interference is a concern when developing therapeutics. 
Although siRNA are very specific in their effect, if they are not carefully 
selected they could be partially complementary to unintended targets (Pai et 
al., 2006). This off target effect increases with higher concentrations, so 
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highly specific siRNAs used at low concentrations should hopefully 
circumvent any potential side effects (Scherer and Rossi, 2003, Dorsett and 
Tuschl, 2004). 
There are many challenges ahead before siRNA molecules can achieve 
their full potential as therapeutics. It is however, a rapidly moving field and 
hopefully these obstacles can be overcome, paving the way for a new 
generation of therapeutics. 
1.7 Aims of PhD thesis 
The aims of this study were to investigate the role of EGFR in feline 
oral SCCs and its potential as a therapeutic target. The first part of the study 
was an immunohistochemical study of EGFR expression in 67 feline oral 
SCC biopsy samples. In addition, these biopsy samples were labelled for 
Ki67, a proliferation marker, and their potentials as prognostic indicators 
were assessed. 
The aim of the second part of the study was to clone the tyrosine kinase 
domain of the feline Egfr, and using this sequence as a basis, to design and 
construct siRNAs against the receptor. These siRNAs were screened using a 
vector based screening system and the most efficient siRNA was then 
selected for further knockdown studies in a feline SCC cell line.  
The effective knockdown of feline Egfr in the cell line was verified by 
Real-Time PCR and western blot analysis. The siRNA sequence was also 
cloned into a hairpin expression vector system to investigate the effect of 
long term Egfr knockdown on the cell line. In parallel, treatment of the cell 
line with gefitinib, an EGFR specific tyrosine kinase inhibitor was evaluated. 
The effect of EGFR targeting on cell proliferation, migration and colony 
formation ability was determined.  
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A gefitinib resistant sub-line of the cell line was developed by long term 
treatment with sub lethal drug concentrations, and the effect of Egfr 
knockdown in the drug-resistant cell line was assessed. In addition, the effect 
of Egfr knockdown in combination with radiotherapy was investigated in the 
cell line. 
The last part of the study investigated potential mechanisms of 
resistance to EGFR targeting therapies and conventional treatments, focusing 
on two potential mechanisms of resistance: cells undergoing an epithelial to 
mesenchymal transition and the presence of a putative cancer stem cell 
population within the cell line. The thesis is divided into an introduction 
with a review of the literature, a comprehensive materials and methods 
section and four individual result chapters with separate introductions, 
methods and discussions. In the final discussion chapter, the findings from 
the study are brought together and critically appraised and future areas of 




Materials and methods 
2 Materials and methods 
2.1 Miscellaneous 
The microscope used for all fluorescence and phase contrast images 
was a Zeiss Axiovert40 CFL (Carl Zeiss Ltd., UK) microscope fitted with 
digital Axiocam monochrome or colour cameras respectively (Carl Zeiss 
Ltd.). Carl Zeiss Imaging systems Axiovision Software (Release 4.27.2) was 
used for image capture and image processing. 
2.2 Immunohistochemistry 
Biopsy samples were routinely fixed, processed and embedded in 
paraffin wax before being cut, mounted onto slides and stained. In short, the 
principle of tissue processing for histology follows five stages. Biological 
tissues are fixed by forming irreversible cross linking of amino acid groups, 
for example formaldehyde causes the formation of methylene linkage of 
proteins. Following preservation, all water has to be removed from the 
tissues. This is achieved through several dehydration steps where the tissues 
are transferred through progressively more concentrated ethanol baths to 
remove all water from the tissues. The next step is then to clear the alcohol 
from the tissues using a hydrophobic clearing agent (e.g. xylene). Following 
clearing, the samples are infiltrated with the embedding material; in most 
cases paraffin wax is used. The samples are then placed into moulds for 
external embedding in liquid embedding material and allowed to harden by 
cooling in the case of paraffin wax.  
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2.2.1 Tissue processing 
Biopsy samples were fixed by immersion in 10% neutral buffered 
formalin for 48 hours before being processed. The samples were processed 
using an automated processor (Pathcentre, Thermo Fischer Scientific, UK) by 
dehydration in alcohol, clearing of alcohol with xylene and infiltration by 
immersion in liquid paraffin wax using the schedule described in Table 2.1. 
At the end of the processing programme, samples were placed in moulds 
filled with liquid paraffin at 60°C and allowed to set for a minimum of 24 
hours before being cut and mounted onto slides (Superfrost Plus, Thermo 
Fisher Scientific). 
Table 2.1: Overview of tissue sample processing schedule used at the Easter Bush 
Veterinary Centre Pathology Unit.  
2.2.2 Immunohistochemical markers 
Two commercially available primary antibodies were used in the study. 
The EGFR antibody (Ab-10, clone 111.6, Thermo Fisher Scientific) had been 
previously used on feline oral squamous cell carcinomas and a range of 
normal feline tissues (Looper et al., 2006). It was further validated for use in 
the cat in this study by western blotting (Chapter 3.3.2). The antibody is a 
monoclonal antibody raised in mouse against human recombinant EGFR 
Processing Stage Agent Time  
Fixation 10% neutral buffered formalin 1 hour 
Dehydration 70% Industrial methylated spirit (IMS) 1 hour 
Dehydration 95% IMS 1 hour 
Dehydration IMS 3 x 1 hour 
Dehydration Absolute alcohol 1 hour 
Clearing 50% Absolute ethanol and 50% Xylene 1 hour 
Clearing Xylene 2 x1 hour 
Infiltration  Paraffin wax 60°C 4 x 1 hour 
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protein. It binds to the extracellular domain of the receptor specifically at the 
EGF binding site, blocking EGF binding.  
The Ki67 antibody (MIB-1, Dako UK Ltd, UK) is a mouse monoclonal 
antibody raised in mouse against human recombinant Ki67 peptide 
corresponding to a 1002 bp cDNA fragment. It recognises a 66 bp repetitive 
element in the Ki67 gene (Key et al., 1993). The antibody was known to cross-
react with the Ki67 equivalent protein in various mammals, including cow, 
dog, horse, sheep and swine according to the manufacturer. A number of 
published studies have also used the MIB-1 clone in feline tumour tissues 
(Castagnaro et al., 1998, Melzer et al., 2006, Roels et al., 2000). The same 
horseradish peroxidase (HRP) conjugated secondary antibodies (Envision 
Kit, Dako UK Ltd.) were used with both primary antibodies.  
For both antibodies, the optimum dilutions were determined by testing 
the dilution ranges recommended by the manufacturers on positive control 
tissues as indicated. For the EGFR antibody, additional optimisation of 
incubation times was performed. Incubation times ranging from 1-24 hours 
were tested, and 24 hours incubations yielded superior results. 
2.2.3 Immunohistochemical labelling 
Following formalin-fixation and paraffin wax embedding as described 
in Chapter 2.2.1, the samples were sectioned. Four micron sections were cut, 
mounted onto electrostatically charged slides (Superfrost plus, Thermo 
Fisher Scientific), dried at 60°C for 1 hour, dewaxed and rehydrated. Antigen 
retrieval was performed in 0.1M citrate buffer pH 6.0 for 15 minutes at 110°C 
(Ki67) or with Proteinase K (Dako UK Ltd.) for 3 minutes at 37°C (EGFR). 
Endogenous peroxidase was blocked using REAL Solution (Dako UK Ltd.) 
for 10 minutes at room temperature (RT). Primary antibodies were incubated 
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at 1:100 dilution for 1 hour at 37°C (Ki67) and for 24 hours at 4°C (EGFR). 
Primary antibodies were substituted for normal mouse serum as a negative 
control on representative samples from each batch. Horseradish Peroxidase 
labelled secondary antibodies (Envision Kit, Dako UK Ltd.) were added to 
the sections and incubated for 40 minutes at RT. Sections were washed 3 
times between each step with 0.5 M tris buffered saline containing 0.1% 
Tween 20 at pH 7.5. Labelling was developed using ImmPACT DAB (Vector 
Labs Ltd., UK) at RT for 10 minutes producing a brown colour in positive 
sections. All samples were counterstained with Harris’ haematoxylin prior to 
dehydrating, clearing and mounting under DPX (Sigma-Aldrich®, UK). 
Positive control tissues used included feline lymph nodes for the Ki67 
antibody and feline skin tissue for EGFR antibody.  
2.3 Cell Tissue Culture 
2.3.1 Cell lines 
The SCCF1 cell line is a previously characterised feline cell line derived 
from a laryngeal squamous cell carcinoma gratefully received from Professor 
T.J. Rosol, College of Veterinary Medicine, The Ohio State University, USA. 
The 293FT cell line was obtained from Invitrogen, UK. It is derived 
from human embryonic kidney epithelial cells and is a commercially 
available and well-characterised cell line commonly used for transfections. 
The MDA-MB-468 cell line was obtained from MD Anderson Cancer Centre 
(USA). It is a fully characterised, commercially available human breast 
carcinoma cell line that overexpresses EGFR and was used as a positive 
control for EGFR expression within a cell line. 
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2.3.1.1 SCCF1 cell line characterisation 
The SCCF1 cell line is a previously characterised cell line (Tannehill-
Gregg et al., 2001). A brief summary of the derivation of the cell line and 
previously published findings is given here. 
 The cell line was derived from a small piece of laryngeal SCC removed 
from a recently euthanised cat with alligator forceps. The tissue was minced 
and washed in William’s E medium containing gentamicin (0.05 mg per ml) 
and amphotericin B (0.25 µg per ml). The tissue was digested with 
collagenase by incubation with agitation at 37°C for 2 hours, washed and 
plated in 10 cm plates and maintained in William’s E medium supplemented 
with 10% Foetal Bovine Serum (FBS), 0.05 mg/ml gentamicin, 2mM L-
glutamine, 10 ng/ml EGF, and 0.1 nM cholera toxin as described by 
Tannehill-Gregg et al., (2001). The medium was changed every 3-5 days and 
the cells were passaged every 7-10 days.  
A growth curve showed the cell line to reach confluence after 
approximately 10 days of logarithmic growth. It grew in an anchorage 
dependent manner showing an epithelial pattern typical of keratinocytes.  
The dominant cell morphology observed was polyhedral cells with a small 
amount of cytoplasm. Single cells formed small colonies that coalesced with 
time and exhibited limited contact inhibition with eventual layering of cells. 
A number of stellate shaped cells were also present, but these became less 
apparent as the cells reached confluence, mainly localising to the edge of the 
expanding cell colonies (Tannehill-Gregg et al., 2001). 
Immunohistochemical labelling of the cell line revealed strong 
expression of cytokeratins and no expression of p53 and vimentin at the 
earlier passages, consistent with cells of epithelial origin. Some vimentin 
labelling did start to appear in scattered cells and the number of positively 
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labelled cells increased with passage number. The authors speculated that 
there was a degree of EMT taking place in the cells, especially in response to 
TGFβ (Tannehill-Gregg et al., 2001).  
Karyotype analysis of the cell line was also compared to normal feline 
peripheral blood mononuclear cells. The SCCF1 cell line was found to be 
aneuploid with a stem line number of 34 chromosomes. Normal diploid 
feline cells have 38 chromosomes (Tannehill-Gregg et al., 2001).   
2.3.2 Cell culture reagents and equipment 
All cell culture reagents were obtained from Gibco® Invitrogen, UK 
unless otherwise specified. The SCCF1 cell line was grown in William’s E 
medium with GlutaMAX I supplemented with 10% FBS, 10 ng per ml EGF 
and 0.05 mg per ml gentamicin sulphate. For selection of SCCF1 cells having 
taken up vectors following some transfections, 0.4 mg/ml Geneticin (G418) 
was added to the medium. 
The 293FT cell line was initially grown in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% FBS, 0.1 M non-essential amino 
acids, 6 mM L-glutamine, 1 mM sodium pyruvate, 1% penicillin-
streptomycin (DMEM start up media). After 24 hours cells could be passaged 
in DMEM medium as above with added 0.5 mg/ml geneticin (G418) (DMEM 
growth medium). During transfections, cells were grown in DMEM medium 
as above without antibiotics (DMEM growth medium 2) and, immediately 
following electroporation, cells were resuspended in RPMI medium 
containing 10% FBS before being plated in DMEM growth medium 2.  
For sphere assays the cells were grown in N2 medium with 
methylcellulose prepared in house (Appendix A). All the constituents for the 
N2 medium was obtained from Sigma-Aldrich®, except the recombinant 
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human EGF and the recombinant human basic fibroblast growth factor 
(bFGF) which were obtained from Pepro Tech EC Ltd., UK. In short, the N2 
medium was prepared in a laminar hood using basic protective clothing by 
making up a two times solution of DMEM/F12 base medium with distilled 
water. To that, 1.2 g of sodium bicarbonate was added and pH was adjusted 
to 7.0 with 1M sodium hydroxide (NaOH). The solution was then 
filter-sterilised through a 0.22 µm filter, which raises the pH to 7.2. To the 2x 
base medium 20 nM progesterone, 100 µM putrescine, 30 nM sodium 
selenite, 25 µg per ml transferrin, 3.48 µM insulin, 10 ng per ml EGF and 
10 ng per ml bFGF were added. The base medium was protected from light 
and stored at 4°C. Equal amounts of 1.6% methylcellulose were prepared by 
adding 1.6 g of methylcellulose per 100 ml of distilled water. To dissolve the 
methylcellulose the water was heated to 80-100°C before adding the 
methylcellulose which was then stirred until cooled to RT. The solution was 
stirred overnight at 4°C before being autoclaved the following day. The 
solution was again cooled to 4°C before an equal volume of 2x N2 base 
medium was added and stirred at 4°C overnight. The 1x N2 medium was 
aliquoted into 100 ml sterile bottles and stored at -20°C until use. Thawed 
medium stored at 4°C were used for up to 4 weeks.  
All other media were made up freshly and stored at 2-8°C and used 
within 4 weeks. To detach cells, 0.25% (SCCF1 cell line) or 0.05% (293FT cell 
line) trypsin-EDTA was used. Cells were frozen down in freezing medium 
containing 10% dimethyl sulphoxide in FBS.   
Tissue culture plastics were obtained from Becton Dickinson-
Biosciences, UK (Falcon tubes and flow cytometer tubes), Sigma-Aldrich® 
(Corning® low adhesion tissue culture plates and pipette tips), Techno 
Plastic Products® AG, Switzerland (routine cell culture plates and flasks) 
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and Thermo-Fischer Scientific (NUNC™ white 96 well plates). Eppendorf 
tubes were supplied by Axygene from VWR, USA and freezing containers 
(Nalgene freezing container “Mr Frosty Control Freeze”) and cryogenic vials 
were obtained from Scientific Laboratory Supplies Ltd., UK and Starlab (UK) 
Ltd. respectively. Pipettes (2-1000 µl Nichipets) were obtained from 
Nichiryo, Japan and Integra, Switzerland (Pipetteboy 1-50 ml). 
2.3.3 Cells from liquid nitrogen 
The SSCF1 cell line was donated as frozen vials stored in liquid 
nitrogen at passage 52. The 293FT cell line was purchased as frozen vials 
stored in liquid nitrogen at unknown passage number. Cells were quickly 
defrosted in a 37°C water bath and by rubbing between fingers before being 
transferred into Falcon tubes containing 5 ml phosphate buffered saline 
(PBS) (Appendix B) and being centrifuged at 200 x g for 5 minutes. The 
supernatant was discarded and the cell pellets were resuspended in 8 ml of 
their respective media, transferred to T25 flasks, and incubated at 37°C/5% 
CO2 overnight.  
2.3.4 Passaging cells 
At first passage, the cell lines were transferred to T75 flasks. Cells were 
routinely passaged at 80-95% confluency every 3-4 days (293FT cell line) and 
at 95-100% confluency every 5-10 days (SCCF1 cell line).  
To passage cells, medium was removed by pipetting, and the cells were 
washed twice in 8 ml of PBS before incubation at 37°C in 0.25% 
trypsin-EDTA (Table 2.2) until detached. Trypsinization was terminated by 
adding at least twice the trypsin volume of FBS-containing media to the cells. 
Cells were split as required (1:2 to 1:20) and seeded directly into new culture 
vessels with fresh media. 
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Table 2.2: Summary of cell culture vessels used during the project and their surface area, 
total volume of media and 0.25% trypsin-EDTA. 
 
2.3.5 Determining cell density and viability  
Following trypsinization as described in 2.3.4, 100 µl of cell suspension 
were transferred to an Eppendorf tube, gently mixed with 10 µl of trypan 
blue stain, and incubated for two minutes. Ten µl of cell suspension were 
then added to the counting chamber of a haemocytometer and the cells were 
counted. Cell viability and cell density were then determined using formulas 
in Table 2.3 and cell culture vessels were seeded accordingly (Table 2.2).  
Table 2.3: Formulas used when determining cell viability and density. DF= dilution factor, # 
stands for number and 0.1 µl is the volume of the haemocytometer counting chamber. 
 
2.3.6 Sphere assay protocol 
2.3.7 Setting up spheres from adherent cells 
The SCCF1 cells were trypsinated as described in Chapter 2.3.4, and 









Volume of 0.25% 
Trypsin-EDTA 




 8 ml 2 ml 




 10-13 ml 3 ml 




 18-30 ml 3-5 ml 




 10 ml 3 ml 




 2-2.5 ml 1-2 ml 




 1 ml 0.5 ml 




 0.05-0.2 ml N/A 
DF= (Volume of cell suspension + Volume of stain)/Volume of cell suspension 
Cell density (cells per ml) = Total cell count / 0.1µl x DF x 10
4
 
Total number of cells = cells/ml x volume of cell suspension 
Cell Viability (%) = [1-(# of stained cells/total # of cells)] x 100 
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and resuspended in 1 ml PBS. Cells were then counted as described in 
Chapter 2.3.5. Six-well low adherence plates were seeded with 8-10 x106 cells 
in 2 ml of N2 media per well. Cells were incubated at 37°C/5% CO2 and fed 
with 500µg per ml of EGF and bFGF each every 48 hours until spheres 
formed.  
2.3.7.1 Passaging spheres 
To passage spheres, cells were collected by pipetting and the wells 
were washed in PBS to maximise collection. The cells were then spun down 
at 200 x g for 5 minutes and the N2 medium was discarded. Five ml of 0.25% 
trypsin-EDTA was added to the cells and incubated at RT for 10 minutes. 
Three ml of FBS-containing media were added to terminate trypsinization 
and cells were collected by centrifugation at 200 x g for 5 minutes. The cell 
pellet was resuspended in 1 ml of PBS and counted as previously described 
in Chapter 2.3.5 and a six-well low adherence plate was seeded with 8-10 
x106cells per well in 2 ml of N2 media.  
2.3.8 Cells into liquid nitrogen 
Cells were grown to near confluency and trypsinated and the total 
number of cells were determined as previously described (2.3.5). The SCCF1 
cell line was frozen down at approximately 3x106 cells in 0.5 ml of freezing 
medium (Appendix B). The cell suspension was centrifuged at 200 x g for 5 
minutes and resuspended in the appropriate volume of freezing medium, 
aliquoted into cryovials, transferred to freezing vehicle and frozen down in a 
minus 80°C freezer. Using a freezing vehicle containing 100% isopropyl 
alcohol allowed for a steady freezing rate of 1°C per minute which ensures 
successful cryopreservation of cells and decreases overall cell death. After a 
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minimum of 3 hours, cells were transferred to liquid nitrogen for long term 
storage.   
2.3.9 Gefitinib treatment of SCCF1 cell line 
Gefitinib (Astra Zeneca, UK) is an EGFR-specific small molecule 
tyrosine kinase inhibitor and was purchased from Tocris Bioscience (UK). 
Ten mg of the drug was supplied in powdered form, and was made up to a 
10 mM stock solution in DMSO and stored in 50 µl aliquots at minus 20°C.  
The SCCF1 cell line was treated with a range of concentrations from 
1 nM to 100 µM in William’s E media for up to 72 hours. Before use, the drug 
was further diluted in William’s E medium to twice the desired 
concentration, before being added to the same volume of medium in each 
well. DMSO control treated cells were treated with DMSO concentrations 
corresponding to the highest drug concentration used in the experiment. 
Untreated control cells were always also included in each experiment.  
2.3.10 Creating a gefitinib resistant SCCF1 cell line 
In order to create a gefitinib resistant SCCF1 cell line, the cells were 
passaged as described in Chapter 2.3.4 for six months in gefitinib containing 
medium. William’s E media was made up as described in Chapter 2.3.2. 
Gefitinib containing medium was made up freshly every week in 100 ml 
aliquots containing 5 µM gefitinib.  
2.3.11 Harvesting adherent cells 
To harvest, cells were washed with chilled PBS, scraped in 5 ml ice-cold 
PBS and pelleted by centrifugation at 2500 x g for 4 minutes at 4°C. 
Supernatant was discarded and cell pellets were snap frozen on dry ice and 
stored at minus 70°C.  
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2.3.12 G418 titration kill curve for SCCF1 cell line 
In order to select for cells carrying the neomycin-resistance gene 
following DNA plasmid transfections, the cells were grown in William’s E 
medium containing the antibiotic geneticin (G418), an analogue of neomycin. 
G418 is an aminoglycoside antibiotic produced from Micromonospora 
rhodorangea, and its mode of action is to block polypeptide synthesis by 
inhibiting the elongation step in both prokaryotes and eukaryotes (Haynes et 
al., 1995). The resistance gene confers resistance by encoding an 
aminoglycoside 3’ phosphotransferase enzyme (Ambion, 2008b).  To 
determine the optimal G418 concentration in the media, a titration kill curve 
was performed to determine the concentration of drug that would cause 
massive cell death in seven days.  
Cells were seeded at 2x104 cells per well in 24 well plates in 1 ml media 
containing no antibiotics and incubated overnight at 37°C/5% CO2. The 
following day, 0.5 ml of medium containing G418 at different concentrations 
was added to each well according to diagram in Figure 2.1, and then 
changed completely to G418 containing medium every 48 hours. The cells 
were checked and photographed 3 times weekly for cell death.  
2.3.13   Optimal plating density for SCCF1 cell line 
To determine the cell plating density that allowed cells to reach 80% 
confluence in selective media before undergoing massive cell death an 
optimal plating density titration was performed. Cells were plated into 24 
well plates at 1.2-6x104 cells per well and incubated at 37°C/5% CO2 in 1 ml 
William’s E medium without antibiotics. The following day one ml of 
G418-containing medium containing the optimum concentration obtained 
from the kill curve described in Chapter 2.3.12 was added to each well 
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according to Figure 2.2. This produced wells containing half the optimum 
G418-concentration determined by the kill curve, and the cells were 
incubated in this for 24 hours. The following day the medium was then 
changed to medium containing the optimum concentration of G418. The cells 
were washed in PBS and fresh G418-containing medium was added every 
48 hours until the experiment was complete. The cell confluence was noted 
and the cells photographed three times weekly until massive cell death 
occurred.  
 
Figure 2.1: 24 well plate set up for G418 titration kill curve for SCCF1 cell line 
 




2.4 Isolation and quantification of nucleic acids 
2.4.1 RNA extraction 
Total RNA was isolated from the cells utilising the RNeasy Mini Kit 
with QIAshredder (UK Qiagen Ltd.) according to the manufacturer’s Animal 
Cells Spin protocol including a DNase on-column digestion step utilising the 
RNase-free DNase Free Set (Qiagen). This commercial kit extracts RNA from 
cells utilising the spin column-based nucleic acid extraction principle.  
Cells were counted as described in Chapter 2.3.5. Up to 1x107 of cells 
were centrifuged at 300x g for 5 minutes and resuspended in 350-600 µl RLT 
lysis buffer. Alternatively, the cell monolayer was directly lysed in the 
culture vessel by adding 350-600 µl of RLT lysis buffer directly to the well. 
Samples were then mixed thoroughly by pipetting or vortexing. RLT is a 
highly denaturing buffer containing guanidine thiocyanate which inactivates 
RNases.  
The cell lysate was then passed through a QIAshredder homogeniser 
by centrifugation at full speed for 2 minutes to reduce the viscosity of the 
lysate and to shear high molecular weight genomic DNA and other cellular 
components which may reduce RNA binding to the silica-gel membrane. 
Seventy percent ethanol was then added and the lysate was transferred to 
the spin column.  
Ethanol in the presence of chaotropic salts from the RLT buffer 
promotes adsorption of RNA to the silica-gel membrane allowing selective 
binding of RNA. The spin column was spun at 8000 x g for 15 seconds and 
the flow through containing denatured protein and cellular debris was 
discarded. A further wash step in 350 µl of buffer RW1 at 8000 x g for 15 
seconds removed further contaminants.  
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To ensure no DNA contamination of RNA sample an on-column DNase 
digestion was performed with the RNase-Free DNase Set. Ten µl of stock 
DNase were added to 70 µl of RDD buffer from the kit and added to the spin 
column membrane. After 15 minutes of incubation at RT a further wash step 
with 350 µl RW1 buffer was performed.  
A further two wash steps with 500 µl RPE buffer containing 80% 
ethanol was then performed, first at 8000 x g for 15 seconds and then a 
further 2 minute centrifugation step at 8000 x g. To ensure no carryover of 
ethanol a one minute centrifugation step at full speed was performed to 
ensure the membrane dried completely. RNA was eluted in 30-50 µl of 
RNase-free water by centrifugation at 8000 x g for 1 minute.  
2.4.2 DNA plasmid purification  
Plasmid purification was performed using the QIAfilter Plasmid Maxi 
Kit from Qiagen following the manufacturer’s protocol with some 
modifications. The kit protocol is based on a modified alkaline lysis 
procedure followed by filtration. Plasmid DNA is then bound to an anion-
exchange resin under low-salt and pH conditions, and impurities are 
removed by medium-salt washes. Plasmid DNA is eluted in a high-salt 
buffer, concentrated by isopropanol precipitation, before desalted with 
ethanol, dried and dissolved in TE buffer (Appendix B).   
2.4.2.1 Transformation reaction 
The transformation reactions were performed using One Shot 
Chemically Competent E. coli (Invitrogen). Either 2 µg of plasmid or 1-3 µl of 
ligation reactions were used directly in the transformation reaction. To prove 
absence of antibiotic resistance in the competent cells, a cells only control 
reaction was always included.  
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One vial of competent cells per sample was slowly defrosted on ice. The 
plasmid or the ligation mixtures were added directly to the cells, incubated 
on ice for 30 minutes before being heat shocked at 42°C in water bath for 30 
seconds. Cells were immediately transferred to ice, 250 µl of S.O.C. media 
was added, and the vials were shaken horizontally at 225 rpm at 37°C for 1 
hour. Ten µl from each transformation reaction in 20 µl of S.O.C. media 
(growth media provided with the competent cells) were plated out on 
separate LB agar plates containing Ampicillin (imMedia™ Amp Blue 
sachets, Invitrogen, Appendix B) and incubated overnight at 37°C. Following 
incubation, plates were checked for growth and colonies were counted. 
2.4.2.2 Bacterial culture 
Single colonies were picked and used to inoculate 250 ml of sterile LB 
broth containing 100 mg/ml Ampicillin (Appendix B). The cultures were 
grown overnight at 37°C at 220 rpm in a shaking incubator.  
2.4.2.3 Bacterial lysis and DNA extraction 
Bacterial cell cultures were harvested by centrifugation at 3000 x g for 
30 minutes at 4°C. The bacterial pellet was then resuspended in 10 ml lysis 
buffer P1 containing RNase A until completely dissolved. An equal volume 
of buffer P2 containing sodium hydroxide was then added, thoroughly 
mixed, and incubated at RT for 5 minutes. The alkaline lysate was then 
neutralised by adding 10 ml of acetic acid containing chilled buffer P3. The 
cell lysate was then incubated at RT for 10 minutes in the QIAfilter cartridge 
before gently inserting the plunger and filtering the lysate directly into a 
QIAGEN-tip previously equilibrated with QBT buffer containing 
isopropanol. The cleared lysate was allowed to enter the anion exchange 
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resin by gravity flow before being washed twice in 30 ml of medium-salt 
QBC buffer. Finally, the DNA was eluted in 15 ml of high-salt QF buffer. 
2.4.2.4 Alcohol precipitation of DNA 
Alcohol precipitation (ethanol, isopropanol) is a commonly used 
technique for concentrating and de-salting nucleic acid preparations in 
aqueous solutions. The basic principle involves adding salt and alcohol to an 
aqueous solution causing the nucleic acids to precipitate. The nucleic acids 
can then be separated out by centrifugation and de-salted by ethanol washes.  
Isopropanol was added to the DNA high-salt eluate at RT and 
centrifuged at 15,000 x g for 30 minutes at 4°C. The supernatant was 
decanted, and 5 ml of 70% ethanol was added followed by a centrifugation 
step at 15,000 x g for 10 minutes. The supernatant was removed, and the 
DNA pellet was air dried for 10 minutes before redissolved in 400 µl of TE 
buffer.   
2.4.3 Quantification and quality assessment of nucleic acids 
RNA and DNA samples were quantified using the NanoDrop™ 
ND1000 (Thermo Fischer Scientific) by measuring absorbance at 230, 260 and 
280 nm (A230, A260, and A280 respectively). Purity of RNA was determined 
using the A260/A280 ratio. Only good quality RNA with a ratio of 1.9-2.1 was 
used in further applications.  
2.4.4 DNA electrophoresis 
Routine analysis of DNA was performed on 1-2% agarose gels in TAE 
buffer (Appendix B). Gels were made from electrophoresis grade agarose 
(Appendix B, Sigma-Aldrich®) melted in TAE buffer. The solution was 
allowed to cool down, and ethidium bromide (Sigma-Aldrich®, from stock 
solution of 0.5 mg per ml) was added to give a final concentration of 0.5 µg 
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per ml. After January 2009 ethidium bromide was replaced with GelRed™ 
Nucleic Acid Gel Stain (10,000 x in water, Biotium, UK). GelRed™ was 
diluted to 1x concentration in the gels. Samples were loaded with 
Blue/Orange 6x loading dye (Promega, UK) and sizes were compared to 1kb 
or 100 bp DNA ladders (Promega). TAE buffer was used as the 
electrophoresis buffer.  
2.4.5 Gel imaging and image capture 
Gels were visualised using the Dual Intensity Transilluminator (UVP 
Ltd., UK prior to January 2009) and the Molecular Imager® Gel Doc™ XR 
Imaging System (Bio-Rad, UK since January 2009) and recorded using the 
CCD digital camera with an Amber emission filter (Bio-Rad). Files were 
analysed using the Quantity One® 1-D Analysis Software (Bio-Rad) and 
stored in a jpeg or tiff format and printed using the Mitsubishi P93D thermal 
printer.  
2.5 DNA sequencing 
All sequencing was performed by The University of Edinburgh 
sequencing service (The Gene Pool, Ashworth Laboratories, King’s 
Buildings, Edinburgh). Samples were prepared in clearly labelled thin 
walled PCR strip tubes. Five µl of nuclease free water containing 
approximately 5-20 ng (PCR products) or 200-500 ng (plasmid vectors) of 
DNA together with 1 µl of primer at 3.2 pmol per µl were prepared. All 
samples were sequenced in both directions using the BigDye® Terminator 
v3.1 (Applied Biosystems, UK) sequencing reaction followed by capillary 
analysis using the ABI3730 DNA analyzer (Applied Biosystems).  
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2.6 Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR)  
The RT-PCR reactions were performed using commercially available 
kits and the optimum conditions had to be established in optimisation 
reactions.   
2.6.1 First strand cDNA synthesis 
Three commercially available first strand cDNA synthesis kits were 
used during the study according to the manufacturers’ protocols. Details of 
the different kits and the protocol used for first strand cDNA synthesis are 
given below. The cDNA synthesis reactions were used immediately for PCR 
or stored at -20°C. 
2.6.1.1 Invitrogen Cloned AMV First-Strand cDNA Synthesis Kit 
The kit contains purified cloned Avian Myeloblastosis Virus (AMV) 
Reverse Transcriptase (AMV-RT). One and a half µg of total cellular RNA, 
0.5 mM dNTP mix and 2.5 µM of oligoT in diethyl pyrocarbonate (DEPC) 
water was denatured at 65°C for 5 minutes and then placed on ice. The first 
strand synthesis reaction was performed in a reaction mix containing the 
denatured nucleotides and RNA, 15 U of AMV-RT, 50 mM dithiothreitol 
(DTT), 40 U RNase OUT™, and DEPC water to a total volume of 20 µl in the 
manufacturer’s buffer. The reaction mixture was incubated at 50°C for 50 
minutes and terminated by a 5 minute incubation step at 85°C in the Bio-Rad 
iCycler thermal cycler.  
2.6.1.2 Qiagen Omniscript® Reverse Transcriptase Kit  
The Omniscript Reverse Transcriptase (O-RT) enzyme, unlike the 
AMV-RT, is not derived from a RNA-containing retrovirus but is derived 
from a different, unnamed source (Qiagen Omniscript® Reverse 
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Transcription Handbook). An aliquot of 2 µg of total cellular RNA in RNase 
free water was heat denatured at 65°C for 5 minutes and quenched on ice. A 
master mix was prepared on ice consisting of 0.5 µM of each dNTP, 1 µM 
oligoT primers (Invitrogen), 10 U of rRNasin® RNase inhibitor (Promega), 
RNase free water, and 4 U of O-RT in the manufacturer’s buffer and then 
aliquoted into PCR tubes (Bio-Rad) containing the denatured RNA. The 
solution was then incubated at 37°C for 1 hour using the Bio-Rad iCycler 
thermal cycler.  
2.6.1.3 Roche Transcriptor High Fidelity cDNA Synthesis Kit 
The Roche Transcriptor High Fidelity cDNA Synthesis Kit was used to 
produce cDNA for downstream Real-Time PCR applications. It contains a 
blend of a recombinant reverse transcriptase (rRT) and an enzyme conferring 
proofreading activity for high accuracy RNA transcription (Roche 
handbook). 
Template-primer mixes were prepared on ice by adding 1 µg total 
cellular RNA and random hexamers to a final concentration of 60 µM into 
PCR-grade water and denaturing at 65°C for 10 minutes in the iCycler 
thermal cycler (Bio-Rad) before being quenched on ice. A master mix 
containing 20 U of Protector RNase Inhibitor, 1 mM of each dNTP, 5 mM of 
DTT and 10 U of rRT in manufacturer’s buffer was aliquoted into the 
template-primer mixes and incubated at 50°C for 30 minutes. The enzyme 
was inactivated by an incubation step at 85°C for 5 minutes. The cDNA 
synthesis reactions were diluted 1:10 for use in subsequent Real-Time PCR 
reactions or stored at minus 20°C.  
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2.6.2 Polymerase Chain Reactions (PCR) 
PCR reactions were set up using two commercially available PCR kits. 
To ensure consistency all experiments were performed on the same thermal 
cycler (iCycler, Bio-Rad) using the optimised conditions for the respective 
primers. To assess consistency of sample loading and PCR conditions 
between separate experiments, primers that amplified cDNA of transcripts 
from the ubiquitously expressed housekeeping gene feline β-actin or feline 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were included in 
separate reactions. The thermal conditions used with both kits are 
summarised in Table 2.4. 
Table 2.4: Summary of PCR reaction cycling conditions used with the two commercial kits.  
 
2.6.2.1 Primer design 
All DNA oligonucleotides were purchased from Eurofins MWG 
Operon (eurofinsdna.com). As the feline Egfr sequence has not been 
published, three intron spanning primer sets were designed to span the 
putative tyrosine kinase region of the feline Egfr gene using areas with a high 
degree of homology between the human, murine and canine published 
PCR Kits GoTaq® PCR Core Systems 
(Promega) 
HotStarTaq® DNA polymerase 
kit (Qiagen) 
Cycle stage # of 
cycles 




Temp °C Time 
(minutes) 






Annealing 59 1 52-62 1 
Extension 72 1 72 1 
Final extension 1 72 5 1 72 10 
Holding step 1 4 ∞ 1 4 ∞ 
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sequences (NCBI, 2010c) and predicted feline sequences (EMBL-EBI, 2010b) 
(Table 2.5).  
The feline housekeeping genes GAPDH and β-actin were designed 
from published sequences (accession numbers AB038241 and AB051104 
respectively (NCBI, 2010c)). To produce intron spanning primers (GAPDH 
only) the published sequence was aligned with the predicted sequence 
(EMBL-EBI, 2010b) using needle alignment tool (EMBL-EBI, 2010a) (Table 
2.5). Primers were designed using the online PCR primer design tool on 
eurofinsdna.com.  
2.6.2.2 GoTaq® PCR Core Systems (Promega) 
Each reaction contained primers at a final concentration of 0.5 µM each, 
dNTP at 0.2 mM each, MgCl at 1.5 mM, 1.25 U of a proprietary formulation 
of Taq DNA polymerase (GoTaq® DNA Polymerase) and nuclease free water 
(Qiagen) in manufacturer’s buffer. Master mixes were prepared on ice and 
aliquoted into thin walled PCR tubes (Bio-Rad) with 2 µl of cDNA synthesis 
reaction described in Chapter 2.6.1.1 as template in 50 µl reaction volumes.  
2.6.2.3 HotStarTaq® DNA polymerase kit (Qiagen) 
Each reaction contained primers at a final concentration of 0.25 µM 
each, dNTP at 0.2 mM each, MgCl2 at 1.5 mM, 1.25 U of modified 
recombinant DNA polymerase originated from Thermus aquaticus 
(HotStarTaq® DNA polymerase) and nuclease free water in manufacturer’s 
buffer. Master mixes were prepared on ice and aliquoted into PCR tubes 
with 3 µl cDNA synthesis reaction described in Chapter 2.6.1.2 as template in 




Table 2.5: Primer sequences for feline cells. EGFR primers were constructed using the 
tyrosine kinase region of human, murine, and canine EGFR sequences. The tyrosine kinase 
region has the greatest sequence homology between species. The control primers were 
produced from published and predicted feline sequences.  
 
2.7 Vector Cloning Experiments 
Vectors psiCHECK™-2 (Promega) and pSilencer™ neo Kit (Ambion, 
UK) were used in the experiments (Figure 2.3). The psiCHECK-2 vector 
system is designed to optimise RNA interference experiments by the rapid 







Forward - GAATATCACCTGCACAGGAC 





Forward - GGAGAAGCTCCCAACCAGGCT 





Forward Xho1 TTACTCGAGGGAGAAGCTCCCAACCAGGCT 





Forward - TGCGAAGGGCATGAACTAC 




Forward  AGCTGCCAAATACGATGAC 




Forward  GATTGTCAGCAATGCCTCC 




Forward  GATTGTCAGCAATGCCTCC 




Forward  GCACCACACCTTCTACAAC 




Forward  TTCGAGACCTTCAACACCCC 




Forward  GCACCACACCTTCTACAAC 




Forward  TTCGAGACCTTCAACACCCC 
Reverse  ATGCCACAGGACTCCATAC 
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and quantitative screening of small interfering RNAs (siRNAs). The 
pSilencer™ neo Kit is a hairpin expression vector system capable of 
generating short hairpin RNA (shRNA) transcripts that can induce long term 
gene silencing in cells.  
 
Figure 2.3 a) Vector map of psiCHECK™-2 vector (from Promega TB 329) and b) 
pSilencer™ 3.1-H1 neo (from pSilencer™ handbook, Ambion) showing antibiotic resistance 
genes, promoters and multiple cloning regions present. 
 
2.7.1 Gel and PCR product clean up 
Prior to cloning, DNA from PCR reactions and DNA plasmids were 
purified using Wizard® SV Gel and PCR Clean-Up System (Promega) 
according to manufacturer’s protocol. The kit is based on the principle of 
selective DNA binding to a silica membrane in the presence of chaotropic 
salts. During subsequent wash steps the salt is removed with ethanol and the 
DNA is eluted under low salt conditions in nuclease free water. 
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An aliquot of the PCR product was assessed by gel electrophoresis as 
described in Chapter 2.4.4 to verify minimal primer-dimer formation and 
that only a single product of expected size was present. The remaining PCR 
products were then purified directly. Alternatively, following restriction 
enzyme digestion, the PCR products and plasmid DNA were separated by 
gel electrophoresis and visualised as previously described in Chapters 2.4.4 
and 2.4.5, and the band excised using a scalpel blade. The gel slices were 
then weighed and Membrane Binding Solution (MBS) was added at a ratio of 
10 µl of solution per 10 mg of gel slice. The gel slices were dissolved by 
incubating them in a heat block at 65°C. For direct purification of PCR 
products, an equal volume of MBS was added to the PCR reaction.  
The volumes were transferred to SV Minicolumns and incubated for 1 
minute at RT before centrifugation at 10,000 x g for 1 minute. The column 
was washed with Membrane Wash Solution in two subsequent wash steps 
and spun at 10,000 x g for 1 minute and 5 minutes respectively. The column 
was centrifuged again for 1 minute with the lid off to allow evaporation of 
ethanol. DNA was eluted by incubation of 50 µl of nuclease free water on the 
column membrane for 1 minute before centrifugation at 10,000 x g for 1 
minute to draw down the DNA. DNA quantity and quality were assessed as 
described in Chapter 2.4.3. 
2.7.2 Restriction enzyme digestion  
The psiCHECK™-2 vector and the PCR product were digested using 
XhoI and NotI restriction enzymes (Promega) in separate reactions. One µg 
aliquots of vector or PCR product were digested by 5 U of each restriction 
enzyme in manufacturer’s buffer D containing 0.1 µg per µl acetylated 
bovine serum albumin (BSA) for 2 hours in a 37°C water bath. Acetylated 
BSA provides additional protein to the reaction which stabilises the enzymes 
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and counteracts any negative effects arising as a result of enzyme interaction 
with solid surfaces and/or the air-liquid interface (Williams et al., 1996). The 
entire reaction volumes were run on a 1.2 % agarose gel for gel purification 
as described in Chapter 2.7.1. 
2.7.3 Ligation  
Gel purified PCR reactions (psi-CHECK™-2 vector) or annealed DNA 
oligonucleotides (pSilencer™ neo Kit, Chapter 5) were ligated into their 
respective vectors using T4 DNA ligase (Bioline, UK) following the 
manufacturer’s protocol. Inserts and vectors were quantified as described in 
Chapter 2.4.3 and used in the ligation reaction at a ratio of 3:1 (psi-
CHECK™-2 vector) or 5:1 (pSilencer™ neo Kit). The ratios were calculated 
using the formula in Table 2.6. Control reactions included no insert and no 
enzyme controls. Vectors and inserts were incubated at 4°C overnight in 
manufacturer’s buffer solution containing 1 mM ATP, 66 mM Tris-HCl (pH 
7.6), 5 mM MgCl2, 10 mM DTT, and 10 U of T4 DNA ligase. The ligation 
reactions were then used directly in One Shot Chemically Competent E.coli 
(Invitrogen) transformation reactions and plated out overnight. Colonies 
were selected the next day and expanded overnight before performing 
plasmid purification as previously described in Chapter 2.4.2. A restriction 
enzyme digest of the purified plasmids was then performed as described in 
Chapter 2.7.2 and the presence of inserts was then confirmed by gel 
electrophoresis as described in Chapter 2.4.4. In addition, each clone was 
then sequenced as described in Chapter 2.5 to ensure only plasmids 




Table 2.6: Formula used to determine the insert to vector ratio for ligation reactions. 
 
2.8 RNA interference  
2.8.1 Small interfering RNA (siRNA) design 
Potential siRNA sequences against the feline Egfr were designed using 
a combination of online design tools including the siRNA finder (Ambion, 
2008b), the siRNA design tool (MWG, 2008) and the siRNA selection server 
at (Yuan et al., 2004). Potential 21 nucleotide sequences that began with an 
adenine dinucleotide (AA) were recorded (Elbashir et al., 2001a). Any 
sequences with four or more guanine or cytosine nucleotides in a row or 
with more than 60% or less than 30% GC content were removed (Reynolds et 
al., 2004). Lastly, BLAST searches against the feline whole genome shotgun 
sequence and nucleotide collection were performed (NCBI, 2010a). Any 
sequences with more than 17 contiguous base pairs of homology to other 
coding sequences were eliminated. Control siRNAs were also designed. A 
negative control was produced by scrambling target sequences siRNA3. The 
sequence was then checked against the feline genome shotgun sequence 
(NCBI, 2010a) for lack of homology. Positive control sequences against 
Renilla Luciferase included a published sequence (Betz, 2005) as well as a 
newly designed sequence. The chosen sequences were the constructed and 
screened for efficiency (Table 2.7). 
 
Amount of vector (ng)     =     Amount of insert (ng) 





Table 2.7: Overview of the siRNA sequences designed against the feline Egfr, Renilla and 
the scrambled control sequence used in the screening process.  
 
2.8.2 Construction of siRNA sequences 
All siRNAs were constructed using Silencer® siRNA Construction Kit 
(Ambion) using DNA oligonucleotide templates purchased from Eurofins 
MWG Operon (eurofinsdna.com). DNA oligonucleotide templates were 
designed by adding the T7 Promoter primer sequence 5’ CCTGTCTC 3’ to 
the 3’ end of both the sense and the antisense templates producing 29-mer 
oligonucleotides. This was done manually or by using the online siRNA 
Template Design Tool for Silencer® siRNA Construction Kit (Ambion, 
2008a). The control DNA oligonucleotide templates supplied with the kit 
was used in parallel when constructing the siRNAs as an internal control of 
the efficiency of the kit.   
2.8.2.1 Transcription template preparation 
The DNA oligonucleotide templates were resuspended to a 
concentration of approximately 200 µM in nuclease free water and then 






1 UUGUGGGAUCCAGAGUCCCUU feline Egfr 52.4% 17/21 
2 UGUGGCUUCUCGAUACUCCUU feline Egfr 47.6% 15/21 
3 CGUAAGCUUCAUCAAGGAUUU feline Egfr 38.1% 16/21 
4 CUGGGAGCCAAUGUUGUCCUU feline Egfr 52.4% 16/21 
5 CUUGACAUGCUGUGGCGUCUU feline Egfr 52.4% 16/21 
6 AAGCUAGAAUUAUCGGCUCUU scrambled 38.1% 15/21 
7 GUUGAUGAAGGAGUCCAGCAC Renilla 1 52.4% 15/21 
8 AGUUCAUCAAGGAUUUCCUU feline Egfr 38.1% 17/21 
9 GUUGAUGAAGGAGUCCAGCCC Renilla 2 57.1% 15/21 
10 CUUCUCGGAAUCAUAGUAGCC Renilla 3 47.6% 15/21 
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quantified as described in Chapter 2.4.3. Each DNA oligonucleotide template 
was then diluted to 100 µM and 2 µl aliquots were hybridised in separate 
reactions with 2 µl T7 Promoter primer supplied with the kit in 
manufacturer’s DNA hybridisation buffer at 70°C for 5 minutes. This step 
anneals the eight nucleotide leader sequence added to the DNA 
oligonucleotide template with the T7 Promoter primer which contains a 
promoter sequence for the T7 RNA polymerase used subsequently to 
produce the RNA (Figure 2.4). In the next step dNTP, manufacturer’s 
reaction buffer and nuclease free water were added to each hybridisation 
reaction and incubated at 37°C for 30 minutes. This step allows the Exo-
Klenow DNA polymerase enzyme to fill in the gaps and produce double 
stranded DNA transcription template containing 21 nucleotides encoding the 
siRNA sequence and the full length T7 promoter site separated by an eight 
nucleotide leader sequence.  
2.8.2.2 Double stranded RNA synthesis 
To synthesise double stranded RNA, the DNA templates were first 
transcribed in separate reactions to eliminate any potential competition 
between templates for transcription reagents that might limit the synthesis of 
one of the two strands (Figure 2.4). Two µl of sense or antisense template 
was mixed with NTPs, T7 RNA Polymerase enzyme and nuclease free water 
in manufacturer’s reaction buffer and incubated at 37°C for 2 hours. The 
antisense and sense siRNA template reactions were then mixed and 





Figure 2.4: Schematic diagram showing the siRNA construction steps using the Silencer® 
siRNA Construction Kit (Ambion). 
 
2.8.2.3 Purification of siRNA 
Double stranded RNA (dsRNA) 5’ overhanging leader sequences 
produced by the in vitro transcription were removed in a digestion step 
using RNase which cleaves single stranded guanine residues (Figure 2.4). In 
the same step, DNase digestion eliminates remaining DNA templates. Three 
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µl of RNase and 2.5 µl of DNase were diluted in 48.5 µl of nuclease free 
water and added to the dsRNA together with manufacturer’s digestion 
buffer and incubated for 2 hours at 37°C.  
The dsRNA was then column purified by adding 400 µl of siRNA 
binding buffer containing ethanol and incubated for 5 minutes at RT. Filter 
cartridges were pre-wet with 100 µl of Binding buffer, the dsRNA solutions 
were transferred to the cartridge, and centrifuged at 4,500 x g for 1 minute. 
The column was washed twice in 500 µl siRNA Wash Buffer by 
centrifugation at 4,500 x g for 1 minute. The RNA was then eluted by adding 
100 µl of nuclease free water pre-heated to 75°C to the cartridge filter and 
incubated at RT for 2 minutes before being centrifuged at 6,500 x g for 
2 minutes. The purified siRNA was quantified as described in Chapter 2.4.3 
and stored in aliquots at minus 20°C. 
2.9 Transfections 
The 293FT and SCCF1 cell lines were transfected using electroporation 
and liposome-mediated transfections respectively. All transfection reactions 
were optimised for the cell lines to achieve maximum knockdown while 
maintaining high cell viability and transfection efficiencies. 
2.9.1 Electroporation optimisation 
Transfections by electroporation were performed using the 
Nucleofector® 96-well shuttle (Amaxa, Lonza, Switzerland) and Cell Line 96-
well Nucleofector® Solution SF Kit (Amaxa). The protocol was optimised for 
cell numbers, DNA plasmid and siRNA concentrations as well as for 
different programs on the Nucleofector® 96-well shuttle using negative 
scrambled and positive Renilla control siRNAs. Transfection efficiency and 
cell viability were determined by flow cytometry (Chapter 2.10) using green 
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fluorescent protein (GFP) expressing vector pmaxGFP™ (Amaxa) and 
propidium iodide (PI, Sigma-Aldrich®).  
2.9.2 Electroporation protocol 
Recently passaged 293FT cells were trypsinized and counted as 
previously described (2.3.4 and 2.3.5) and a total of 7.6x106 cells were spun 
down at 90 x g for 10 minutes. The supernatant was discarded and the cell 
pellet was resuspended in 760 µl of Nucleofector™ Solution SF. Five 
hundred µl of the SF solution were added to 25 µl of psiCHECK™-2.EGFR at 
a concentration of 1 µg/µl to produce master mix A (Table 2.8). The 
remaining cell suspension was used as master mix B. The Nucleocuvette™ 
96 well plate was prepared by adding the required amount of each substrate 
to the corresponding wells according to Figure 2.5. Twenty µl of master mix 
A or B was then added to the wells according to Table 2.8. The 
Nucleocuvette™ 96 well plate was electroporated in the Nucleofector® 96 
well shuttle using program DS-150. Immediately after electroporation the 
cells were resuspended in 80 µl of RPMI media pre-warmed to 37°C. 
Twenty-five µl of each samples were seeded in triplicate into an opaque 96 
well plate containing 175 µl of DMEM growth 2 media per well. The entire 
volume of the pmaxGFP™ transfected samples were used to seed wells of a 
24 well plate and grown for 24 hours before being analysed by flow 
cytometry as described in Chapter 2.10 to determine cell viability and 
transfection efficiency.  
The pGL3 basic vector (Promega, UK) contains a Firefly luciferase gene, 
and it was used to monitor the performance of the Dual-Glo™ Stop & Glo® 
reagent in quenching the Firefly reaction. The ‘no program’ control was used 
as a cells only control to allow for background subtraction from all 
luminescence readings. Two siRNA controls were used, one targeting the 
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Renilla part of the mRNA constructs (positive control siRNA10), and one 
scrambled control sequence (negative control siRNA6) made up by 
scrambling sequence siRNA3. To determine the effect of the scrambled 
control siRNA, a vector only transfection was performed. The effect on the 
scrambled control on the luciferase readings could then be compared to the 
vector only control to investigate if the scrambled control caused any 
reduction in luciferase readings. 
Table 2.8: Overview of the setup of the siRNA screening process using the psiCHECK-2 
vector system (Promega) and the 
Nucleofector® 96 well shuttle 
(Amaxa). 
Figure 2.5: Schematic diagram to 
show setup of the siRNA screening 
process. 
Column DNA siRNA Cell # Program siRNA target 
1 psiCHECK™-2.EGFR siRNA1 2x10
5
 DS-150 feline Egfr 
2 psiCHECK™-2.EGFR siRNA2 2x10
5
 DS-150 feline Egfr 
3 psiCHECK™-2.EGFR siRNA3 2x10
5
 DS-150 feline Egfr 
4 psiCHECK™-2.EGFR siRNA4 2x10
5
 DS-150 feline Egfr 
5 psiCHECK™-2.EGFR siRNA5 2x10
5
 DS-150 feline Egfr 
6 psiCHECK™-2.EGFR siRNA6 2x10
5
 DS-150 scrambled 
7 psiCHECK™-2.EGFR siRNA8 2x10
5
 DS-150 feline Egfr 
8 psiCHECK™-2.EGFR siRNA10 2x10
5
 DS-150 Renilla 
9 pmaxGFP™ - 2x10
5
 DS-150 n/a 
10 pGL3 plasmid - 2x10
5
 DS-150 n/a 
11 psiCHECK™-2.EGFR - 2x10
5
 DS-150 No siRNA control 
12 psiCHECK™-2.EGFR - 2x10
5
  No program control 
Master mix A 




Add 25 µl of psiCHECK™-2.EGFR vector 
@ 1µg/µl to produce 1 µg DNA plasmid per 
well. 
Add 20 µl to wells A,B&C 1-8 containing the 
respective siRNA according to diagram 
Master mix B 




Add 20 µl to wells A,B&C 9-12 containing 




2.9.3 Liposome-mediated transient transfections  
2.9.3.1 Naked siRNA transient transfection optimisation 
The SCCF1 cell line was optimised for naked siRNA transfections using 
Silencer® FAM™-Labeled Negative Control #1 siRNA (Ambion), and 
transfection efficiency was determined by fluorescence microscopy and flow 
cytometry as described in Chapter 2.10. Transfections were performed in 
triplicate in a 24 well format at three different confluences (30, 50 and 80%), 
three different siRNA concentrations (20, 50 and 100 nM), and with two 
different amounts of Lipofectamine 2000™ reagent (Invitrogen) (1.0 and 1.5 
µl per well in 24 well plate) and assessed by fluorescence microscopy using 
the FAM/FITC filters on a Zeiss Axiovert40 CFL microscope.  
To further assess transfection efficiency and cell viability by flow 
cytometry the transfections were repeated in a six well format with 50nM 
and 100nM of siRNA and 7.5 µl of Lipofectamine 2000™ reagent on cells 
grown to 30% confluence.  
2.9.3.2 Naked siRNA transient transfection protocol 
The SCCF1 cell line was cultivated, trypsinized, and counted as 
previously described (2.3.4, 2.3.5) and seeded into culture vessels in 
William’s E medium without antibiotics to achieve 30% confluence the 
following day.  
Lipofectamine 2000™ was diluted in OptiMEM® I Reduced-Serum 
medium and incubated at RT for 5 to 25 minutes and the required amounts 
of RNA were similarly diluted in OptiMEM® I Reduced-Serum medium to 
achieve an end concentration of 50 nM RNA in the wells (Table 2.9). The 
solutions were mixed and incubated for 20 minutes at RT to allow RNA-
Lipofectamine 2000™ complexes to form. The complexes were then added 
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dropwise to the wells and the plates were incubated at 37°C/5%CO2 for 72 
hours. The medium was changed to William’s E medium with antibiotics 
6 hours following transfection, and the cells were analysed at 24, 48, and 72 
hours following transfection. 
Table 2.9: Naked siRNA transfections using Lipofectamine 2000™ setup. 
 
2.9.3.3 DNA plasmid transfections optimisation 
The SCCF1 cell line was optimised for two transfection agents 
following the manufacturer’s protocol for Lipofectamine 2000™ and 
siPORT™ XP-1 (Ambion) and their transfection efficiencies were compared. 
The GFP expressing plasmid pmaxGFP™ (Amaxa) was used for the 
optimisations, and assessed by fluorescence microscopy and flow cytometry 
as described in Chapter 2.10.  
To compare transfection reagents, SCCF1 cells were seeded to achieve 
between 30 to 60% and >90% confluency the next day for siPORT™ XP-1 and 
Lipofectamine 2000™ transfections respectively. The transfections were 
performed at four different ratios for both reagents (Table 2.10) following the 
manufacturers’ protocols. In brief, DNA and transfection agents were diluted 
in OptiMEM® I Reduced-Serum media before mixed and incubated for 20 
minutes at RT to form complexes. The complexes were then added to the 
culture wells dropwise, and the plates were incubated at 37°C/5%CO2 for 72 
Constituent 96 well plates 6 well plates 10 cm plates 
siRNA 50 nM 50 nM 50 nM 
Lipofectamine 2000™ 0.4 µl 7.5 µl 45 µl 
Opti MEM® I Reduced serum media 
Dilution of RNA 










End volume of media per well 100 µl 2.5 ml 13 ml 
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hours. Transfection efficiencies were compared by fluorescent microscopy 
using a FAM/FITC filter at 24, 48, and 72 hours following transfections. 
Table 2.10: Comparison of the two transfection reagents used for naked siRNA transfections 
of the SCCF1 cell line. 
 
The Lipofectamine 2000™ transfections were then further optimised by 
repeating the transfections with pmaxGFP™ plasmid DNA: Lipofectamine 
2000™ ratios of 1:4 and 1:5 in 96 and 6 well plates. The cells were assessed 
after 48 hours by flow cytometry for transfection efficiency as described in 
Chapter 2.10 and for cell viability using CellTiter-Glo® Luminescent Cell 
Viability Assay as described in Chapter 2.11.2.  
2.9.3.4 Plasmid DNA stable transfection protocol  
The SCCF1 cell line was cultivated, trypsinized and counted as 
described in Chapter 2.3 and seeded into 6 well plates in William’s E 
medium without antibiotics to achieve >90% confluence the following day. 
Each transfection was performed in triplicate and the transfections were 
performed at a ratio of 1:5 DNA: Lipofectamine 2000™. In brief, 20 µl of 
Lipofectamine 2000™ was diluted in 250 µl OptiMEM® I Reduced-Serum 
medium per sample and incubated at RT for 5 to 25 minutes. Similarly, 4 µg 
of DNA was diluted in 250 µl of OptiMEM® I Reduced-Serum medium for 
Transfection agent 
siPORT™ XP-1 Lipofectamine 2000™ 
Ideal confluence to reach for cells at 
transfection: 30-60 % 
Ideal confluence to reach for cells at 
transfection: >90 % 
Ratio Reagent (µl) DNA (µg) Ratio Reagent (µl) DNA (µg) 
2:1 0.4 0.2 1:2 0.4 0.8 
3:1 0.6 0.2 5:2 2.0 0.8 
4:1 0.8 0.2 4:1 3.2 0.8 
3:2 0.6 0.2 5:1 4.0 0.8 
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each sample. The dilution mixes were combined and incubated for 20 
minutes at RT. Five hundred µl of DNA-reagent complexes were then added 
dropwise to each well, and the plates were incubated at 37°C/5%CO2 for 24 
hours.  
The cells were then trypsinated and counted as described in Chapter 
2.3 and seeded into 6 well plates at their optimal plating density as 
determined in Chapter 2.3.13. After 24 hours of incubation at 37°C/5%CO2 
cells containing the plasmid was selected for using G418 containing 
William’s E medium as described in 2.3.12. Cells were grown for 
approximately 20 days until confluent, when they were passaged as 
previously described in Chapter 2.3.4. 
2.10  Flow Cytometry 
Flow cytometry was performed following transfections with Silencer® 
FAM™-Labeled Negative Control #1 siRNA (2.9.3.1) or with pmaxGFP™ 
plasmid (2.9.1 and 2.9.3.3) to determine transfection efficiency and cell 
viability. 
In brief, cells were washed and detached by adding 1 ml of 0.25% 
trypsin-EDTA to each well. The trypsinization was terminated by addition of 
2 ml of PBS/0.5% BSA (Appendix B) and cell suspensions were transferred to 
Falcon tubes. The cells were centrifuged at 90 x g, 4°C for 10 minutes and the 
cell pellets were resuspended in 1-5 ml of PBS/0.5% BSA. The cell 
suspensions were then put through a BD Falcon cell strainer with 40 µm 
pore size to stop cells from clumping before transferring to flow cytometer 
tubes and stored on ice until analysed. Flow cytometer analysis was 
performed using a BD FACSCalibur (Becton Dickinson-Biosciences, USA) 
instrument using the FITC and PI channels. For each sample 10,000 events 
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were counted, then 0.2 mg/ml PI (Appendix B) to a final concentration of 0.5 
µg/ml was added to the cell suspensions to stain dead cells before a further 
10,000 events were counted. The data were analysed using Cell Quest Pro 
software (Becton Dickinson-Biosciences, USA) and transfection efficiency 
and cell viability were determined for each sample.  
2.11  Luminescence assay systems 
Two luciferase based assay systems were used following transfection 
experiments; both purchased from Promega, UK. The Dual-Glo™ Luciferase 
System was used with the psiCHECK™-2 vector system and the CellTiter-
Glo® Luminescent Cell Viability Assay was used to assess cell viability 
following transfection experiments.   
2.11.1 Dual-Glo™ Luciferase System 
The Dual-Glo™ Luciferase System (Promega) allows for sequential 
measurements from a single sample of luminescence signals from the two 
reporter genes present in the psiCHECK™-2 vector. The control reporter 
Firefly (Photinus pyralis) luciferase is a 61 kDa protein that does not require 
post translational processing for enzymatic activity. Similarly, Renilla 
luciferase purified from Renilla reniformis, a 36 kDa protein functions as an 
enzyme immediately after translation. The Firefly luciferase substrates are 
beetle luciferin, ATP, magnesium, and oxygen while Renilla luciferase 
requires only coelenterazine and oxygen. Both Firefly and Renilla undergo 
spontaneous inactivation after generating luminescence. The Dual-Glo™ 
Luciferase System allows for effective cell lysis and activation of Firefly 
luciferase directly in the sample well. Following Firefly luminescence 
measurements the signal is then quenched and Renilla luciferase is activated 
and measured in the same sample well. 
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To perform the assay the 96 well plates and all the reagents were 
equilibrated to RT and 125 µl of media was removed from each sample well. 
An equal volume of Dual-Glo™ Luciferase Reagent (75µl) was added to each 
sample well and mixed well. After 10 minutes incubation at RT the plate was 
inserted into the 1420 Multilabel Counter Victor3™ (Perkin Elmer, Germany) 
using the Wallac 1420 Manager program (Perkin Elmer) and luminescence 
was measured for 30 seconds per well. Seventy-five µl of Dual-Glo™ Stop & 
Glo® Reagent was then added to each well and incubated for a further 
10 minutes before luminescence was measured for 30 seconds per well. 
Background readings were subtracted and Renilla readings were normalised 
to Firefly readings by dividing the Renilla readings by the Firefly readings for 
each well.  
2.11.2 CellTiter-Glo® Luminescent Cell Viability Assay 
The CellTiter-Glo® Luminescent Cell Viability assay determines the 
relative number of metabolically active cells present in culture based on 
quantification of the ATP present. The assay utilises a thermostable 
recombinant luciferase which catalyses the same reaction with the same 
substrates as described in 2.11.1. The luminescence signal is proportional to 
the amount ATP present which again is directly proportional to the number 
of metabolically active cells present in culture.  
Reagents and culture plates were equilibrated to RT before assaying. 
The cell culture medium in the 96 well plate was adjusted to 100 µl per well 
before 100 µl of CellTiter-Glo® reagent was added to each well. The 
solutions were thoroughly mixed on an orbital shaker for 2 minutes to 
induce cell lysis before being incubated at RT for 10 minutes to stabilise the 
luminescent signal. The luminescence was then recorded for 1 second per 
well using the Perkin Elmer 1420 Multilabel Counter Victor3™ plate reader.  
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2.12  Real-Time Polymerase Chain Reaction (Real-Time PCR) 
All Real-Time PCR reactions were performed on the Roche 
LightCycler® 480 Instrument using LightCycler® 480 Multiwell Plate 96 
following manufacturer’s recommendations. To compare relative mRNA 
levels in transfected samples the samples analysed were transfected in 
triplicate and each triplicate was run as three technical replicates in the 
Real-Time PCR analysis. Two negative controls were included in all assays; 
no template control (replace cDNA template with PCR grade water which 
reveals possible contamination problems) and no reverse transcriptase 
control (omit addition of reverse transcriptase to the cDNA synthesis 
reaction which indicates possible genomic DNA contamination of RNA 
samples). 
2.12.1 Real-Time PCR primers and probes 
The cloned feline Egfr sequence and the published feline β-actin 
sequence (accession number AB051104) (NCBI, 2010c) were used in 
conjunction with their predicted sequences (EMBL-EBI, 2010b) to design 
intron spanning primers and probes utilising the Roche Universal Probe 
Library Assay Design Centre (Roche, 2009). Primers and probes were 
selected and HPLC purified primers were ordered from Eurofins MWG 
Operon (eurofinsdna.com). FAM labelled probes number 147 (cat # 
04694333001) for the feline Egfr sequence and number 11 (cat # 046851105001) 
for the feline β-actin sequence were ordered from Roche Applied Science. 
The primer sequences can be seen in Table 2.11. For relative quantification 
Eukaryotic 18S rRNA Endogenous Control Set (Applied Biosystems) was 
used as internal calibrator. The control set contained VIC labelled minor 
groove binder (MGB) probes to allow for multiplexing and was supplied in a 
primer limiting ready to use solution. 
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Table 2.11: Real-Time PCR primer sequences 
 
2.12.2 Real-Time PCR reactions 
The Real-Time PCR reactions were performed using LightCycler® 480 
Probes Master (Roche) master mixes with a reaction volume of 20 µl in a 96 
well plate format. Real-Time PCR reactions contained 0.5 µM of each primer, 
0.1 µM of each probe in manufacturer’s reaction buffer and 2 µl of a one in 
ten dilution of cDNA synthesis reaction described in Chapter 2.6.1.3 as 
template. The cycling conditions used are summarised in Table 2.12. 
2.12.3 Data Analysis of Real-Time results 
All data analysis was performed and all graphs were generated using 
Microsoft Office Excel 2003 program (Microsoft Corporation, USA). 
Statistical analyses of data were performed using Minitab© 15 Statistical 
Software (Minitab Ltd., UK). 
2.12.3.1 Primer efficiency 
To determine primer efficiency cDNA from untreated SCCF1 cell line 
was used as template. Serial dilutions of cDNA reaction mixtures from 1:10 
to 1:10,000 were made and Real-Time PCR reactions were performed in three 
technical replicates with each primer set individually (EGFR, 18S rRNA and 
β-actin primers) as well as multiplexed (EGFR and 18S rRNA primers). 
The primer efficiency was calculated according to the Pfaffl method 
(Table 2.13) (Pfaffl, 2001). The cycling threshold (Ct) or Crossing point (Cp) 
Primer set Sequence 
RT-F.EGFR Forward GGAGCATTTGGCACAGTGTA 
Reverse TGGAGATGTGGCTTCTCGTA 




values of each of the dilutions were plotted against the cDNA concentrations 
and the slopes were calculated from the graphs. High primer efficiency 
produces graphs with a high correlation coefficient (Pearson’s correlation 
coefficient r>0.99) and with high linearity in the investigative range. E values 
of approximately 2 for primer pairs are required as that equates to a 
doubling of transcript in each PCR cycle. This is a prerequisite in order to use 
the comparative delta-delta method, which is based on the assumption of 
100% primer efficiency (Pfaffl, 2001). 
 
Table 2.12: Real-Time PCR cycling conditions for mono- and dual-colour hydrolysis probes.  
 
 
Real-Time PCR Setup 
Detection Format Block type Reaction volume 
Mono or Dual Colour Hydrolysis Probes 96 well 20 µl 
Programs 
Program Name Cycles Analysis method 
Pre-Incubation 1 None 
Amplification 45 Quantification 
Cooling 1 None 
Temperature targets 
Target (°C) Acquisition Mode Hold Ramp rate (°C/s) 
Pre-Incubation 
95 None 10 minutes 4.4 
Amplification 
95 None 10 seconds 4.4 
54 None 30 seconds 2.2 
72 Single 1 second 4.4 
Cooling 
40 None 10 seconds 1.5 
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2.12.3.2 Relative Expression Analysis 
All analyses of relative gene expression levels were performed using 
the comparative delta-delta method (Pfaffl, 2001). The equations used are 
shown in Table 2.13. The method assumes 100% primer efficiencies for both 
reference and target genes. Following primer efficiency estimations, Real-
Time PCR reactions are performed in triplicate on transfected samples and 
negative scrambled control transfected samples. The reference gene and the 
target gene primers were either added to separate wells (EGFR and β-actin 
primer sets) or in the same well (multiplexing EGFR and 18S rRNA primer 
sets). The delta Cp value (ΔCp= mean Cp target gene- mean Cp reference 
gene) for each sample was calculated, and the negative control samples were 
then averaged to produce negative control ΔCpNC value. The delta-delta Cp 
value (ΔΔCp) was the difference between the ΔCp value for the transfected 
cells and the negative control sample. The relative expression level of the 
target gene was then calculated from the formula in Table 2.13b where 2 
represents 100% primer efficiencies of both primer pairs resulting in 
doubling of product in each PCR cycle to the power of negative ΔΔCp. 
Relative knockdown was then calculated from formula c (Table 2.13).  
 
Table 2.13: Calculation of a) primer efficiency, b) relative expression (RE) and c) percentage 
knockdown of target gene using equations from Pfaffl (2001). E= efficiency of primers, slope 
is taken from the linear graph produced when plotting cDNA concentrations against Cp 
values. RE= Relative expression, ∆∆Cp=∆Cptreated sample-∆Cpnegative control. ∆Cp=Cp for target 







c) Percentage knockdown= (1-2
-∆∆Cp
) x 100 
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2.13 Recovery and detection of protein  
2.13.1 Reagents and antibodies 
All reagents used were purchased from Sigma-Aldrich unless 
otherwise specified. The primary antibodies used were mouse monoclonal 
EGFR (MS-400-P0, Thermo-Scientific, UK) at a 1:100 dilution, rabbit 
monoclonal phospho-MAPK (Erk1/2) (D13.14.4E, Cell Signalling 
Technologies, USA) at 1:2,000 dilution, rabbit monoclonal phospho-Akt 
(4060S, Cell Signalling Technologies, USA) at 1:1,000 dilution, mouse 
monoclonal phospho-STAT-3 (SC-81523, Santa Cruz, USA) at 1:200 dilution, 
and mouse monoclonal β-actin at 1:40,000 dilution (ab6276-100, Abcam, UK). 
The secondary antibodies used were polyclonal swine anti-rabbit (SAR) HRP 
conjugated immunoglobulins (P0217) and polyclonal rabbit anti-mouse 
(RAM) HRP conjugated immunoglobulins (P0260), both purchased from 
Dako Cytomation, Denmark. Optimum dilutions were determined for each 
antibody by testing a range of dilutions on feline cell lysates before using the 
antibodies for the experiments.  
2.13.2 Cell lysis 
All manipulations were performed on ice. Cells were harvested as 
described (2.3.11) and twice the pellet volume of chilled urea buffer 
(Appendix B) was added to the frozen cell pellet, and allowed to thaw on ice. 
The pellet was then mixed by pipetting until no cell clumps were visible and 
incubated for 15 minutes on ice. The cell lysates were cleared by 
centrifugation at 4°C at 15,000 x g for 15 minutes, snap frozen on dry ice, and 
stored at minus 70°C.  
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2.13.3 Bradford assay 
Two µl of cell lysates or 5 µl of known BSA protein standards were 
mixed with 200 µl of Quick Start™ Bradford Dye Reagent (BioRad) and 
added to a clear 96 well plate. The absorbance at 595 nm was measured and 
the protein concentrations were determined from a standard curve generated 
from the known BSA concentrations.  
2.13.4 SDS polyacrylamide gel electrophoresis (SDS PAGE) 
Protein samples were resolved on denaturing SDS-polyacrylamide gels 
by electrophoresis. Different percentage SDS-polyacrylamide gels were 
poured according to size of protein of interest with low percentage gels used 
to separate high molecular weight proteins (e.g. EGFR: 176 kDa) and higher 
percentage gels for lower molecular weight proteins (e.g. MAPK: 42 and 44 
kDa). 
The SDS-polyacrylamide gels were prepared and assembled using Bio-
Rad Protean II minigel system. The resolving gel (Appendix B) was poured 
and overlaid with isopropanol to remove air bubbles. The gel was allowed to 
set at RT, and the isopropanol was removed. The stacking gel (Appendix B) 
was poured and ten well loading combs were inserted and the gel was 
allowed to set at RT.  
Protein samples were prepared into 60 µg aliquots in 2 x Laemmli 
Sample buffer (Appendix B) and boiled in a heat block for 2 minutes at 100°C 
to denature the proteins. The gel was immersed in running buffer (Appendix 
B), and the samples were loaded into wells in the stacking gel and subjected 
to electrophoresis at 150 V until the gel front had run off the bottom of the 
resolving gel. Five µl of pre stained Full Range Rainbow Marker (Amersham 
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Pharmacia Biotech) was run in parallel with the protein samples to allow size 
comparison of protein bands.    
2.13.5 Immunoblotting 
The resolved proteins were electrophoretically transferred onto 
nitrocellulose membranes (Hybond™-C, Amersham Biosciences, UK) in 
transfer buffer (Appendix B) at 75 V for 90 minutes. Nitrocellulose 
membranes were ink stained (0.4% ink (Pelikan, UK) in PBS) for 15 minutes 
to visualise protein bands and ensure equal loading. The membranes were 
blocked for 1 hour at RT in PBST/5% Milk (Appendix B) or TBST/5% BSA 
(Appendix B) before being incubated overnight with primary antibodies at 
4°C in blocking solution.  
After three 15 minutes washes in PBST or TBST the membranes were 
incubated for 1 hour at RT with HRP-conjugated secondary antibodies 
diluted 1:2,000 in blocking solution. After a further three 15 minutes washes 
with TBST or PBST the blots were developed using Immun-Star™ 
WesternC™ Kit (Bio-Rad) and protein bands were visualised by exposure to 
X-ray film (Hybond™-ECL™ Film, Amersham Biosciences).  
2.14  Cell proliferation assays 
Cells were seeded into 96 well plates at 1,500-3,000 cells/well and 
allowed to attach overnight at 37°C/5% CO2 before being exposed to 
different drug concentrations or being transfected. Cellular proliferation was 
measured using the CellTiter 96® AQueous One Solution Cell Proliferation 
Assay (Promega) at different time points. Controls were untreated cells and 
DMSO vehicle treated cells for the drug assays. For transfection experiments 
scrambled control siRNA transfected, mock transfected and untransfected 
cells were used as controls. The assay is a colorimetric assay based on the 
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addition of a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] 
and an electron coupling reagent (phenazine ethosulfate; PES) which forms a 
stable solution (AQueous One Solution), in culture medium. The tetrazolium 
compound (MTS) is then bioreduced by the viable cells to formazan, a 
coloured substance which is soluble in culture medium. Absorbance at 
490 nm is then measured and is directly proportional to the number of living 
cells in culture. 
 To perform the assay, 20 µl of AQueous One Solution was added to each 
well containing 100 µl medium and incubated at 37°C/5%CO2 for 3 hours. 
Absorbance at 490 nm was then determined on a plate reader (Perkin Elmer 
1420 Multilabel Counter Victor3™) using the Wallac 1420 Manager program 
(Perkin Elmer).  
2.15  Colony Formation Assays 
Cells were counted as described in Chapter 2.3.5 and seeded at a 
density of 300 to 500 cells per 10 cm plate containing 10 ml of normal or 
selective medium. The medium was changed and the plates were checked 
for colony formation twice weekly. When visible colonies had formed after 
10 to 20 days the colonies were fixed. The medium was removed from each 
plate, and the cells were washed twice in PBS. Five ml of cold methanol were 
then added to each plate and left to stand at RT for 30 minutes to fix the cells. 
The methanol was removed and 5 ml of 10% Giemsa stain (Sigma-Aldrich®, 
Appendix B) was used to stain the colonies for 15 minutes. The plates were 
rinsed thoroughly in tap water before allowed to dry. The colonies were then 
either counted manually or counted using the colony counting program from 
Quantity One® 1-D Analysis Software (Bio-Rad) on the Molecular Imager® 
Gel Doc™ XR Imaging System (Bio-Rad). Colonies were photographed using 
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the CCD digital camera (Bio-Rad) and files were stored in a jpeg or tiff 
format and printed using the Mitsubishi P93D thermal printer. 
2.16 In vitro scratch assay 
Cells were passaged and counted as previously described (Chapter 2.3). 
The cells were seeded at high density into 6 well plates and allowed to reach 
confluency (usually after 24 hours). A scratch was then created with a 1 ml 
pipette tip in the monolayer as described by (Liang et al., 2007). Following 
the creation of the scratch, the medium was removed and the wells were 
washed with 2 ml PBS per well until all floating cells were removed and a 
clean, sharp edge of cells could be visualised in all wells by phase contrast 
light microscopy. The cells were then treated with drugs at different 
concentrations as described in Chapter 2.3.9 and photographed using the 
10x objective at 0, 12, and 24 hours following drug treatments. The area 
photographed was marked by permanent marker on the lid for each well so 
that the same area could be photographed at every time point. The gap 
width was then measured at ten different points for each photograph and the 
mean was determined for each time point. The mean was then expressed as 
percentage of gap width at 0 hours and compared between treatment groups 
to compare migratory ability between treatment groups and cells. 
2.17  Irradiation treatment of SCCF1 cell line 
All cells were irradiated in William’s E culture medium using a 
Faxitron® cabinet X-ray system 43855D (Faxitron X-ray Corporation, 
Lincolnshire, IL, USA) at a central dose rate of 2 Gray (Gy)/min. All 
irradiation was given as a single fraction at room temperature at doses of 0.5, 
1, 3, 4 and 5 Gy and incubated at 37°C/5% CO2.   
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2.18  Magnetic cell sorting (MACS sorting) 
The separation columns, magnetic separator and the CD133 MicroBead 
Kit were all purchased from Miltenyi Biotec Inc., Germany. Cells were 
harvested and counted as described in Chapter 2.3. A maximum of 1x108 
cells per sample were pelleted by centrifugation at 80 x g for 5 minutes and 
resuspended in 300 µl of chilled separation buffer (Appendix B). One 
hundred µl of FcR blocking reagent and 100 µl of CD133 MicroBeads were 
added and the solution was incubated for 30 minutes at 4°C with rotation.  
The cells were washed by adding 5 ml of cold separation buffer and 
centrifuged at 300 x g for 10 minutes at 4°C before resuspended in 1 ml of 
separation buffer and transferred to a pre-wet separation column mounted 
on the magnetic separator. The column was washed three times with 3 ml of 
separation buffer and the flow through containing the negative fraction was 
collected. The column was then removed from the magnetic separator and 
the labelled fraction was flushed out in 5 ml of separation buffer using the 
plunger. The labelled and unlabelled fractions were counted and seeded at 
required density for cell culture or pelleted and snap frozen for RNA or 
protein analysis.   
2.19  Statistical analysis 
All experiments with the exception of the radiosensitivity assay were 
repeated at least on two separate occasions with similar results. All 
quantitative analysis was based on a minimum of three replicates for 6 well 
plates and 10 cm plates or a minimum of four wells for 96 well plates.  
Data were analysed using Minitab® 15 Statistical Software (Minitab 
Ltd., UK) and all graphs and diagrams were generated using Microsoft 
110 
 
Office 2003 software (Microsoft Corporation). P values < 0.05 were 
considered statistically significant.  
When data followed a normal distribution, parametric tests were 
performed. If parametric tests could not be used, non-parametric testing was 
performed. One-way ANOVA was used to compare differences between 
more than two samples. Two sample t-tests or Mann Whitney U-tests were 
used to compare differences between two samples. Correlations between two 
groups were assessed using Pearson’s correlation coefficient. Survival 
analysis was performed using Kaplan-Meier survival curves and the survival 
plots were compared using the Log Rank test. To assess combined treatment 
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3.1 Abstract 
The aims of this study were to establish the level of expression of EGFR 
and Ki67 in feline oral squamous cell carcinomas (FOSCCs) and to establish 
if the expression of either marker was predictive of survival. Scoring systems 
were developed for each marker from immunolabelling of biopsy samples.  
Sixty seven archived biopsy samples of FOSCC were scored. Statistical 
analyses of data, including Kaplan Meier survival curves, were performed. 
All samples expressed both markers although levels differed between 
samples. Median overall survival was 46 days and one year survival was five 
percent. There was no correlation between Ki67 and EGFR scores (Pearson’s 
correlation coefficient, p=0.861). Low cellular proliferation (low Ki67 score) 
was positively correlated with an overall longer survival (Log Rank, p=0.02) 
and a trend towards better survival for the high EGFR group was observed 
(Log Rank, p=0.076). Ki67 and EGFR immunolabelling in FOSCC may be of 






Traditionally, the methods used in oncology to aid the clinician in 
providing a prognosis in both the human and veterinary field are based on 
an histological evaluation of the tumour sometimes in combination with 
labelling for specific immunohistochemical markers (Partridge et al., 2005, 
Pircher et al., 2010). In some instances, the predictive value of these 
parameters can be limited (Pircher et al., 2010). With the advent of targeted 
therapies in oncology, the ability to screen tumours for different markers that 
can predict prognosis, response to therapy and potentially resistance to 
therapy (Pircher et al., 2010, Wheeler et al., 2010a) is an attractive possibility. 
In veterinary medicine, currently few such markers are routinely used. The 
most widely used marker to date is Ki67, a nuclear protein expressed only 
during G1 to M phase of the cell cycle (Partridge et al., 2005). It has been 
reported to have prognostic value in HNSCC (Partridge et al., 2005), and has 
been extensively used as a tumour proliferation marker (Brown and Gatter, 
2002). Ki67 is already an established immunohistochemical marker in feline 
tumours (Melzer et al., 2006, Morris et al., 2008).  
A small immunohistochemical study recently reported that FOSCCs 
expressed EGFR (Looper et al., 2006). A subset of HNSCC has been found to 
commonly overexpress EGFR (Grandis and Tweardy, 1993, Mrhalova et al., 
2005), and the prognostic value of EGFR expression in HNSCC has been 
widely reported in the literature. Several studies have demonstrated that 
high EGFR expression correlates with poor overall survival (Bankfalvi et al., 
2002, Hitt et al., 2005, Ma et al., 2003) although others have contradicted this 
(Gupta et al., 2002). High EGFR expression has also been shown to predict a 
better response to accelerated radiotherapy compared to longer overall 
treatment times (Bentzen et al., 2005, Eriksen et al., 2004).  
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The central aims of this study were to establish whether EGFR and Ki67 
were expressed in feline squamous carcinoma and whether they could be 
used as predictors of survival. The expression of EGFR in feline tumours 
would support the investigation of EGFR targeted therapy in the cat and 
would also indicate that the natural disease in cats might be a good model 
for human HNSCC. 
3.3 Materials and Methods 
3.3.1 Samples and clinical data 
Biopsy samples from cats diagnosed with oral squamous cell 
carcinomas submitted to the Animal Health Trust (AHT), Newmarket (54 
samples) and the Veterinary Pathology Unit, Royal (Dick) School of 
Veterinary Studies, Edinburgh (18 samples) were collected. The original 
histopathological diagnosis of each case was re-evaluated and validated by a 
veterinary pathologist (Mrs Linda Morrison). Samples that were not 
confirmed to be FOSCC or lacked sufficient tissue for processing were 
excluded. Clinical histories were collected by means of a questionnaire as 
previously described (Hayes et al., 2007) (Appendix C), by telephone to 
submitting veterinary surgeons and from the clinical records in the Hospital 
for Small Animals at the R(D)SVS using the questionnaire as a template.  
3.3.2 Validation of antibodies 
The EGFR antibody has previously been used on FOSCC biopsy 
samples and on a range of normal feline tissues (Looper et al., 2006), and on 
feline cutaneous squamous cell carcinomas (Sabattini et al., 2010). To further 
validate the EGFR antibody for use in the cat the same antibody clone was 
used for western blotting (EGFR antibody Ab-12, Thermo Fisher Scientific, 
UK) on cell lysates from human EGFR overexpressing breast cancer cell line 
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MDA-MB-468 (MD Anderson Cancer Centre, Texas, USA) and the SCCF1 
cell line (Tannehill-Gregg et al., 2001). In addition, feline skin was used as 
positive control tissue for immunohistochemical labelling. 
The Ki67 antibody has been used for immunolabelling of biopsy 
samples in previous feline studies (Castagnaro et al., 1998, Eckstein et al., 
2009, Melzer et al., 2006, Morris et al., 2008, Roels et al., 2000). To validate the 
antibody for use in the set-up for this study, feline lymph nodes were used 
as positive control tissues.  
3.3.3 Immunohistochemical labelling 
Immunolabelling was performed on paraffin wax embedded FOSCC 
biopsy samples. The biopsy samples were sectioned, mounted, processed 
and stained using the protocols described in Chapter 2.2.  
3.3.4 Immunohistochemical Scoring 
All scoring was carried out blinded by two independent observers. 
Separate scoring systems were developed for Ki67 and EGFR due to the 
different labelling patterns produced by the two antigens.  
3.3.4.1 Ki67 Scoring 
Three representative high power fields (x40 microscope objective) of 
each Ki67 slide were photographed and the areas containing tumour nests 
were outlined using Image-Pro Plus Software (Media Cybernetics, Inc., USA) 
to remove stromal cells from the count. All positive and negative cells were 
counted and each photograph was counted twice. The mean of the two 




3.3.4.2 EGFR Scoring 
Labelling criteria were reviewed in a random subset of samples before 
scoring all cases. EGFR slides were scored independently three times in 
random order by each assessor. Overall percentage of EGFR positive cells 
and the pattern of labelling (membranous, cytoplasmic and nuclear) were 
subjectively assessed. The overlying epithelium if present was excluded from 
the EGFR scoring area as keratinized epithelial cells cause artifactual EGFR 
immunolabelling (Gupta et al., 2002). All membranous labelling was 
considered significant. Cytoplasmic labelling was also considered significant 
unless only fine, pale brown stippling was present as this was considered 
non-specific background and was disregarded. Approximately 30% of the 
samples had some discrepancy between one of the six scores. These samples 
were scored again and the scorers came to a consensus agreement. The EGFR 
score was expressed as a percentage EGFR positive cells obtained from the 
mean of the six readings.  
3.3.5 Statistical analysis 
Data were analysed using Minitab® 15 Statistical Software (Minitab 
Ltd., UK). P values < 0.05 were considered statistically significant. When data 
followed a normal distribution, parametric tests were performed. If 
parametric tests could not be used, non-parametric testing was performed. 
Correlation between the Ki67 and EGFR scores was assessed using Pearson’s 
correlation coefficient.  
Survival according to Ki67 scores, EGFR scores, and tumour sites was 
assessed using Kaplan-Meier survival curves and the survival plots were 
compared using the Log Rank test. The influences of age (less than vs. 
greater than/ equal to median age,) and gender (female vs. male) on survival 
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and EGFR scores were assessed using the Mann Whitney U-test while their 
influences on Ki67 scores were assessed using the two sample t-test.  
Cats that were lost to follow up (n=6), euthanised for reasons other than 
complications arising from oral cancer (n=1, due to progression of pre-
existing, chronic renal failure) or alive at end of study period (n=1) were 
right censored. All but one of the remaining cases were euthanised for 
reasons relating to the disease and were classified as having died of the 
disease for the purposes of this study (Table 3.1).  
In this study, survival data may have been skewed by the premature 
euthanasia of some cats due to the widely reported poor prognosis 
associated with this diagnosis (Hayes et al., 2007) rather than due to 
progression of disease. To account for this effect, survival data from patients 
that were euthanised within the first seven days of diagnosis were separated 
into an early euthanasia group and the remainder of the data were grouped 
into a late euthanasia group (Table 3.1). Analyses of the influence of Ki67 
expression and EGFR scores on survival were performed on the entire data 
set and separately on data from both the early and the late euthanasia 
groups. Ki67 levels and EGFR scores were compared between the early and 










Descriptive Statistics N Value (%) N Value (%) N Value (%) 
Age 57*   9   47   







   Median 13.9 years 13.1years 13.6 years 
   Range 5-20 years 7-20 years 5-20 years 
Breed 59*   9   49   
   Non pedigree  56 (95)  7 (78)  48 (98) 
Gender 60   9   51   







   Male neutered 26 (43) 3 (33) 23 (45) 
   Male entire 4 (7) 1 (11) 3 (6) 
Reason for presentation 59   9   50   







   General health concerns 14 (24) 1 (11) 13 (26) 
   Oral health concerns 38 (64) 7 (78) 31 (62) 
Therapy 59   9   50   







   Definitive treatment 5 (8) 1 (11) 4 (8) 
   No treatment 8 (14) 2 (22) 6 (12) 
Tumour location 59   9   50   







   Tongue  3 (5) 0 3 (6) 
   Mandible 16 (27) 2 (22) 14 (28) 
   Maxilla 7 (12) 1 (11) 6 (12) 
   Palate 2 (3) 0 2 (4) 
   Cheek 4 (7) 0 4 (8) 
   Unknown site oral cavity 1 (2) 0 1 (2) 
   Larynx/pharynx 3 (5) 1 (11) 2 (4) 
Median survival according  








   Sublingual  23 64 days 5 N/A 18 98 days 
   Mandible 16 35 days 2 N/A 14 41 days 
   Other sites 20 44.5 days 2 N/A 18 49 days 
Survival 60   10   50   







   Median survival 46 days  6 days 59 days 
Ki67 score 67*   10   50   







   median 54.6 49.4 53.9 
   range 4.8-91 22.0-81.0 4.8-91.0 
EGFR score 67*   10   50   







   median 20.0 9.0 22.5 
   range 5.0-93.0 5.0-93.0 5.0-91.0 
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Table 3.1: (Table previous page). Summary of data from the study divided into three groups: 
all cases, the early, and the late euthanasia groups. * Whole group includes cases with 
incomplete clinical data which could not be allocated to the early or late euthanasia groups.  
3.4 Results 
3.4.1 Samples and descriptive data 
A total of 72 biopsies where evaluated for inclusion in the study. Two 
samples were excluded as they were classified on re-evaluation as squamous 
cell carcinoma in situ and three were excluded due to there being insufficient 
tissue. Clinical histories were available for 60 cases. These are summarised in 
Table 3.1.  
Age did not influence the Ki67 expression level assessed by two sample 
t-test (p=0.613), the EGFR score or survival assessed by Mann-Whitney U-test 
(p=0.081 and p=0.588 respectively). Gender did not influence the EGFR score 
or survival as assessed by Mann-Whitney U-test (p=0.156 and p=0.779 
respectively) nor did it influence the level of Ki67 expression as assessed by 
the two sample t-test (p=0.251).  
Presenting signs included ptyalism, halitosis, swellings, dysphagia, 
anorexia, weight loss, mouth pain, and reduced grooming and/or poor coat 
condition. Approximately two thirds of the cases were presented to the 
veterinary surgeon because of owner concerns regarding the oral health of 
the animal, while one quarter of cases was presented due to concerns about 
general health. In the remaining 14% of cases, the tumour was an incidental 
finding during a routine health check (Table 3.1). Reported signs had been 
present for a few days to over six months prior to presentation.  
Therapy was recorded for 59 cases. Only five cases had treatment with 
curative intent (surgery in all cases), eight cases had no treatment at all while 
the remaining 46 cases had some form of palliative treatments (non-steroidal 
anti-inflammatory drug therapy, antibiotic therapy and steroid therapy) 
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including two cats which received palliative tracheostomy tube placements 
(Table 3.1). 
 The most commonly affected sites were the sublingual region and the 
mandible (Table 3.1). Tumour location correlated with survival. When 
compared to all other locations, cases with sublingual tumours had the best 
survival and mandibular tumours had the worst survival in the late 
euthanasia group (Figure 3.1, p=0.026 and Table 3.1).  
3.4.2 Immunohistochemistry 
The EGFR mouse monoclonal antibody was validated by western 
blotting (Figure 3.2). Human and feline cell line lysates produced similar 
bands of expected size when analysed in parallel by western blotting, 
validating the use of the antibody on feline tissues. Paraffin wax embedded 
samples of feline skin were used as positive control tissue, and showed 
strong membranous labelling of keratinocytes. The Ki67 antibody has 
already been validated for use in feline tissues (Castagnaro et al., 1998, 
Eckstein et al., 2009, Melzer et al., 2006, Morris et al., 2008, Roels et al., 2000). 
In this study, paraffin wax embedded sections of feline lymph node were 
used as positive control tissues and showed strong nuclear labelling.  
All biopsy samples showed both Ki67 and EGFR positive 
immunolabelling, but there was a large variation between samples with Ki67 
expression in 4.8 to 91% of cells and EGFR expression in 5 to 93% of cells. 
There was no correlation between the two scores by Pearson’s correlation 
coefficient (r=0.022, p=0.861).  
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3.4.2.1 High Ki67 proliferation index is associated with decreased 
overall survival 
An average of 1307 cells (range 262-2312) was counted for each biopsy 
sample. Samples with positive Ki67 labelling exhibited strong nuclear 
labelling. In tumours with low level of Ki67 labelling (Figure 3.3a) the 
positive cells were located mainly at the periphery of the tumour cell nests. 
As the percentage of positive cells increased the labelling became more 
diffuse and included cells in the centre of the nests (Figure 3.3b& c). The 
mean Ki67 score was 52.7% (95% CI 46.7-57.5%) and the median score was 
54.6% (95% CI 45.4-62.2%). More than half of the samples showed Ki67 
positive labelling in more than 50% of cells (39/67).  
Samples were separated into two groups on the basis of Ki67 
expression. Low Ki67 expression was defined as expression below the 
median level (54.6%). High Ki67 expression was defined as expression at or 
above the median level. In the late euthanasia group the Kaplan Meier 
Survival Plots, (Figure 3.4), showed statistically significant difference 
between the low and high Ki67 expression groups by Log Rank test (p=0.02). 
The Ki67 scores of the early euthanasia group (≤ 7 days post presentation) 
and the late euthanasia group (> 7 days post presentation) did not differ 
significantly (p=0.835).  
3.4.2.2 High EGFR score shows a trend towards better overall 
survival 
Tumours exhibited membranous or cytoplasmic labelling, or a mixture 
of both (Figure 3.5). No nuclear labelling was seen. Approximately 94% of 
the samples showed membranous labelling and just over half (54%) showed 
cytoplasmic labelling. The labelling varied markedly in intensity as well as in 
area covered. The mean EGFR score (percentage of positive cells) was 32.9% 
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(95% CI 24.4-38.1%) and the median score was 20.0% (95% CI 13.0-30.0%). 
Just over a quarter of the cases showed positive EGFR immunolabelling in 
more than 50% of cells (19/67). The EGFR scores separated into two distinct 
groups when plotted as a histogram giving high EGFR scores >50% (15/49) 
and low scores ≤50% (34/49). A trend towards a better survival for the high 
EGFR group was observed by Log Rank Test (p=0.076) in the late euthanasia 
group (Figure 3.6). The EGFR scores of the early euthanasia group (≤ 7 days 
post presentation) and the late euthanasia group (> 7 days post presentation) 
(p=0.320) did not differ significantly. 
 
Figure 3.1: Kaplan Meier Survival Plot according to tumour location. Sublingual tumours had 
a statistically significantly better survival than mandibular tumours and tumours of other 
sites, p=0.026 by Log Rank test, N=49. Ticks on graph represent censored observations. 
 
Figure 3.2: Western blot showing EGFR protein labelling in cell lysates from human and 
feline cell lines. MDA-MB (lane 1) contains lysate from the MDA-MB-468 cell line, a human 
breast cancer cell line that overexpresses EGFR. It was used as positive control to validate 
the antibody for the use on feline protein lysates. Lane 2 shows lysate from SCCF1 cell line. 





Figure 3.3: Example of low (a), medium (b), and high (c) Ki67 scoring FOSCCs. Positive 
cells are predominantly present in the periphery of the tumour nests in the lower scoring 
tumours (a). In the higher scoring tumours increasingly more cells towards the centre of the 
tumour nests exhibit positive labelling (b & c).  Bars 100 µm. 
 
 
Figure 3.4: Kaplan Meier Survival Plot according to Ki67 score. The low Ki67 scoring 
tumours had a statistically significantly better survival p=0.02 by Log Rank test, N=49. Ticks 





Figure 3.5: EGFR immunohistochemistry of FOSCCs (a) Example of high intensity 
membranous labelling combined with cytoplasmic labelling, bar 10 µm, (b) cytoplasmic 
labelling of high intensity with marked granularity, bar 10 µm, (c) low intensity membranous 
labelling, bar 50 µm, (d) medium and high intensity membranous labelling, bar 25 µm. 
 
Figure 3.6: Kaplan Meier Survival Curve according to EGFR score. The tumours with high 
EGFR score had a trend towards better survival compared to the low scoring tumours, 





3.5.1 Study Population 
The breed, sex, and age of cats in this study were similar to what has 
been previously reported (Bregazzi et al., 2001, Fidel et al., 2007, Postorino-
Reeves et al., 1993). Patients were predominantly non-pedigree and this is 
representative of the overall cat population in the UK (pfma.org.uk, 2010). 
FOSCC occurred in older cats in agreement with previous studies (Gardner, 
1996, Stebbins et al., 1989). 
This study showed no sex predisposition associated with development 
of FOSCC. This is also in agreement with previous studies (Gardner, 1996, 
Stebbins et al., 1989). This differs from HNSCC where gender has a marked 
influence on incidence and men are affected more frequently than women 
(cancerresearchuk.org, 2005). The higher incidence of HNSCC seen in men 
can be partly explained by a higher alcohol consumption combined with 
tobacco use, but a gender factor cannot be ruled out (Dobrossy, 2005). 
Gender is unlikely to influence the exposure to environmental toxins in 
neutered cats. In this study gender did not influence survival in FOSCC. In 
HNSCC, women have a significantly higher survival rate than men 
(Dobrossy, 2005). It is tempting to speculate that as animals in this study 
(and other veterinary reports) are predominantly neutered at an early age, 
this may remove any effect of gender on survival.  
The range of presenting signs reported in this study was mainly 
associated with oral health and included salivation and difficulty eating. 
These were similar to clinical signs reported in previous studies (Bertone et 
al., 2003, Kapatkin et al., 1991). 
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Only five cases in this study received any treatment with curative 
intent after diagnosis. This may be because a large proportion of the samples 
in this study were collected as part of a previous study looking at survival in 
FOSCC in general practice in the UK (Hayes et al., 2007) skewing the 
population away from referral cases that are more likely to have further 
specific treatments performed. Disappointingly, nine cases received no 
treatment including pain relief at any time and 40% of cases received no pain 
relief at the time of biopsy even though oral pain was one of the presenting 
signs recognised by the owners. This may reflect the historical nature of the 
data set used representing a time when analgesia for cats was not as widely 
used or as readily available in easy-to-use formulations. Definitive 
treatments were only attempted in a very small number of cases in this study 
(Table 3.1) so meaningful analysis could not be performed on the influence 
of treatment on survival.  
The sublingual area was the most commonly affected site followed by 
the mandible and the maxilla consistent with previous reports (Dorn and 
Priester, 1976, Postorino-Reeves et al., 1993, Stebbins et al., 1989). Sublingual 
tumours have been reported to have a worse prognosis than other oral 
tumours (Evans et al., 1991), and were excluded from surgical treatments in 
one study (Hutson et al., 1992). In the study reported here the sublingual 
tumours did significantly better than tumours of other sites, indicating that 
exclusion of sublingual FOSCC cases from treatment may be unwarranted if 
they are not inoperable.  
3.5.2 Statistical Analysis of Survival Data 
Analysing survival data in veterinary epidemiological studies is 
frequently problematic because companion animals are likely to be 
euthanised and do not die naturally from progression of the disease leading 
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to possible bias of survival data. Euthanasia was used as the end point 
criterion for inclusion in this study but this practice has been criticised as the 
decision to euthanise animals is affected by many factors other than disease 
progression such as financial constraints on treatment, predicted prognosis, 
age at presentation and concurrent disease (Hosgood and Scholl, 2001, 
Johnson et al., 2004). In addition, individual owner and veterinarian attitudes 
towards euthanasia and treatment vary, influencing the timing of 
euthanasia. It has been suggested that all euthanised animals should be right 
censored for Kaplan Meier survival analysis (Hosgood and Scholl, 2001) but, 
when this is done in studies such as this one where 53 out of 54 cases were 
euthanised, censoring becomes too restrictive. Johnson and colleagues (2004) 
demonstrated that when euthanised client-owned animals were treated as 
having reached the end point and were included in survival analyses a more 
complete analysis was possible.  
In order to account for the possible influence of anticipated poor 
prognosis of FOSCC on the survival data (Hayes et al., 2007, Looper et al., 
2006), animals were divided into early and late euthanasia groups and 
animals from the early euthanasia group were excluded from subsequent 
survival analyses. The EGFR scores and Ki67 expression levels of the early 
euthanised groups did not differ significantly from the scores of the 
remainder of the population indicating that early euthanasia could not be 
linked to either EGFR score or Ki67 expression. This supports the decision to 
divide these observations into two separate groups as the euthanasia of these 
cases may have been driven by other factors than the severity of their 
disease. 
The overall survival in this study, in which cases largely received only 
palliative care, was very poor with one year survival of only 5%. In 
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comparison, in other studies in which patients received radical surgery or 
radical surgery with radiotherapy, one year survivals of 43% (Northrup et 
al., 2006) and 57% (Hutson et al., 1992) have been reported. These latter 
studies were of limited size and excluded some patients, but do demonstrate 
that, with treatment, some cats survive for longer.  
3.5.3 Immunohistochemical labelling 
The tumours in this study exhibited irregular nests and cords of 
stratified squamous epithelial cells which crossed the basement membrane 
and invaded the underlying lamina propria and submucosa, the 
characteristic appearance of oral squamous cell carcinomas (Van Kruiningen, 
1995). Depending on aggressiveness, the tumours on occasions also invaded 
underlying bone and muscle.  
These irregular nests of cells resembled to a varying degree the normal 
architecture of stratified squamous epithelia. The equivalent of the cuboidal 
basal cells responsible for cell division which rest on the basement 
membrane in normal stratified squamous epithelia (Young and Heath, 
2002a) were observed occupying the periphery of the tumour nests. In 
normal oral epithelium, cells become more flattened with pyknotic nuclei as 
they move away from the basal layer towards the surface (Young and Heath, 
2002a). In the tumours, flattening of cells could be observed in the cells 
towards the centre of the tumour nests.  
Normal oral stratified squamous epithelium can become keratinised in 
exposed areas if subjected to excessive desiccation or abrasion like, for 
example, in the palatal regions (Young and Heath, 2002b).  In neoplastic 
tissues, the amount of keratin present varies depending on the degree of 
differentiation present, with poorly differentiated tumours containing few 
keratinized cells and numerous mitotic figures (Van Kruiningen, 1995). Most 
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tumour samples in this study contained few keratinized cells, but numerous 
keratin pearls were observed in a small number of specimens, which is a 
marker of well differentiated tumours (Van Kruiningen, 1995).  
No correlation was seen between the two labelling patterns of Ki67 and 
EGFR. Since EGFR can be a driver of proliferation (Yarden and Sliwkowski, 
2001) it would be reasonable to assume that high EGFR scores would 
correlate with a high proliferation index. This was not the case, which may 
indicate the heterogeneity of the underlying molecular pathways driving 
these tumours (Yarden and Sliwkowski, 2001). Similar results have been 
reported in HNSCC (Bentzen et al., 2005).  
3.5.3.1 Ki67 immunolabelling 
The high number of Ki67 positive labelling cells in the majority of 
tumours seen here supports the suspected fast growth rate of squamous cell 
carcinomas (Melzer et al., 2006). The Ki67 labelling pattern observed in these 
tumours, with the low grading tumours only exhibiting positive cells in the 
periphery of the tumour nests and the higher grades showing positive 
nuclear labelling towards the centre of the tumour nests, reflects the 
remnants of the normal epithelial architecture (Young and Heath, 2002a). 
These labelling patterns with high scoring tumours exhibiting more 
heterogeneous labelling were similar to what has been previously reported 
in HNSCC (Rittà et al., 2009) and in feline mammary carcinomas (Castagnaro 
et al., 1998).  
In this study the median Ki67 score was chosen as a cut-off point to 
differentiate the high and low scoring groups as has been described for other 
feline tumours (Castagnaro et al., 1998, Eckstein et al., 2009). The Ki67 data 
did follow a normal distribution, hence the median and mean scores were 
approximately equal (Table 3.1) (Petrie and Watson, 2006b).  However, when 
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a data set includes censored observations, the mean score should not be used 
(Castagnaro et al., 1998, Petrie and Watson, 2006b). The median Ki67 score 
was therefore considered to be an appropriate cut-off point for the purpose 
of this study. 
The Ki67 antibody clone used in this study (MIB-1) is raised against 
human Ki67 recombinant protein, but it has been shown to cross-react with 
cow, dog, sheep, horse and swine. It has also been used in previously 
published feline tumour studies (Castagnaro et al., 1998, Melzer et al., 2006, 
Roels et al., 2000). No further validation of the antibody was performed in 
this study other than the use of feline lymph nodes as positive control tissues 
to aid in optimisation of the labelling protocol.  
The Ki67 proliferation index was found to correlate with worse 
outcome in FOSCC in this study mirroring the findings of some reports on 
the evaluation of Ki67 in HNSCC where it has been found to be associated 
with a poor prognosis (Partridge et al., 2005, Rittà et al., 2009). However, 
other reports have found no association between Ki67 proliferation index 
and prognosis in HNSCC (Ma et al., 2003, Quon et al., 2001). While Ki67 
expression is a well-established marker of proliferation in a range of human 
tumours, its role as a prognostic indicator is more controversial (Partridge et 
al., 2005, Pich et al., 2004).  Similarly, Ki67 is an established proliferation 
marker in cats (Castagnaro et al., 1998, Eckstein et al., 2009) but in addition 
has shown value as a prognostic indicator in feline mammary carcinoma 
(Castagnaro et al., 1998). High Ki67 expression has also been associated with 
an increased response to accelerated radiation therapy in cats with cutaneous 
SCC (Melzer et al., 2006). It also correlates strongly with histological 
differentiation (Lörz et al., 1994) and provides an indication of the 
aggressiveness of the tumour. This study indicates that Ki67 labelling of 
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FOSCCs may function as a useful guide for clinicians to assess the potential 
prognosis of patients.  
3.5.3.2 EGFR immunolabelling 
In this study, all tumours showed some degree of EGFR labelling, with 
25% of samples showing labelling in over half of the cells. The majority of 
tumours showed membranous labelling with or without cytoplasmic 
labelling. This is in agreement with previously published results in FOSCC 
(Looper et al., 2006). Membranous labelling demonstrates receptor at the 
plasma membrane while cytoplasmic labelling is caused by either newly 
synthesized receptors located in the Golgi apparatus (Damjanov et al., 1986) 
or internalised receptors (Wiley, 2003). Some authors disregard cytoplasmic 
labelling when scoring tumours and only take the membranous labelling 
into account (Agulnik et al., 2007, Hitt et al., 2005) while others include it 
(Grandis et al., 1996, Looper et al., 2006). In this study we included both 
cytoplasmic and membrane labelling as receptor located in the cytoplasm is 
part of the normal receptor life cycle (Wiley, 2003), and dysregulation of 
receptor processing may be involved in tumorigenesis (Wheeler et al., 2008). 
No nuclear labelling was seen in these samples. Translocation of EGFR to the 
nucleus has been reported as a mechanism of resistance to therapy by cancer 
cells (Li et al., 2009). All the biopsy samples used in this study were taken 
prior to treatments. Further studies investigating the pattern of EGFR 
labelling in tumours following therapy, in particular with EGFR targeting 
drugs if they became available, could reveal if nuclear translocation of EGFR 
plays a role in acquired resistance in FOSCC.  
Immunohistochemistry is a commonly used technique for evaluation of 
EGFR expression in HNSCC tumour samples, and a high EGFR score is 
extensively reported to be inversely correlated to overall survival (Grandis et 
131 
 
al., 1996, Hitt et al., 2005, Kumar et al., 2007, Ma et al., 2003). All these studies 
used different scoring systems with arbitrary cut off values. Extrapolation 
from published EGFR scoring systems used in HNSCC for use in this study 
was problematic as these were based on much larger sample sizes allowing 
for division into multiple groups. In this study the EGFR scores separated 
into two distinct groups when plotted on a histogram and this was used to 
select the cut-off point between low and high scores. Lack of a properly 
validated cut off point is a major limitation in this and similar studies.  
A trend towards a better survival in the high scoring EGFR group was 
observed although statistical significance was not reached. This could be due 
to a number of factors including the small sample size of the study, the 
considerable heterogeneity in the patients with regard to early and late stage 
disease and potentially due to an inappropriate cut off point (Kumar et al., 
2007). 
This study has established that FOSCC frequently express EGFR and 
that patients with high EGFR expression may have a better prognosis. Recent 
advances in treatment of HNSCC have included therapies targeting EGFR 
with radiotherapy, surgery, and/or chemotherapy (Baselga et al., 2005, 
Bonner et al., 2006). HNSCC with high EGFR expression responded better to 
an overall shortened treatment time for radiotherapy (Bentzen et al., 2005, 
Eriksen et al., 2004). In FOSCC, targeting EGFR in combination with 
established treatment protocols such as radiotherapy or surgery may offer 
patients an improved survival and warrants further investigations. 
Evaluation of EGFR expression in FOSCC for selecting patients for 




In summary, FOSCC is a disease with a very poor prognosis but better 
selection of patients may enable more targeted treatments and improve 
survival. This study demonstrates that Ki67and EGFR labelling of biopsy 
samples have potential in this selection process. A low Ki67 score showed 
correlation with better survival in this cohort, while cases with high EGFR 
labelling showed a trend towards better survival times. In addition, we have 
established that EGFR expression is a feature of FOSCC with a subset of 
tumours showing high expression levels similarly to what has been reported 
in HNSCC. Further studies are indicated to establish the role of EGFR in 
FOSCC, in particular the effect of potential EGFR targeting as a treatment 





Development of RNA interference 
targeting strategies against feline 
EGFR 
4     Development of RNA interference targeting 
strategies against the feline EGFR 
4.1 Abstract 
Feline squamous cell carcinomas exhibit similarities to human head and 
neck cancer with a subset of tumours overexpressing EGFR. In order to 
investigate the potential role of EGFR in the feline tumour, targeting 
strategies have to be developed. In this study, the feline Egfr tyrosine kinase 
domain was sequenced and showed high degree of homology to the human 
EGFR sequence and a conserved ATP binding region. Six small interfering 
RNAs targeting the feline Egfr were developed and screened using an in vitro 
vector system, and the most effective siRNAs against the feline Egfr was 
determined. These results pave the way for further gene silencing studies to 
determine the effect of EGFR knockdown in feline squamous cell 
carcinomas.  In addition, conservation of the ATP binding pocket between 
the human and feline receptors suggests EGFR targeting with human small 






In man, targeting EGFR using a range of strategies has been widely 
evaluated for treating HNSCC.  RNA interference is a highly specific method 
of gene silencing which utilises small interfering RNA molecules (siRNAs) 
complementary to the target sequence (Pai et al., 2006). These bind to gene 
transcripts targeting them for early destruction before translation can occur 
(Pai et al., 2006). RNA interference techniques are extensively used in 
research in gene function studies, but also carry promise for the 
development of drugs capable of targeting specific proteins (Scherer and 
Rossi, 2003, Dorsett and Tuschl, 2004, Davis et al., 2010) including EGFR 
(Nozawa et al., 2006). RNA interference allows for rapid and highly specific 
gene targeting allowing for the effect of silencing a particular gene to be 
assessed in both in vitro and in vivo systems (Scherer and Rossi, 2003, Dorsett 
and Tuschl, 2004). It is a particularly powerful tool when assaying gene 
function in mammalian cancer cell lines for potential drivers of oncogenic 
pathways (Kittler and Buchholz, 2003).  
Although EGFR is widely expressed in feline oral SCC (Looper et al., 
2006, Bergkvist et al., 2010) no studies have investigated the effect of EGFR 
targeting in the veterinary species (Bergkvist and Yool, 2010). The full 
human EGFR cDNA sequence was first published in 1984 by Ullrich and 
colleagues (Ullrich et al., 1984). Since then, the Egfr cDNA sequences for a 
range of mammals have been published, and a high degree of homology 
between species, particularly in the tyrosine kinase region (NCBI, 2010b) is 
present. Although the cat genome is now available (Pontius et al., 2007, 
NCBI, 2010a), no annotations to the feline Egfr sequence have been made.  
The aims of this study were to sequence the tyrosine kinase region of 
the feline Egfr receptor and design and screen a set of siRNAs sequences 
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against it to evaluate the potential of using RNA interference as a targeting 
strategy in feline squamous cell carcinomas. In addition, sequence homology 
between the human and the feline receptors were investigated to assess the 
potential of using currently available human EGFR targeting drugs in cats. 
4.3 Materials and Methods 
4.3.1 Cloning and sequencing of feline EGFR tyrosine kinase 
region  
Total cellular RNA was isolated from the SCCF1 cell line as described 
in Chapter 2.4.1, and first strand cDNA was synthesised as described in 
Chapter 2.6.1.2 and 2.6.1.2. Since the feline Egfr sequence has not been 
published, three primer sets were designed to span the putative tyrosine 
kinase region of the feline Egfr gene using areas with a high degree of 
homology between the human, murine and canine published sequences 
(EMBL-EBI, 2010b, NCBI, 2010c) (primer pairs A, B & D, Table 4.1). Primers 
were designed (Chapter 2.6.2.1) and PCR reactions were performed as 
described in Chapter 2.6.2.2 and 2.6.2.3. 
Samples were sequenced in both directions as previously described in 
Chapter 2.5. The sequences were then checked against the feline genome 
(NCBI, 2010a) using a Basic Local Alignment Search Tool (BLAST) 
nucleotide search, and sequence homology to other species were compared 
(NCBI, 2010b).  
4.3.2 Vector cloning 
The psiCHECK™-2 vector from Promega was used in the experiments. 
The psiCHECK-2 vector has two reporter genes. The primary reporter gene 
is fused with the target gene allowing monitoring of target gene expression. 
The secondary reporter gene acts as an internal control for normalisation of 
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data to correct for variations due to different transfection efficiency between 
samples. The principle of the psiCHECK™-2 vector system is summarised in 
Figure 4.1.  
Restriction enzyme sites XhoI and NotI were added to the 5’ end of the 
upstream and downstream primer sequences respectively to allow for 
directional cloning (primer set C, Table 4.1), and PCR reactions were 
repeated as described in Chapter 2.6.2.2. The psiCHECK-2 vector and the 
PCR product were then digested using Xho1 and Not1 restriction enzymes in 
separate reactions as described in Chapter 2.7.2 before being gel purified as 
described in Chapter 2.7.1. The digested plasmid and PCR products were 
combined using the ligation protocol (Chapter 2.7.3).    
Table 4.1: Egfr primers were constructed using the tyrosine kinase region of human, murine, 
and canine EGFR sequences. The tyrosine kinase region has the greatest sequence 
homology between species. 







Forward - GAATATCACCTGCACAGGAC 





Forward - GGAGAAGCTCCCAACCAGGCT 





Forward Xho1 TTACTCGAGGGAGAAGCTCCCAACCAGGCT 





Forward - TGCGAAGGGCATGAACTAC 




Figure 4.1: Schematic diagram to illustrate the principle of psiCHECK™-2 vector system. 
The gene of interest is cloned into the vector by directional cloning downstream of the 
Renilla luciferase translational stop codon resulting in a fused mRNA being transcribed. 
Cells are co-transfected with vector and siRNAs against the Renilla sequence (positive 
control siRNA) or the gene of interest, which leads to targeting of the mRNA sequence for 
degradation and no luminescence signal. No siRNA or scrambled negative control siRNAs 
allows Renilla protein translation which leads to a luminescence signal. Based on a diagram 
from Promega Technical Bulletin #329. 
 
The ligation reactions were used directly in the transformation 
reactions as described in Chapter 2.4.2.1, see Figure 4.2. Colonies were 
selected and expanded overnight before performing plasmid preparations as 
described in Chapters 2.4.2.2 to 2.4.2.4. The vector was then sequenced as 




Figure 4.2: Schematic diagram illustrating the restriction enzyme digestions and the ligation 
process.  
 
4.3.3 Design, production and screening of siRNAs 
4.3.3.1  Design and production of siRNAs  
Six siRNAs (Table 2.7) against the feline Egfr tyrosine kinase region 
sequenced using primer pair B (Table 4.1) were designed. In addition one 
scrambled sequence negative control siRNA and three positive control 
siRNAs against the vector’s Renilla sequence were designed as described in 
Chapter 2.8.1. All ten siRNAs were produced by in vitro transcription using 
the Silencer® siRNA Construction Kit (Ambion) following manufacturer’s 
recommendations as described in Chapter 2.8.2.  
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4.3.3.2  Optimisation of electroporation of 293FT cell line 
Several optimisation experiments were performed to optimise an 
electroporation protocol for the 293FT cell line as described in Chapter 2.9.1. 
A more detailed description complementary to Chapter 2.9.1 is given below. 
 Firstly, optimum cell numbers per well were determined by 
transfecting the 293FT cells at a range of cell numbers with 1 µg 
psiCHECK™-2 vector. The normalised Renilla readings as measured by the 
Dual-Glo™ Luciferase System (Promega, Chapter 2.11.1) were compared 
after 24 hours to establish the optimum cell number per well.  
The cell line was then co-transfected with the psiCHECK™-2 vector 
containing the insert (psiCHECK™-2.EGFR) and one of the three positive 
control siRNAs designed against the Renilla sequence or the scrambled 
control siRNA6 sequence. The efficiencies of the three Renilla siRNA 
sequences in reducing normalised Renilla luminescence as percentage of 
scrambled control were compared.  
To determine if DNA vector concentrations influenced knockdown 
efficiency, 200nM positive control Renilla siRNA and 1, 3 and 5 µg of 
psiCHECK™-2.EGFR vector was co-transfected into the cell line, and the 
impact on normalised Renilla luminescence was assessed. 
Next, the optimum electroporation program was evaluated. The 
positive control Renilla siRNA was co-transfected with the 
psiCHECK™-2.EGFR vector using three of the pre-programmed 
electroporation programs on the Nucleofector® 96-well shuttle (Amaxa). The 
pmaxGFP™ control plasmid was also transfected into the cell line using all 
four programs to determine transfection efficiency and cell viability by flow 
cytometry (Chapter 2.10). The optimal program was then selected based on a 
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combination of transfection efficiency achieved with pmaxGFP™ control 
plasmid and cell viability following transfections as assessed by flow 
cytometry (Chapter 2.10) and relative reduction in normalised Renilla 
readings achieved following siRNA control transfections.  
Finally, optimum siRNA concentrations were determined comparing 
250 nM and 500 nM final concentrations of control siRNAs in wells.  
4.3.3.3  Electroporation protocol  
The electroporation protocol is described in detail in Chapter 2.9.2. In 
short, 293FT cells were trypsinated and counted as described in Chapter 2.3.4 
and 2.3.5 and 2x105 cells were seeded into a Nucleocuvette™ 96 well plate. 
Control plasmid pmaxGFP™ or 1 µg psiCHECK-2.EGFR vector was 
co-transfected with 250 nM siRNAs in triplicate by electroporation as 
described in Chapter 2.9.2. Renilla luminescence was read 24 hours after 
transfection and normalised against Firefly luminescence of the secondary 
reporter as previously described (Chapter 2.11.1). The experiments were 
repeated on two different occasions with similar results.  
4.4 Results 
4.4.1 The feline Egfr tyrosine kinase region is highly conserved 
between species 
The sequences obtained with the primers designed from the known 
human, canine, and murine EGFR sequences had a 100% sequence homology 
with the feline genome as assessed by performing a BLAST search (GenBank 
accession number Felis HQ185236) (Appendix D). The feline DNA sequence 
has 92% sequence homology to the canine Egfr sequence and 89% sequence 
homology with the human EGFR sequence. The feline Egfr tyrosine kinase 
region amino acid sequence has 97% and 95% homology with the canine and 
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human EGFR protein sequences respectively. The amino acid sequence of 
the ATP binding pocket in the human EGFR was conserved in the feline 
EGFR.  Table 4.2 shows an overview of the degree of homology between 
EGFR tyrosine kinase regions in a range of species. 
Table 4.2: Overview of degree of homology between species in the tyrosine kinase region of 
Egfr sequences. 
 
4.4.2 Synthesis of siRNAs by in vitro transcription yielded 
adequate amounts of good quality siRNAs 
Ten siRNA sequences were designed and synthesised; six against the 
feline Egfr, three positive control sequences against the Renilla sequence in 
the psiCHECK™-2 vector and one scrambled control sequence. The 
manufacturers provided a DNA control to assess yield of siRNA 
construction, and a yield of 68 µg of RNA was produced in this study using 
the control DNA (the manufacturer recommended that a minimum yield of 
Species % homology to feline Egfr 
Latin name Common name DNA Amino acid 
Homo sapiens Man 89% 95% 
Callithrix jacchus Marmoset 89% 96% 
Canis familiaris Dog 92% 97% 
Sus scrofa Wild boar 88% 95% 
Bos taurus Ox 88% 95% 
Equus caballus Horse 92% 97% 
Monodelphis domestica Opossum 83% 93% 
Rattus norvegicus Rat 87% 94% 
Mus musculus Mouse 87% 95% 
Gallus gallus Chicken 81% 90% 
Felis catus Cat 100% 100% 
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10 µg RNA using the control DNA indicated satisfactory siRNA 
construction).  Five of the siRNA templates designed in this study yielded 
satisfactory amounts of RNA of 10 µg or more, while two yielded less. These 
yields were however, adequate for the screening process, and the quality of 
all siRNA samples was satisfactory with A260/A280 ratios between 1.9 and 2.1. 
4.4.3 Optimisation of the electroporation protocol resulted in a 
threefold increase in positive control siRNA efficiency  
A total of 2x105 cells per well in a 96 well format gave the highest 
normalised Renilla reading following transfection of psiCHECK-2 vector 
(data not shown).  This cell density was used for all further experiments.  
 
Figure 4.3: Results of electroporation screening of the three positive control Renilla 
sequences showed variable reduction in normalised luminescence, with Renilla 3 (siRNA10) 
producing the overall largest reduction in luminescence readings.  
 
The three positive control sequences targeting the Renilla sequence in 
the psiCHECK-2 vector produced 22-39% reduction in normalised Renilla 
luminescence readings (Figure 4.3). The most effective siRNA (siRNA10, 
Table 2.7) was then used for the remaining optimisation. Further 
optimisation for DNA vector concentrations showed no increase in siRNA 
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control knockdown efficiency or in transfection efficiency with increasing 
DNA concentrations, so 1 µg of DNA template per reaction was used for 
subsequent experiments (data not shown).  
Four pre-programmed electroporation programs were compared for 
transfection efficiency, post-transfection cell viability and reduction in 
normalised Renilla luminescence (Table 4.3). Program DS-150 produced the 
maximum reduction in Renilla luminescence (Figure 4.4) and an 
approximately equal transfection efficiency and post electroporation cell 
viability when compared to the other programs, and was therefore chosen 
for further experiments. 
Table 4.3: Results of electroporation screening using siRNA10 Renilla showing effect of four 
different pre-programmed programs on Renilla knockdown, transfection efficiency and cell 
viability. 
 
Finally, the effect of increasing the siRNA concentration from 250 to 500 
nM was investigated, and the higher siRNA concentration of 500nM 
produced a 71% reduction of Renilla luminescence compared to scrambled 
control (Figure 4.5).  Overall, optimisation of transfection conditions resulted 












DS-130 50% 62% 44% 61% 84% 
DG-130 28% 70% 60% 83% 84% 
CM-130 20% 54% 48% 78% 84% 




Figure 4.4: Percentage of scrambled control Renilla luminescence achieved using the four 
different programs. An almost doubling in efficiency was seen between the worst and the 




Figure 4.5: Result of screening using two different siRNA concentrations of 250 and 500 nM 
siRNA. The higher siRNA concentration yielded a greater reduction in Renilla luminescence 
readings. Bars are average of six luminescence readings with +/- standard deviations 
 
4.4.4 The siRNA screening produced three efficient siRNAs 
targeting the feline Egfr 
Both siRNA screening experiments had transfection efficiencies of 
between 40-65% as measured by flow cytometry on pmaxGFP™ transfected 
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cells. Residual background Firefly activity as determined with plasmid pGL3 
was < 0.06%. Scrambled control siRNA transfected cells exhibited a 12% 
reduction in normalised Renilla levels when compared to vector only 
controls. Renilla positive controls produced an average 40% reduction in 
Renilla luminescence when compared to scrambled control transfected cells 
(Figure 4.6).  
 
Figure 4.6: Result of siRNA screening using psiCHECK™-2 vector system and 
Nucleofector® 96-well shuttle. Upper left and right panels show results of individual 
experiments, where each bar represents an average of nine replicates +/- standard 
deviations. The lower panel show an average of all experiments where each bar represents 




Table 4.4: Summary of results from siRNA screens using psiCHECK™-2 vector system and 
Nucleofector® 96-well shuttle.  
 
The results of the siRNA screening are summarised in Table 4.4 and 
Figure 4.6. The most effective siRNAs overall were siRNAs 2, 5 & 8 when 
compared to scrambled control cells. These siRNAs were consistently more 
effective than the positive control in reducing Renilla luminescence. Two 
siRNAs (siRNA1 & 3) were consistently less efficient than the positive 
control siRNA, while the remaining siRNA, (siRNA4) exhibited an 
intermediate level of efficiency. The overall most efficient siRNA was 
siRNA8, which on average caused a 64% reduction in luminescence, so this 
siRNA sequence was therefore used for all further Egfr knockdown 
experiments in this study. 
4.5 Discussion 
This study demonstrated that the tyrosine kinase region of the feline 
Egfr gene has a high degree of homology with the human gene and other 
mammals (NCBI, 2010b) as well as a conserved ATP binding pocket. The 
ATP binding pocket has been shown to be essential for receptor tyrosine 
siRNA Target 
% of scrambled control 
Screen 1 Screen 2 Average 
6 Scrambled 100 100 100 
1 Egfr 80 97 89 
2 Egfr 27 48 38 
3 Egfr 55 72 64 
4 Egfr 37 59 48 
5 Egfr 29 48 39 
8 Egfr 23 49 36 
10 Renilla 48 74 61 
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kinase activity as point mutations in the binding pocket severely affects 
receptor activity (Redemann et al., 1992). A favoured therapeutic approach 
for EGFR blockade is the use of small molecule competitive inhibitors that 
bind to the ATP binding pocket (Arteaga, 2003). A number of EGFR specific 
tyrosine kinase inhibitors are currently in use in human medicine (Lurje and 
Lenz, 2009). The high degree of homology of this key domain between man 
and cat indicates that small molecule tyrosine kinase inhibitors targeting this 
domain in man may be effective in inhibiting feline Egfr activity.  
This study has also demonstrated that a commercially available 
monoclonal antibody produced against the EGF binding region of the 
human protein (EGFR Ab-12, Thermo-Scientific) also binds specifically to 
feline EGFR epitopes showing species cross reactivity (Chapter 3.3.2). In 
addition to TKIs, specific therapeutic monoclonal antibodies (mAbs) have 
been approved for clinical use in a range of solid tumours including HNSCC 
(Lurje and Lenz, 2009). The mAbs block the ligand binding region of the 
receptor preventing activation of the receptor and target it for antibody 
dependent cell-mediated cytotoxicity (Lurje and Lenz, 2009).  
This study aimed to investigate means of targeting the feline EGFR.  
According to these results both drug classes may potentially have activity in 
feline cells; TKIs by binding to the ATP binding pocket and mAbs via 
interactions with the ligand binding domain of the receptor.  However, 
mAbs used in human medicine are either humanised or chimeric antibodies. 
If used in veterinary species they are likely to cause anti-human antibody 
responses similar to the human anti-mouse antibody responses seen in man 
to murine antibodies (Nissim and Chernajovsky, 2008, Bergkvist and Yool, 
2010). TKIs on the other hand, have no such known complications, and these 
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results suggest that TKIs used in human medicine may be effective in feline 
patients. 
In this study siRNAs were developed to target the feline Egfr. When 
RNA interference techniques were in their infancy, it was thought that all 
siRNAs produced were equally efficient in producing gene silencing 
(Kurreck, 2006). It soon became apparent that this was not the case, as 
different siRNAs against a particular target gene caused widely differing 
effects (Scherer and Rossi, 2003, Reynolds et al., 2004).  A number of design 
rules and algorithms have been suggested for the design of efficient siRNAs.  
Early on the optimum siRNA length was suggested to be 21 base pairs 
(Elbashir et al., 2001a). When RNA interference was first described in 
Caenorhabditis elegans (Fire et al., 1998), long double stranded RNA (dsRNA) 
was used. In mammalian cells, long dsRNA induces an interferon response 
which activates a ubiquitously expressed serine/threonine protein kinase 
(PKR) (Williams, 1999). PKR is a member of the antiviral arm of the 
mammalian stress response which is activated by dsRNA, cytokines, growth 
factors and other stress signals (Williams, 1999). If triggered, PKR initiates 
overall inhibition of gene expression and cell death (Kittler and Buchholz, 
2003). The exact length at which dsRNA triggers the interferon response is 
not known, but dsRNA shorter than 30 base pairs long does not trigger cell 
death in most cell lines (Kittler and Buchholz, 2003). In this study 21mere 
siRNAs were used, as most design tools are designed to produce siRNAs of 
this length.  However, later evidence suggested that 27meres may be the 
optimum length for siRNA efficiency (Kurreck, 2006). 
An early criterion used for selection of potential sequences was the 
Tuschl rule (Elbashir et al., 2001b). According to this rule, sequences starting 
with an AA dinucleotide which produces siRNAs with 3’ overhanging UU 
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dinucleotides are more efficient (Elbashir et al., 2001b). This is in agreement 
with several other authors (Khvorova et al., 2003, Schwarz et al., 2003).  
However, some authors claim that this is unnecessarily limiting and risks 
exclusion of effective siRNAs (Naito et al., 2004), while others suggest that 
the 3’ UU overhang need not match the target sequence (Yu et al., 2002, 
Schwarz et al., 2003), avoiding exclusion of sequences that do not start with 
an AA dinucleotide.  
All siRNAs in this study complied with the Tuschl rule, except the 
positive control siRNAs targeting the Renilla gene. Positive controls Renilla 1 
and 2 were based on a published sequence (Betz, 2005) and had previously 
been used in the psiCHECK-2 vector system. The third Renilla sequence was 
designed using online siRNA design programs as previously described 
(Chapter 2.8.1). In this study, the positive control siRNAs were not as 
efficient in gene silencing as the best siRNAs against the Egfr, all of which 
were designed according to the Tuschl rule indicating that it may be relevant 
in siRNA design.  
A further design criterion is that there should be no G residues in the 
3‘-overhangs of the siRNA molecule. RNases used in the clean-up step in the 
Ambion Silencer® siRNA Construction Kit cleave single stranded RNA 
containing G residues (Ambion, 2008b), and would truncate the siRNA if it 
contained this residue. Free nucleotide overhangs have been shown to be 
crucial for siRNA activity (Patzel et al., 2005), so this criterion was critical in 
the design of these nucleotides. 
The proportion of functional siRNAs increases when their GC content 
is between 36 and 52% (Elbashir et al., 2002, Reynolds et al., 2004, Kurreck, 
2006) or 30 and 70% (Kumar et al., 2003). All but one (Renilla 2/siRNA9) of 
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the siRNAs used in this study achieved the more stringent criteria set by 
Reynolds and colleagues (Reynolds et al., 2004).  
RISC preferentially incorporates antisense strands with relatively lower 
5’- end thermodynamic stability (Khvorova et al., 2003, Schwarz et al., 2003). 
It has been proposed that a lower internal stability at one end of the duplex 
aids duplex unwinding and increases efficient entry into the silencing 
complex (Khvorova et al., 2003, Schwarz et al., 2003). A relatively simple way 
of achieving a lower thermodynamic stability at one end is to increase the A 
or U base pair content of one end. According to the second criteria of 
Reynolds et al. (2004) there should be at least one, or preferably more than 
three A or U base pairs at positions 1-5 of the antisense strand. Eight of the 
siRNAs in this study had three A or U base pairs at this position; one had 
two U’s and one had only one U. The three most effective siRNAs in this 
study had two or three A or U base pairs at this position.  
To minimise off target effects of the siRNAs the sequences should have 
no more than 16-17 contiguous base pairs homology when performing a 
BLAST search (Reynolds et al., 2004, Kurreck, 2006, NCBI, 2010a).  Some 
authors suggest that as little as eleven contiguous base pairs may cause off 
target effects (Naito et al., 2004), and that BLAST searches are not stringent 
enough to predict all possible off target effects (Naito et al., 2004, Zhou et al., 
2006). All our sequences had between 15 and 17 base pairs sequence 
homology with other genes according to a BLAST search of the feline 
genome. Although adhering to the criteria set by Reynolds and colleagues 
(Reynolds et al., 2004), ideally the homology to other sequences should have 
been less in this study. However, the choice of sequences was restricted due 
to the constraints of only having a 500 base pairs long sequence to design the 
siRNAs from.  
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In order to achieve maximal efficiency of knockdown, an optimal 
transfection protocol has to be established for each cell line, as efficiency of 
siRNA knockdown is directly related to the delivery of siRNA into cells 
(Kittler and Buchholz, 2003). The results of the optimisation performed in 
this study illustrated this with a threefold increase in knockdown efficiency 
achieved for the positive control siRNA following optimisation. The amount 
of siRNA used is of particular importance. A dose dependent increase in 
efficiency is observed with increasing siRNA concentrations (Kumar et al., 
2003), but the effect does eventually tail off, and too high concentrations are 
undesirable for several reasons. Higher siRNA concentrations can lead to 
increased off target effects and increased toxicity (Scherer and Rossi, 2003, 
Dorsett and Tuschl, 2004). In addition, the cost of producing siRNAs is 
significant (Takasaki, 2010), so finding the lowest effective siRNA 
concentration is highly desirable.  
As discussed, there are currently a number of design rules and 
algorithms published on how to design a highly effective siRNAs (Takasaki, 
2010), as well as statistically based computer software designed to aid in this 
process (Naito et al., 2004, Takasaki, 2010). Despite all these available tools, 
the consensus is that siRNA sequences produced by in vitro transcription or 
chemical synthesis all require screening in order to establish their efficiency 
(Kittler and Buchholz, 2003, Scherer and Rossi, 2003). Endoribonuclease 
prepared siRNAs (esiRNAs), on the other hand produce multiple siRNAs 
against a given mRNA and do not require screening (Yang et al., 2002, 
Kurreck, 2006). This approach produces a mix of siRNAs that can be 
transfected together into cells to cause gene silencing. This approach was not 
appropriate for this study, however, as we required a known effective siRNA 
sequence that we could use in further studies. The siRNAs in this study were 
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therefore produced by in vitro transcription using T7 RNA polymerase 
necessitating a screening process.  
The maximum effect obtained by the siRNA in this study was 77% 
reduction in target gene expression. The reports in the literature vary in what 
constitutes an efficient siRNA. In general highly effective siRNAs are defined 
as producing more than 95% (Reynolds et al., 2004) or more than 90% 
(Khvorova et al., 2003) gene silencing and functional siRNAs are defined as 
producing more than 70% gene silencing (Khvorova et al., 2003). According 
to these criteria the siRNAs in this study can only be classified as functional 
siRNAs. The vector based screening method used here has been shown to 
produce a relatively larger reduction in target gene protein levels compared 
to the normalised reduction in luminescence seen from control gene 
expression during screening (Kumar et al., 2003). For example, a siRNA 
which produced a 50% reduction in normalised fluorescence during 
screening achieved an 80% reduction in protein levels expressed as a relative 
reduction in band intensity by western blotting. The study also confirmed 
that siRNAs chosen using vector based screening also suppressed 
endogenous gene product in vitro (Kumar et al., 2003), which suggests that 
the siRNAs screened in this study should be efficient in suppressing 
endogenous feline EGFR levels as well. 
Three of the siRNAs screened in this study showed that they could 
efficiently reduce the level of feline Egfr mRNA in the psiCHECK-2 vector 
system, while the remaining siRNAs showed poor efficiency. The probability 
of designing a high potency siRNA is low, so screening of potential 
candidates is essential (Yang et al., 2002, Scherer and Rossi, 2003). Reynolds 
and colleagues (2004) suggest that on average only one in ten to one in four 
siRNAs designed produce over  95% gene suppression, while others report 
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that one in five achieve this level (Kumar et al., 2003). In this study six 
siRNAs were screened, and three of these showed acceptable to moderate 
efficiency, which would be as expected according to the reports in the 
literature.  
The reasons why siRNAs differ so widely in their efficiency can largely 
be explained by different sequence properties of the individual siRNAs. In 
addition to the rules discussed above, five different studies have produced 
specific recommendations for preferred nucleotides at specific positions 
within the siRNA sequence (Takasaki, 2010). The recommendations from 
these studies do correlate well (Takasaki, 2010), but they can severely limit 
the number of available sequences in studies were the target sequence is 
relatively short, as was the case in this study.  
Internal repeats or palindromes within the siRNA can also limit the 
effectiveness of a siRNA (Reynolds et al., 2004). These can lead to increased 
internal stability and secondary structure of the siRNAs, causing reduced 
uptake into the RISC complex (Reynolds et al., 2004, Patzel et al., 2005). Some 
authors propose that secondary structures of the target mRNA also affect 
siRNA efficiency (Kurreck, 2006, Takasaki, 2010), while others propose that 
target mRNA secondary structure has little effect on siRNA efficiency 
(Elbashir et al., 2002). The consensus is now that a combination of the 
thermodynamic properties of the siRNA which affects the asymmetric strand 
incorporation into RISC as well as accessibility to the target site all contribute 
towards silencing efficiency (Kurreck, 2006). In this study the structure of the 
mRNA could not be taken into account when designing the siRNAs as the 
full length feline Egfr mRNA sequence is not known. The screening process 
allowed for a selection of the potentially most efficient siRNA. The chosen 
sequence can now be used to assess the effect of Egfr gene silencing in a 
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feline model system, the feline squamous cell carcinoma cell line SCCF1 
(Tannehill-Gregg et al., 2001). 
4.6 Summary 
These findings facilitate further investigation of Egfr targeting in feline 
oral SCC suggesting two potential mechanisms for EGFR targeting. A 
specific siRNA against the feline Egfr sequence have been developed, and the 
efficiency of this siRNA against the feline Egfr and the effect of Egfr gene 
silencing on the SCCF1 cell line can now be further elucidated.  
This study also discovered that the ATP binding pocket was conserved 
between the feline and human EGF receptors, suggesting that TKIs designed 
to target the human EGFR may be effective in feline cells. These results 
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5.1 Abstract 
This study investigated different methods of EGFR targeting in a feline 
squamous cell carcinoma cell line. Both RNA interference techniques and a 
small molecule tyrosine kinase inhibitor reduced cell proliferation and 
migration in the cell line. The use of hairpin expression vectors was explored 
to evaluate the potential for long term EGFR suppression, and they 
produced sustained knockdown of EGFR in the cell line. EGFR targeting 
with RNAi also reversed acquired gefitinib resistance in the cell line, and 
produced an additive effect when used in combination with radiotherapy. 
These results support the use of EGFR targeting as a viable therapeutic 




In feline oral SCC, current treatment options include surgery (Northrup 
et al., 2006), radiotherapy (Fidel et al., 2007), chemotherapy (Fox et al., 2000), 
or a combination of these (LeBlanc et al., 2004), but overall survival remains 
poor (Hayes et al., 2007). Treatment is often hampered by the locally 
aggressive nature of these tumours (Hayes et al., 2007) and the high 
morbidity that may be seen with treatment (Northrup et al., 2006). New 
approaches to the treatment of feline SCC would be beneficial, and are likely 
to include combination therapies with current established treatment 
protocols.  
Since the early nineties when the first reports on the potential 
involvement of EGFR in the carcinogenesis of HNSCC were published 
(Weichselbaum et al., 1989, Grandis and Tweardy, 1993), developing 
strategies to target EGFR in HNSCC has been the main focus of research in 
this area. Several EGFR targeting drugs are now available which belong to 
two drug classes, the small molecule tyrosine kinase inhibitors (TKIs) and 
the therapeutic monoclonal antibodies (mAbs) (Chen et al., 2010). The 
response to TKIs have been modest in HNSCC (Ratushny et al., 2009, Chen 
et al., 2010) due to tumour cells either exhibiting an inherent resistance to the 
drugs or through acquiring resistance over time (Li et al., 2009, Chen et al., 
2010). The search is on to find molecular markers that can predict response to 
therapy by identifying tumours that possess intrinsic resistance to therapy 
(Wheeler et al., 2010a). Some success has already been achieved in some 
tumour types, for example the identification of activating mutations located 
in the tyrosine kinase domain which predicts response to gefitinib in non-
small-cell lung cancer (NSCLC) (Pircher et al., 2010, Wheeler et al., 2010a). By 
selecting individuals more likely to respond these trials have achieved 
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response rates of 50 to 70% (Wheeler et al., 2010a) compared to 12 to 18% 
reported in earlier trials (Pircher et al., 2010). However, identifying the 
molecular mechanisms utilised by cells to acquire resistance is equally 
important. In NSCLC such a mutation has been identified in the tyrosine 
kinase region, and it is thought that with the advent of irreversible TKIs 
these cells will become sensitised again (Wheeler et al., 2010a). Although 
mutations conferring oncogene addiction have been identified in other solid 
tumours, in HNSCC similar tyrosine kinase mutations seem to be rare events 
(Chen et al., 2010).  
The aim of this study was to investigate the role of EGFR in feline SCCs 
by using two mechanisms to inhibit receptor signalling. RNAi was used to 
investigate the effect of Egfr specific gene silencing on the cell line by 
evaluating cell proliferation, cell migration and downstream targets of the 
EGFR signalling pathways. In addition, the observation that the feline ATP 
binding pocket was conserved (Chapter 4) paved the way for investigating 
the use of TKIs in a feline cell line SCCF1. The ability of the SCCF1 cell line to 
develop resistance to TKI after prolonged exposure, a common treatment 
failure in man (Chen et al., 2010, Wheeler et al., 2010a), was assessed by 
chronic exposure of the cell line to sub-lethal doses of TKIs. The ability of 
feline Egfr RNAi to rescue TKI resistance in the cell line was then assessed. 
Finally, the effect of combining EGFR targeting with conventional therapies 
was investigated in the cell line.  
5.3 Materials and Methods 
5.3.1 Gefitinib treatment of SCCF1 cell line 
The SCCF1 cell line was cultured as previously described in Chapter 
2.3. The cell line was treated with different concentrations of gefitinib and 
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SCCF1G, the gefitinib resistant cell line, was developed as described in 
Chapter 2.3.8 and 2.3.9 respectively. To investigate the acquisition of point 
mutations as a potential mechanism of acquiring resistance in the cell line, 
the tyrosine kinase domain of the SCCF1G cell line was sequenced using the 
same primer sets as described in Chapter 4.2.1. Following gefitinib 
treatments, cell proliferation assays (Chapter 2.14) and in vitro scratch assays 
(Chapter 2.16) were performed.  
5.3.2 Liposome-mediated transfections of SCCF1 cell line 
The SCCF1 cell line was optimised for both transient siRNA and 
plasmid DNA transfections as described in Chapters 2.9.3.1 and 2.9.3.3, and 
the optimised Lipofectamine 2000™ protocols (Chapters 2.9.3.2 and 2.9.3.4) 
were used in the study. Real Time PCR primer efficiencies were determined 
for the primer sets as described in Chapter 2.12.3.1. Following transient 
siRNA and hairpin expression vector transfections, Real-Time PCR analysis, 
western blot analysis and cell proliferation assays were performed as 
described in Chapters 2.12, 2.13 and 2.14 respectively. In addition, following 
plasmid transfections colony formation assays (CFAs) as described in 
Chapter 2.15 were performed. CFAs were performed during G418 selection 
as well as after 20 days of G418 selection.  
Cells were transfected with siRNAs against the feline Egfr, scrambled 
sequence Silencer® Negative Control #1 siRNA (Ambion), or with pSilencer™ 
neo Kit hairpin expression vectors containing the sequence directed against 
the feline Egfr or a scrambled control sequence. Cells transfected with the 
hairpin expression vectors were trypsinated and counted 24 hours following 
transfection, seeded at their optimal cell density into six well plates before 
adding selective G418 containing media for 20 days.  
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5.3.3 Hairpin expression vector 
The 3.1pSilencer™ neo Kit (Ambion) is a hairpin expression vector 
system capable of generating short hairpin RNA (shRNA) transcripts that 
can induce long term gene silencing in cells (Figure 2.3). The vector contains 
an H1 RNA polymerase III promoter which provides high levels of 
constitutive expression across a variety of cell types. The terminator 
sequence is a short stretch of uridines, which is compatible with the most 
commonly used siRNA design consisting of two 3’ uridine overhangs 
(Elbashir et al., 2001b).  In order to facilitate selection of transfected cells 
following transfections the vector also harbours a neomycin resistance gene. 
To select cells a neomycin analogue, G418 was used after establishing the 
optimum concentration (Chapter 2.3.11) and cell plating density (Chapter 
2.3.12) for the SCCF1 cell line.   
To design shRNA DNA oligonucleotide templates for the hairpin 
expression vector the sequence of siRNA8, the most effective sequence 
against the feline Egfr (Chapter 4), was entered into the online pSilencer 
converter tool (Ambion, 2008a). The DNA oligonucleotides templates were 
ordered from eurofinsdna.com and used directly in the ligation reaction as 
described in Chapter 2.7.3. The DNA oligonucleotide sequences can be seen 
in Table 5.1. 





Table 5.1: DNA oligonucleotide template sequences contained the target sense and 





5.3.4 Radiosensitivity assay 
SCCF1 cells were transfected (with siRNA8 and scrambled control) or 
treated with 5 µM gefitinib in six and 96 well plates and incubated for 24 
hours before being irradiated. All cells were irradiated in culture medium 
using a Faxitron® cabinet X-ray system 43855D (Faxitron X-ray Corporation, 
Lincolnshire, IL, USA) at a central dose rate of 2 Gray (Gy)/min. All 
irradiation was given as a single fraction at room temperature. The 96 well 
plates were irradiated at 0, 0.5, 3, and 5 Gy and incubated for 72 hours prior 
to performing cell proliferation assays. Cells from the six well plates were 
trypsinated and counted 24 hours after transfections and 300 cells were 
seeded in triplicate into ten cm plates and irradiated in suspension at 0, 0.5, 
and 3 Gy prior to performing CFAs as previously described (Chapter 2.15).   
5.3.5 Statistical analyses 
All statistical analyses were performed as described in Chapter 2.19. To 
assess the effect of combining radiation with EGFR knockdown in the SCCF1 
cell line the Bliss additivism model was used as previously described (Buck 
et al., 2006). A theoretical curve was calculated for combined inhibition using 
the equation Ebliss = EA + EB – (EA x EB), where EA and EB is the fractional 
inhibition obtained by siRNA alone and radiation alone at different doses 
respectively. Combined treatments with experimental values equal to the 
theoretical Ebliss value show an additive effect, while experimental values 
displaying a larger inhibition compared to Ebliss represent synergism. 
Conversely, combined treatments with experimental values below the Ebliss 




5.4.1 Inhibition of EGFR signalling causes reduced cellular 
proliferation and migration in the SCCF1 cell line 
Following 72 hours of continuous exposure to gefitinib in the cell line, a 
reproducible reduction in cell proliferation was observed (Figure 5.1). The 
effect was dose-dependent and approximately linear through the range of 1 
to 10 µM. Doses in the nanomolar range had no effect on proliferation of the 
cell line when compared to untreated and DMSO treated controls. Average 
inhibitory concentration causing 50% reduction of proliferation in the SCCF1 
cell line was approximately 5 µM (Figure 5.1).  
To investigate the effect of inhibition of EGFR signalling on cellular 
migration, scratch assays were performed on cells treated with gefitinib. The 
SCCF1 cell line showed a dose-dependent reduction in migration following 
gefitinib treatment (Figure 5.2).  
In contrast, using proliferation assays following gefitinib treatment the 
SCCF1G cell line showed no significant inhibition of proliferation at the 
5 µM drug dose (Figure 5.1), and was consistently more resistant at 
concentrations of 1-15 µM gefitinib. Scratch assays performed on the gefitinib 
resistant cell line showed a comparatively faster migration in the resistant 
cell line when compared to the parent cell line (Figure 5.3). Gefitinib had no 





Figure 5.1: Cell proliferation assay showing proliferation of SCCF1 and SCCF1G after 72 
hours of gefitinib treatment at variable concentrations. X axis represents gefitinib 
concentrations in µM and Y axis represents % of proliferation as compared to DMSO control 
treated cells. Error bars show standard deviations, and * denotes p<0.05 with two sample t-
test showing statistically significant difference in proliferation ability. 
 
To investigate the acquisition of point mutations as a potential 
mechanism of acquiring resistance in the cell line, the tyrosine kinase domain 
of the SCCF1G cell line was sequenced. No mutations were found in the 





Figure 5.2 a) In vitro scratch assay of SCCF1 cell line showing effect of EGFR specific 
tyrosine kinase inhibitor gefitinib on cellular migration. Each box shows top left DMSO 
control, top right 1 µM gefitinib, bottom left 5 µM gefitinib, bottom right 10 µM gefitinib at i) 0 
hrs, ii) 12 hrs and iii) 24 hrs. b) Histogram showing relative migration of the SCCF1 cell line 
after 24 hrs of gefitinib treatment compared to DMSO control treated cells. The 10µM 
gefitinib dose produced a 23% reduction in gap width after 24 hours compared with the 





Figure 5.3 a) In vitro scratch assays comparing migratory ability of the two cell lines. Top row 
0 hours, middle row 9 hours and bottom row 24 hours following gefitinib treatment. b) 
Histogram showing relative migration of cell lines after 9 and 24 hours. After nine hours, the 
DMSO control treated SCCF1 had closed the gap created for the assay by less than half 
while the SCCF1G cell line had reduced the width with over two thirds (*p<0.001, two 
sample t-test). Similarly, a dose of 10 µM gefitinib had different effect on the cell lines. At 9 
hours the resistant cell line had reduced the gap width with approximately half compared to 
only a fifth in the parent cell line (**p<0.001, two sample t-test), and at 24 hours the resistant 
cell line had migrated and filled the gap completely while the parent cell line had only 




5.4.2 Optimisation of liposome mediated transfections increased 
the transfection efficiency in the SCCF1 cell line 
The use of the Silencer® FAM™-Labelled Negative Control #1 siRNA 
allowed for direct visualisation and assessment of transfection efficiency 
using fluorescent microscopy. This method was used for the initial screening 
performed in a 24 well format where the SCCF1 cell line was transfected at 
three different confluences, two different concentrations of transfection agent 
and three different siRNA concentrations (Figure 5.4). The cells were 
assessed at 24, 48 and 72 hours after transfection.  However, by 72 hours the 
wells where the cells had been transfected at 75% confluence became over-
confluent and significant cell death started to occur making comparison 
between wells unfeasible. For that reason only the 24 and 48 hour time 
points were used to assess relative transfection efficiency. Best transfection 
efficiency was achieved with the higher amount of transfection agent using a 
concentration of 50 nM or 100 nM siRNA in the wells transfecting cells at low 
confluence. To further optimise the protocol, the transfections were repeated 
in a six well format on low confluence cells using the higher Lipofectamine: 
RNA ratio (Table 2.9) with 50 nM and 100 nM siRNA for flow cytometry 
assessment of cell viability and transfection efficiency. The cells were 








Figure 5.4 (Figure on previous page): Fluorescent microscopy of the SCCF1 cell line using a 
FITC filter showed increased transfection efficiency seen as increased green fluorescence 
from cells. The cells were transfected in a 24 well format and photographed at 24 and 48 
hours following transfections. The result of this screen showed that the cells exhibited 
maximum fluorescence at 24 hours after transfection. The cells transfected at confluency of 
less than 30% and with the higher siRNA concentrations and the higher Lipofectamine: RNA 
ratios showed the highest transfection efficiency.  
 
 
Figure 5.5: Fluorescent microscopy of SCCF1 cell line using a FITC filter. Photographs were 
taken 24 hours following transfection with two different siRNA concentrations using the 
higher Lipofectamine: RNA ratio and compared to mock transfected cells. Green 
fluorescence was observed in the siRNA transfected cells but not in the mock transfected 
control cells. No significant difference between the two siRNA concentrations was observed.  
168 
 
Flow cytometry showed that both 50nM and 100nM of siRNA 
produced approximately 69% transfection efficiency for both, but cells 
transfected with the lower siRNA concentration had better cell viability. The 
mock transfected cells had cell viability of 99% compared to 95% and 89% for 
the 50 and 100 nM siRNA concentrations respectively (Figure 5.6).  
SCCF1 cell line DNA plasmid transfection optimisation was performed 
using the pmaxGFP™ plasmid in a similar manner with an initial screening 
using two transfection agents at different ratios between DNA and 
transfection reagent (Figure 5.7). Lipofectamine 2000™ gave far superior 
transfection efficiencies at all four ratios when assessed by fluorescence 
microscopy. The two highest DNA: Lipofectamine 2000™ ratios gave the 
best results, so these transfections were repeated in six and 96 well format. 
Transfection efficiency was estimated by flow cytometry to be 40% and 53% 
for the 1:4 and 1:5 ratios respectively. Cell viabilities for the two ratios were 
similar at 96% and 94% of untransfected cell viability respectively as 
assessed by CellTiter-Glo® Luminescent Cell Viability Assay. Increasing the 
transfection agent amount increased the transfection efficiency without a 
detrimental effect on cell viability, so the higher Lipofectamine 2000™ 





Figure 5.6: Flow cytometry results of siRNA optimisation. X-axis shows forward scatter 
(proportional to cell size) (a-f), plotted against FL3-H channel (detects GFP fluorescence) (a-
d) and FL1-H channel (detects PI fluorescence) (e, f) on y-axis. Mock transfected SCCF1 
cells with (a) no added PI allows for a cut off line to be set, and after adding PI (b) mock 
transfected SCCF1 cells are shown to exhibit 99% cell viability. SCCF1 cells transfected with 
50nM siRNA (c) and 100nM siRNA (d), revealed cell survival of 95% and 89% respectively 
when adding PI. GFP fluorescence were positive in 68.5% (e) and 68.7% (f) of SCCF1 cells 












Figure 5.7: Transfection optimisation of SCCF1 cell line comparing two transfection agents 
(siPORT and Lipofectamine 2000™) at four different ratios assessed by fluorescent 
microscopy using a FITC filter. i-iv: siPORT: DNA ratios of 2:1, 3:1, 4:1 and, 3:2 
respectively,  v-viii: DNA: Lipofectamine ratios of 1:0.5, 1:2.5, 1:4 and, 1:5 respectively. 







Figure 5.8: Kill Curve performed on SCCF1 cell line to determine G418 sensitivity a) no 
antibiotic added, b) 100 µg/ml, c) 200 µg/ml, d) 400 µg/ml, e) 800 µg/ml, f) 1600 µg/ml G418 
added to media respectively. 1) 24 hours following seeding of cells when 1 ml of 
corresponding media a-f was added to each well already containing 1 ml of media without 
antibiotics, 2) 48 hours later after having been in G418-containing media only for 24 hours, 
no cell death was noted, 3) 96 hours in G418 containing media, cell death starting to appear 
in wells e & f, 4) 1 week of antibiotics and wells a & b are fully confluent, well c was 90% 
confluent, and wells d-f marked and massive cell death, 5) after 9 days a-c are all fully 
confluent while all cells are dead in e & f, while massive cell death was observed in well d, 6) 
wells a-c were now over-confluent while wells d-f all showed complete cell death.
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5.4.3 G418 titration curve and optimal plating density results for 
SCCF1 cell line 
The G418 titration curve of the SCCF1 cell line determined that a 
concentration of 0.4mg/ml G418 added to the normal William’s E growth 
medium produced massive cell death in the SCCF1 cell line after seven days 
of culture (Figure 5.8). This G418 concentration was then used to determine 
an optimal cell density for seeding the SCCF1 cells 24 hours after 
transfection. Cells seeded at 6x104 cells into a 24 well plate achieved 80% 
confluency before massive cell death occurred. This cell density was scaled 
up for a six well plate format giving an optimal cell density of 3x105 cells 
seeded per well 24 hours following hairpin expression vector transfections. 
The optimal G418 concentration and the optimal cell density determined in 
these assays were used for all technical replicates in all the hairpin 
expression vector transfections.   
5.4.4 The Real Time PCR primer pairs showed adequate primer 
efficiencies in the investigative range 
All Real-Time PCR reactions used cDNA of at least 1:10 dilutions 
because, when using lower dilutions, an inhibitory action had been observed 
previously by colleagues in the lab (data not shown). After investigations by 
the Roche technical support team it was presumed to have been caused by 
an unidentified ingredient in the Roche Transcriptor High Fidelity cDNA 
Synthesis Kit reaction mixture (Dr Karen Tan, personal communications). 
This effect was also seen in the SCCF1 samples at cDNA reaction mixture 
dilutions of 1:5 (Figure 5.9), so all cDNA samples were diluted 1:10 before 




Figure 5.9: Graphs showing the inhibitory effect observed with higher cDNA dilutions using 
the 18s rRNA primers. Graph a) shows an example of a graph plotted to assess primer 
efficiency with the cDNA dilutions shown on the x-axis and the Cp values plotted on the y-
axis. The R squared value is approximately one, b) shows when the 1:5 dilution Cp value is 
included, the R squared value is approximately 0.75. A marked inhibitory effect can be seen 
when the lower dilution is included.  
 
Results of the evaluation of the efficiencies of the primer sets used for 
Real Time PCR reactions are summarised in Table 5.2. All primer sets used 
showed acceptable primer efficiencies in the investigative range, allowing for 
the delta-delta method to be used to assess relative mRNA levels.  
 
Table 5.2: Table showing the results of the evaluation of primer efficiencies for Real Time 
PCR reactions.  
 
5.4.5  Feline Egfr siRNA transfections cause reduced cell 
proliferation and EGFR knockdown in SCCF1 cell line 
SCCF1 cells transfected with siRNA8 against the feline Egfr exhibited 
reduced proliferation ability compared to mock and scrambled transfected 
cells as well as untreated cells for up to 72 hours following transfection 
Primer Set E value R
2
 value Pearson’s correlation coefficient, (p value) 
EGFR primers 2.07 1.00 0.991 (0.0001) 
18 s rRNA primers 2.00 1.00 0.991 (0.0001) 
β-actin primers 1.96 0.99 0.989 (0.0001) 
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(Figure 5.10a). Transfecting the cells with siRNA8 reduced cell proliferation 
to a level equivalent to that achieved with a 10 µM dose of gefitinib in the 
SCCF1 cell line (Figure 5.10b).  
 
Figure 5.10: a) Cell proliferation assay showing proliferation of SCCF1 cells up to 72 hrs 
following siRNA8 transfections compared to untreated SCCF1 cells, mock and scrambled 
control transfected cells (* p<0.0001, at 48 and 72 hrs by One-Way ANOVA). b) Cell 
proliferation assay comparing the effect on proliferation of siRNA transfection against Egfr 
and gefitinib at 72 hours. A single transfection of cells with siRNA produced an equivalent 





Real Time PCR revealed a 55% relative reduction in Egfr mRNA levels 
as compared to scrambled control transfected SCCF1 cells at 24 hours 
following transfection (Figure 5.11). Western blot analysis showed reduction 
in EGFR protein levels at 72 hours following transfection when compared to 
untreated cells and scrambled control transfected cells (Figure 5.12).  To 
investigate the effect of Egfr knockdown on signalling pathways 
downstream of EGFR, western blot analyses were performed on markers of 
the major downstream elements of the EGFR signalling pathway in 
transfected cells. Reduction in phosphorylated Erk1/2 and phosphorylated 
STAT-3 were seen following Egfr knockdown, but phosphorylated Akt 
protein levels remained unchanged (Figure 5.13).  
 
 
Figure 5.11: Histogram showing Real Time PCR result of EGFR mRNA levels in SCCF1 
cells transfected with siRNA8 against the feline EGFR expressed as percentage of 
scrambled control levels. EGFR results shown are an average of triplicate transfections and 
each transfection was run in three technical replicates for the Real Time PCR analysis. 




Figure 5.12: Western blot showing reduction in EGFR protein levels 72 hours post siRNA 
transfection of SCCF1 cell line. Lysates from mock transfected (M) and scrambled control 
transfected cells (S) are show next to lysates from SCCF1 cells transfected with siRNA8 
against the feline EGFR in triplicate (E). The lower band on gel show β-actin protein levels 
as a loading control. Similar results were obtained in separate experiments. 
 
Figure 5.13: Western blot showing levels of phosphorylated downstream targets of EGFR in 
siRNA8 transfected SCCF1 cells (E) compared to scrambled control transfected cells (S). A 





5.4.6 siRNA transfections rescue gefitinib resistance in cell line 
Transfection of the resistant SCCF1G cell line with siRNA8 rescued the 
gefitinib resistance in the cell line and produced a marked reduction in 
cellular proliferation at 72 hours following transfections when compared to 
mock transfected cells. In comparison, gefitinib treatment at 5 µM of the 
resistant cell line caused no significant reduction in proliferation when 
compared to DMSO control (p=0.898, two sample t-test), and 10 µM of 
gefitinib only had a modest effect on proliferation (Figure 5.14).  
 
 
Figure 5.14: Mock transfections and DMSO treatments of both cell lines had minimal effect 
on proliferation, while gefitinib treatment and EGFR siRNA transfections caused marked 
effects on the SCCF1 cell line. The SCCF1G cell line exhibited resistance to doses of 
gefitinib of up to 10 µM while siRNA transfections against the feline EGFR still caused 
reduction in proliferation in the cell line. Bars show standard deviations, * p<0.001, 
** p<0.001 compared to DMSO control and mock transfected respectively by two sample t-




5.4.7 Hairpin expression vectors cause long term knockdown of 
EGFR and reduced proliferating ability and colony formation in 
the SCCF1 cell line 
Real Time PCR analysis (Figure 5.15) showed variable reduction in Egfr 
mRNA levels in shEgfr transfected cells compared to scrambled control 
transfected cells with an average reduction of 35% (SD 18%, range 10-53%). 
Similarly, western blot analysis (Figure 5.16) of cell lysates produced three 
weeks after transfection showed variable reduction in EGFR protein levels 
when compared to scrambled controls.  
 
Figure 5.15: Real Time PCR results showing EGFR mRNA levels as percentage of 
scrambled control in hairpin expression vector transfected SCCF1 cells after 3 weeks culture 
in selective G418 containing media. Each individual result is representative of three 






Figure 5.16: Western blot showing variable reduction in EGFR protein levels in two lysates 
from different hairpin vector transfections. MDA-MB (lane 1) contain lysate from the MDA-
MB-468 cell line (MD Anderson Cancer Centre, Texas, USA), a human breast cancer cell 
line that overexpresses EGFR. It was used as positive control to validate the antibody for the 
use on feline protein lysates. Lanes 2-5 contains lysates from SCCF1 cell line: EGFR: 
transfected with vector expressing shRNA against EGFR, Scram: transfected with vector 
with scrambled control sequence, SCCF1: untransfected cells. Protein loaded: 30 µg MDA-
MB, 60 µg remaining samples. Lower bands show β-actin for loading control.  
 
 
Figure 5.17: Colony formation assay performed during 3 weeks of G418 selection post 
hairpin expression vector transfection. A 45% reduction in colony formation ability was seen 
in the shEgfr transfected cells when compared to scrambled control transfected cells. Inset 
shows average number of colonies counted with bar showing standard deviation. Bars are 
average of 8 (shEgfr) and 9 (Scrambled) 10 cm plates for each sample and represent 
transfections performed in triplicate. The difference in colonies showed a trend towards 
statistical significance (p=0.06, Mann Whitney U-test).
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Colony formation assays were performed during antibiotic selection 
(Figure 5.17) and after 20 days of antibiotic selection of cells (Figure 5.18). 
The ability of the cell lines to form colonies was reduced on average by 45% 
and 22% compared to scrambled control transfected cells during and after 
antibiotic selection, respectively. 
 
Figure 5.18: Histogram showing average number of colonies formed (light grey bars show 
individual counts, while the dark grey bar shows the average of the three counts) when CFA 
were set up after 20 days of G418 selection of SCCF1 cells following transfections. EGFR 
knockdown still had some effect on colony formation ability (on average 22% reduction 
compared to scrambled control transfected cells) for up to 5 weeks after transfections, but 
the effect was reduced compared to during the first three weeks (Figure 5.16). 
 
Cell proliferation assays performed on the cell line after 20 days of 
antibiotic selection (Figure 5.19) showed a statistically significant difference 
between the cell proliferation rates at all three time points. The effect on cell 
proliferation observed after the G418 selection period was less pronounced 




Figure 5.19: Cell proliferation assay showing SCCF1 cell lines proliferating ability after 20 
days of selection with G418 containing media. EGFR transfected cells showed a statistically 
significant lower proliferation rate when compared to scrambled transfected cells at 24, 48 
and 72 hours following seeding into 96 well plates (* p=0.001, p=0.003 and p<0.001 
respectively, two sample t-test). Each point shows an average absorbance value of four 
wells with the background subtracted, bars show standard deviation. Similar results were 
obtained in two separate experiments. 
 
 
5.4.8 Radiation and EGFR knockdown show an additive effect in 
the SCCF1 cell line 
To investigate the effect of Egfr targeting in combination with 
conventional therapies a radiosensitivity assay was performed. Radiation 
doses of up to 5 Gy had no effect on SCCF1 cell line proliferation ability 72 
hours following irradiation (Figure 5.20). The modest effects seen of Egfr 
knockdown by siRNA or treatment with gefitinib were not enhanced by any 




Figure 5.20: Cell proliferation assays performed 72 hours following radiation treatment and 
96 hours after transfection and gefitinib treatment. The radiation treatments had minimal 
effect on cell proliferating ability at this early stage following therapy. The EGFR targeting 
has had some effect on cell proliferation when compared to scrambled and untreated 
controls, but no enhancement is seen at any of the radiation doses. Each point on the chart 
represents an average of absorbance readings from six wells with bars showing standard 
deviations. 
 
However, ten days after radiation exposure, colony formation assays 
showed a dose dependent reduction in colony formation ability in the 
irradiated cells which was enhanced in the siRNA8 but not the scrambled-
control transfected or gefitinib treated cells (Figure 5.21). An additive but not 
a synergistic effect was seen when siRNA8 transfections were combined with 




Figure 5.21: a) Histogram showing colony formation assay following EGFR targeting by 
either siRNA or with gefitinib in combination with radiation doses of 0, 0.5 and 3 Gy 
compared to untreated and scrambled control transfected cells. Gefitinib at a dose of 5 µM 
had no effect on colony formation ability compared to Egfr targeting by siRNA. b) Graph 
comparing colony formation ability of untreated cells and cells transfected with scrambled 





Figure 5.22: Graph showing additive effect of combining EGFR siRNA8 knockdown and 
radiation. The predicted graph show the calculated Ebliss values expected if radiation 
treatment and EGFR inhibition were causing an additive effect according to the Bliss 
Additivism Model. The graph showing the effect of combined siRNA8 EGFR transfection and 




Small molecule TKIs like gefitinib bind to the ATP binding pocket in 
the tyrosine kinase domain of the receptor and block phosphorylation 
(Arteaga, 2003). Since the ATP binding pocket was conserved in the feline 
cell line (Chapter 4), we hypothesised that human drugs like gefitinib would 
be effective against the feline receptor. As RNAi targeting feline Egfr was an 
unproven approach to EGFR inhibition, gefitinib was assessed in tandem 
with the RNAi strategies.  
In this study gefitinib did effectively reduce cellular migration and 
proliferation in the feline cell line, but at the relatively high dose rate of 
10µM. An in vitro dose of gefitinib of 1 µM is equivalent to a clinical dose of 
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250 mg per day used in NSCLC (Sharma et al., 2007). In NSCLC in vitro 
studies doses of gefitinib above 2 µM would class the cell line as insensitive 
to the drug (Sharma et al., 2007). Early studies on HNSCC cell lines used 
much higher doses than this (Huang et al., 2002) while more recent studies 
all have used doses below 2 µM gefitinib (Huang et al., 2004, Erjala et al., 
2007). In conclusion, the SCCF1 cell line can therefore be classed as being 
relatively insensitive to gefitinib, requiring a relatively high dose (when 
compared to therapeutic doses of gefitinib currently used in man) in order to 
show a significant effect on proliferation and migration. Following chronic 
exposure to gefitinib the cell line became resistant to the drug, further 
reducing its effect on the ability of the cell line to proliferate and migrate. 
Development of resistance to TKIs during treatment is well 
documented in human cancers, and mutations in the tyrosine kinase domain 
of the receptor are one of the mechanisms involved.   In NSCLC in man, the 
T790M mutation in the tyrosine kinase domain has been associated with the 
development of resistance to gefitinib (Wheeler et al., 2010a). It results in a 
substitution of methionine for threonine in the ATP binding site increasing 
the receptor affinity for ATP (Wheeler et al., 2010a). To evaluate if a similar 
mechanism was responsible for development of resistance in this cell line, 
the ATP binding pocket of Egfr in the resistant cell line was sequenced but, 
as no mutations were found, this was not the mechanism of resistance in 
these cells. This is similar to the development of resistance to TKIs in 
HNSCC in which tyrosine kinase mutations of Egfr are rare events (Chen et 
al., 2010).   The mechanism of the development of acquired gefitinib 
resistance in the SCCF1G cell line in this study is not known, but some of the 
previously reported mechanisms of resistance could be consistent with an 
apparent resistance to tyrosine kinase inhibition but not to siRNA. Nuclear 
186 
 
translocation has been implicated in resistance to the monoclonal antibody 
cetuximab (Li et al., 2009). Although it has been suggested that small 
molecule TKIs affect nuclear EGFR (Li et al., 2009), their relative efficiencies 
in the nucleus are unknown. siRNAs exert their effect mainly in the 
cytoplasm of cells (Kittler and Buchholz, 2003), but if efficient will reduce 
nuclear as well as membranous and cytoplasmic receptor levels. Increased 
expression of receptor ligands (Li et al., 2009) would have limited effect on 
transfected cells as the receptor levels would be markedly reduced. If the 
cells upregulated other members of the receptor family like for example 
ErbB3 (Wheeler et al., 2008), the siRNA would not be expected to be 
effective. A novel resistance pathway relies on transactivation of EGFR by 
the cytosolic tyrosine kinase Src (Chaturvedi et al., 2009). siRNAs targeting 
Egfr would still be effective in this scenario as the reduction in receptor 
protein levels would counteract the increased phosphorylation. Likewise, if 
the receptor ubiquitination and degradation pathways were dysregulated 
(Shtiegman et al., 2007), siRNAs targeting Egfr would still be effective. 
Regardless of the mechanism used by the cells in this study, the net effect 
was that resistance to gefitinib could be reversed by using siRNA to target 
Egfr. As discussed, the vast majority of the resistance mechanisms reported 
in the literature would be less effective against RNAi targeting. RNAi works 
on the mRNA level, while the majority of the resistance mechanisms are 
modifications affecting the cell at the protein level. This study illustrated 
how the resistant cancer cells were still dependent on EGFR for proliferation, 
despite acquiring resistance to an EGFR targeting drug. This suggests that 
the resistance mechanism used by the cell line in this study circumvented the 
effect of the drug not by relying on other pathways but by a mechanism that 
rendered the drug ineffective against EGFR.  
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RNAi was used in this study as it is a highly selective method of 
evaluating the effect of gene silencing of a target gene (Pai et al., 2006). We 
demonstrated that our siRNA8 Egfr reduced both Egfr transcripts and EGFR 
protein in the SCCF1 cell line. The relatively poor reduction of Egfr mRNA 
levels seen in this study with a reduction in mRNA levels of on average 55% 
(siRNA) and 35% (shRNA) would class the siRNA8 sequence as an non-
functional siRNA by some authors (Khvorova et al., 2003). The SCCF1 cell 
line was found to have a relatively low basal level of Egfr mRNA with Cp 
values in the mid-twenties as seen when testing primer efficiencies for Real 
Time PCR reactions using untreated SCCF1 cDNA. Similarly, when 
comparing protein levels of EGFR with the human EGFR overexpressing cell 
line MD-MBA-468 by western blot analysis, the SCCF1 cell line had a low 
basal level of receptor expression (Figure 5.16). It is tempting to speculate 
that when starting from such a low level of transcript, the relative reduction 
achieved is likely to be less pronounced. The net effect in the cell line did 
nonetheless translate into a measurable reduction in protein level and a 
profound effect on cell proliferation and colony formation ability and this 
effect could be sustained over time. This study supports the observation that 
the level of EGFR expression in tumours does not necessary directly correlate 
with tumour EGFR dependency and response to EGFR targeting therapy as 
was first anticipated (Wheeler et al., 2010a). These results demonstrated that 
EGFR is an important oncogenic driver in this model of feline oral SCC 
despite the relatively low receptor level present in the cell line, and that 
targeting EGFR in feline oral SCC has potential as a therapeutic strategy. It 




This study also investigated the effect of EGFR targeting on the 
pathways downstream of the receptor and demonstrated that the MAPK and 
STAT3 pathways involved in cell proliferation and angiogenesis were 
downregulated while the PI3K pathway was not. A marked reduction in 
proliferation seen following EGFR knockdown is consistent with a reduction 
in phosphorylation in these two pathways. Although EGFR has been shown 
to directly activate the PI3K pathway mediated by growth factor receptor 
binding 2 (Grb-2)-associated binding protein 1 (Gab1) (Cao et al., 2009), 
ErbB3, a closely related member of the Egfr gene family, is the major 
activator of the PI3K pathway with six separate phosphorylation sites for the 
p85 subunit of PI3K (Baselga and Swain, 2009). EGFR targeting may be less 
likely to cause a major reduction in PI3K pathway activation if ErbB3 
receptor remains active. The clinical responses to EGFR targeting therapies 
in human trials have so far been modest (Ratushny et al., 2009) and this may 
be because tumours have an intrinsic resistance to EGFR-targeted therapy (Li 
et al., 2009, Ratushny et al., 2009). These problems may be overcome by using 
combination therapies that target these alternative resistance pathways and 
by improved selection of patients that are more likely to respond to EGFR 
targeting (Ratushny et al., 2009). The results of this study suggest that 
inhibiting Akt concurrently may improve the response to EGFR targeting.  
Part of effective clinical application of Egfr RNAi is likely to include 
inducing prolonged EGFR inhibition to have a sustained effect in tissues. 
Direct transfection of siRNA molecules produces only transient inhibition of 
Egfr gene expression as siRNA molecules become depleted or destroyed (Pai 
et al., 2006). To evaluate the effect of sustained Egfr gene knockdown, a 
plasmid that expressed short-hairpin RNA molecules was developed. This 
study demonstrated that a hairpin expression vector can be effectively taken 
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up by cells and lead to sustained production of shRNAs. The short hairpin 
expression vector transfection efficiency was lower than the naked siRNA 
transfection efficiency (53% vs. 69% for plasmid and siRNA transfections 
respectively). To counter this effect, antibiotic selection was used to enrich 
for cells incorporating the expression vector. Despite selection, the efficacy of 
gene knockdown and the variability between transfection replicates were 
greater when using hairpin expression vectors compared to naked siRNAs. 
Possible explanations for this include that some clones may have developed 
resistance to the shRNAs by acquiring mutations rendering them insensitive 
to interference by the shRNA. Alternatively, as experiments have shown, 
between 1-10% of vectors integrated into the genome during stable 
transfection experiments are not intact (Recillas-Targa, 2006). These clones 
may have acquired the antibiotic resistance gene without acquiring 
functionally intact shRNA expression. Considering that EGFR knockdown is 
deleterious to cell proliferation, these clones would have a growth advantage 
over the cells expressing shRNAs against the feline Egfr. Whichever 
mechanism was at play in this study is unknown. It highlights however, the 
limitations of RNAi techniques for therapeutic use; achieving efficient and 
reliable tissue delivery remains a major obstacle for the development of 
RNAi therapeutics.  
In HNSCC the role of chemoradiation is well established (Ratushny et 
al., 2009), and a monoclonal antibody targeting EGFR, cetuximab, has been 
given FDA approval for use in combination with radiotherapy for HNSCC 
(Lurje and Lenz, 2009, Ratushny et al., 2009). Combination of EGFR targeted 
therapy and radiotherapy for management of feline oral squamous cell 
carcinoma is attractive as EGFR-mediated therapy may be able to augment 
the efficacy of radiotherapy, an established treatment option (Fidel et al., 
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2007). Combined therapy with radiation and RNAi against feline Egfr 
produced an additive effect similar to that observed in human HNSCC cell 
lines (Huang et al., 2002, Zhang et al., 2009) and xenograft models (Huang et 
al., 2002). A study investigating the effect of cetuximab in combination with 
cisplatin and irradiation in HNSCC cell lines reported an additive effect in 
five cell lines while two cancer cell lines exhibited a synergistic effect (Zhang 
et al., 2009). When comparing EGFR basal and phosphorylated levels 
between the cell lines exhibiting additive versus synergistic effects, they 
found that the cell line that exhibited synergy had a much higher basal level 
of EGFR and that the receptor became phosphorylated upon irradiation 
(Zhang et al., 2009). This supports the theory that overexpressing EGFR cell 
lines are more likely to respond to EGFR targeting therapy (Erjala et al., 
2006), although as previously discussed, not all tumour types exhibit a direct 
correlation between EGFR expression levels and response to therapy 
(Wheeler et al., 2010a). In these responsive cell lines combination treatments 
are thought to act synergistically because the cell lines utilise EGFR 
pathways like the PI3K and MAPK pathways to counteract the effect of 
radiation (Thariat et al., 2007). When these pathways are blocked, the cells 
become more sensitive to radiation (Thariat et al., 2007).  
As previously discussed, the SCCF1 cell line has a relatively low basal 
level of EGFR. HNSCC cell lines with low basal levels of EGFR showed 
additive rather than synergistic effects when cetuximab was combined with 
radiation (Zhang et al., 2009), which is similar to the findings in this study. 
EGFR-targeted therapy may be of clinical value in augmenting radiotherapy 
in feline oral SCC but tumours expressing higher EGFR levels may be more 
sensitive to combined treatment. 
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In contrast to the Egfr transfected cells, the gefitinib treatment of cells in 
combination with irradiation had no effect on colony formation in the cell 
line. As previously discussed, a 10 µM dose of gefitinib was required to 
produce an equivalent effect on cell proliferation as transfection with 
siRNA8 against the feline Egfr. A 5 µM dose was chosen for the combined 
treatment in order to use a sub-lethal dose that should still produce a 
significant reduction of proliferation in the cell line, but that would be closer 
to the therapeutic dose of the drug used in patients (Sharma et al., 2007). 
Gefitinib at this dose did not produce any beneficial effect when used in 
combination with radiotherapy, suggesting that therapeutic use of this drug 
in feline patients would necessitate a relatively higher daily dose than that 
currently used in man.  
In this study RNAi was used for EGFR targeting, and it proved to 
efficiently reduce the target protein levels and cell proliferation in the cell 
line.  RNAi techniques have wide research applications and are now 
showing promise for therapeutic use (Pai et al., 2006). RNA interference may 
prove to be a powerful tool for the new generation of targeting therapies 
where acquired resistance to drugs has developed over time. In a recent 
study, transfection of cetuximab resistant HNSCC cell lines with siRNA 
against EGFR reversed the acquired resistance in the cell lines (Wheeler et 
al., 2008). This is similar to the findings in this study, where transfection of 
the gefitinib resistant cell line caused similar reduction in cell proliferation as 
in the non-resistant parent cell line SCCF1. The major obstacle to wider 
clinical use of RNAi-based drugs is the lack of a good in vivo delivery system 
(Pai et al., 2006) but this area is advancing and the first siRNA-based clinical 
trial using a nanoparticle delivery system has recently been reported (Davis 
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et al., 2010). If a suitable delivery vector can be found, RNAi may become an 
attractive option for achieving EGFR-targeted therapy.  
Feline SCCs are naturally occurring tumours that have developed in 
pet animals which possess an intact immune system and which share their 
environment with man. The aetiopathogenesis of the disease in cats is not 
fully characterised, but environmental factors similar to those in human 
patients have been postulated as risk factors (Tannehill-Gregg et al., 2006). 
Evaluating drug strategies in naturally occurring disease in pets may help 
bridge the gap between in vitro research and clinical application in man 
(Paoloni and Khanna, 2008). This study supports the use of feline SCC as a 
model for HNSCC, an approach that could potentially benefit both felines 
and humans alike. During the development of a TKI against KIT (SU11654, 
toceranib) (London et al., 2009) the human field benefitted greatly from the 
canine studies (Paoloni and Khanna, 2008), and the development of acquired 
resistance to single-agent TKIs in dogs with mast cell tumours is of particular 
interest (Paoloni and Khanna, 2008). Further studies in cats with SCCs using 
EGFR targeting siRNA based therapies in combination with radiotherapy 
would potentially advance the treatment of the disease in both species. 
5.6 Summary 
Two methods of EGFR targeting were investigated in a feline SCC cell 
line. Following extensive optimisation of all the methods used, this study 
showed that both RNA interference techniques and a TKI, gefitinib, reduced 
cell proliferation and migration in the cell line. Targeting of EGFR using 
RNA interference caused a reduction in Egfr mRNA and protein levels, and 
the effect could be sustained over time when using hairpin expression 
vectors. EGFR targeting with RNAi also reversed acquired gefitinib 
resistance in the cell line, and produced an additive effect when used in 
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combination with radiotherapy. These results support the use of EGFR 
targeting as a viable therapeutic strategy for the management of feline oral 
SCC. Further studies in cats with SCCs using EGFR targeting siRNA based 
therapies in combination with radiotherapy would potentially advance the 




Mechanisms of resistance to cancer 
therapies in the SCCF1 cell line 
6 Mechanisms of resistance to cancer therapies 
in the SCCF1 cell line 
6.1 Abstract 
Tumours consist of heterogeneous populations of cells that exhibit 
different sensitivities to cytotoxic therapies and irradiation. These 
subpopulations of cells utilise a range of mechanisms to evade apoptosis, 
and are effectively selected for when using current cancer treatment 
strategies causing development of resistance from previously sensitive 
tumours over time. Two mechanisms that have been implicated in tumour 
progression are cells undergoing an epithelial to mesenchymal transition 
(EMT) and the presence of a subpopulation of stem cell-like cells with 
inherent drug resistance in tumours. 
In this study the gefitinib resistant SCCF1G cell line underwent 
morphological changes consistent with an EMT. Both SCCF1G and the 
parent cell line SCCF1 were investigated for markers of EMT and for their 
ability to form tumour spheres in non-adherent conditions. The presence of 
CD133 positive stem cell-like cells was investigated in the cell lines and the 
subpopulations were tested for inherent resistance to radiotherapy as well as 
to cytotoxic drugs.  
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The SCCF1G cell line had increased levels of fibronectin, vimentin and 
Slug consistent with an EMT but unchanged levels of E-cadherin and 
β-catenin. Both cell lines formed spheres in non-adherent conditions and 
contained a CD133 positive subpopulation. Resistance to gefitinib and to 
irradiation were increased in the SCCF1 CD133 positive population and 
overall in the SCCF1G cell line. The SCCF1G cell line had an increased 
CD133 positive subpopulation compared to the parent cell line, similar to an 
epithelial-mesenchymal to stem-like transition. 
6.2 Introduction 
Tumours of epithelial origin are by far the most commonly diagnosed 
group of cancers in man accounting for 80% of tumours (Visvader and 
Lindeman, 2008). Despite recent advances in the treatment of these tumours, 
they are still a major cause of death worldwide (Visvader and Lindeman, 
2008, Harper et al., 2010). Death is usually due to tumour recurrence 
following treatment caused by resistance to therapies including EGFR 
targeting drugs developing in initially responsive tumours (Harper et al., 
2010). Several mechanisms including epithelial to mesenchymal transition 
(EMT) (Wheeler et al., 2010a) and the presence of a subpopulation of stem 
cell-like cells with inherent drug resistance (Visvader and Lindeman, 2008) 
have been implicated in tumour progression and the development of 
resistance to therapy. 
EMT is a fundamentally important, reversible cellular mechanism that 
occurs during development and wound healing. It allows tightly anchored 
epithelial cells to break down their cellular adhesions and acquire migratory 
and invasive properties (Barr et al., 2008, Thiery et al., 2009). During 
development cells undergo cycles of primary, secondary and tertiary EMT 
where they also undergo the reverse process, a mesenchymal to epithelial 
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transition (MET) (Thiery et al., 2009). These subsequent rounds of EMT and 
MET allow the normally tightly anchored epithelial cells to break down their 
adhesions and migrate to different niches in different areas of the developing 
embryo. When reaching their respective niches the cells then undergo MET 
and then differentiate into specialised cells. These cycles of EMT and MET 
are crucial for the development of the complex three-dimensional structures 
of organs present in the body (Thiery et al., 2009). Primary EMT takes place 
during gastrulation when, for example, parietal endodermal cells migrate 
from the inner cell mass to form the primitive endoderm. Secondary EMT 
takes place in the transient epithelial tissues of the notochord, the somites, 
the somatopleure and the splanchnopleure (Thiery et al., 2009). Upon 
undergoing EMT these structures generate mesenchymal cells that will 
differentiate into specialised cell types of the different organs like, for 
example, the pancreas and liver (Thiery et al., 2009). Tertiary EMT is a crucial 
step in the formation of the cushion mesenchyme in the heart from the 
atrioventricular canal which gives rise to the cardiac valves (Thiery et al., 
2009). Similarly, during tissue healing, keratinocytes undergo a partial EMT 
which allows cells to migrate across a wound as a sheet while maintaining 
loose connections (Thiery et al., 2009).   
During EMT, cells undergo distinct morphological changes. Both 
squamous cell carcinoma cells and normal keratinocytes form three inherent 
cellular colony morphologies when grown in culture, the holoclones, the 
meroclones and the paraclones (Costea et al., 2006). The holoclones exhibit 
the typical epithelial morphology of tightly packed cells with small 
cytoplasm giving rise to a cobblestone pattern (Oda and Watson, 1990, 
Costea et al., 2006, Barr et al., 2008). Meroclones and paraclones contain more 
loosely packed ovoid cells, but these cells are still of a predominantly 
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epithelial morphology (Costea et al., 2006). Mesenchymal cells in contrast 
have larger cytoplasm and a more spindle shaped morphology (Barr et al., 
2008, Rho et al., 2009). They also exhibit reduced polarity and increased 
pseudopodia formation compared to epithelial cells (Rho et al., 2009, Thiery 
et al., 2009). On the molecular level these changes are associated with the 
downregulation of E-cadherin and β-catenin (Barr et al., 2008) and the 
upregulation of fibronectin, vimentin, Twist, Slug, Snail and Zeb1 (Barr et al., 
2008, Eyzaguirre et al., 2008, Thiery et al., 2009).  
 
Recently, EMT has been shown to be a necessary step to enable 
metastasis although it is insufficient to induce metastasis in isolation. EMT 
has also been reported to have an important role in the acquisition of 
resistance to therapy in a range of epithelial tumours (Barr et al., 2008, Thiery 
et al., 2009). 
Markers of 
EMT 
Description Expected changes during EMT 
E-cadherin Cell adhesion molecule Decreased expression  
β-catenin Adherens junction  Decreased membranous expression 
Fibronectin Binds extracellular matrix 
components, important in 
cell migration 
Increased expression 
Vimentin Component of 
cytoskeleton 
Increased expression 
Twist bHLH transcription factor, 
represses E-cadherin 
Increased expression 
Slug Zn-finger transcription 
factor,  represses 
E-cadherin 
Increased expression 
Snail Zn-finger transcription 
factor,  represses 
E-cadherin 
Increased expression 
Zeb1 Zn-finger transcription 
factor,  represses 
E-cadherin 
Increased expression 
Table 6.1: Summary of markers involved in EMT   
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The cancer stem cell (CSC) hypothesis is a separate model put forward 
to account for the heterogeneity and inherent differences in tumour 
regenerating capacity that exist between individual cells within tumours 
(Prince et al., 2007, Visvader and Lindeman, 2008). It proposes a hierarchical 
tumour organisation containing subpopulations of stem-cell like cells 
responsible for sustaining tumour growth (Visvader and Lindeman, 2008). 
These putative CSCs have been shown to be more resistant to current 
treatment modalities (Visvader and Lindeman, 2008). Several putative stem 
cell markers have been used in oral squamous cell carcinomas to isolate a 
subset of cells enriched for CSCs, including CD133 (Harper et al., 2007, Xia et 
al., 2010), CD44 (Harper et al., 2007, Prince et al., 2007, Okamoto et al., 2009, 
Harper et al., 2010), CD29 (β-integrin) (Harper et al., 2007), CD34 (Locke et 
al., 2005), Aldehyde dehydrogenase 1 (ALDH 1) (Chen et al., 2009) and 
podoplanin (Atsumi et al., 2008).  Another favoured assay for the 
identification of CSCs is the non-adherent sphere assay. It is an in vitro assay 
based on the assumption that only individual cancer stem cells present will 
survive serial passages under non-adherent conditions. Following serial 
passages, the cells should give rise to the full range of morphologies 
observed in the original cell line when returned to adherent conditions; in 
the cases of oral squamous carcinoma cells this would be the three clonal 
morphologies previously described (Costea et al., 2006, Visvader and 
Lindeman, 2008). For solid tumours, the most widely reported successful 
sphere assays are the neurosphere and the mammosphere (Visvader and 
Lindeman, 2008).  
The mechanisms behind the apparent inherent resistance to therapy 
harboured by CSCs are unknown, but it is likely that several mechanisms are 
responsible. Current cancer treatment modalities are based on the classic 
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assumption that all tumour cells proliferate at a high rate and cancer drugs 
and irradiation preferentially kill rapidly dividing cells (Costea et al., 2006, 
Harper et al., 2010). CSCs, however, have been shown to rarely divide, and 
often exist in a quiescent state (Costea et al., 2006, Visvader and Lindeman, 
2008). This is likely to contribute to their inherent resistance to treatment. 
However, most CSCs also appear to use active mechanisms to evade 
cytotoxic drugs or radiation treatment (Visvader and Lindeman, 2008, Xia et 
al., 2010). For example, in glioma tumour xenographs CD133 positive cells 
showed increased resistance to radiotherapy due to a more efficient DNA 
damage repair (Visvader and Lindeman, 2008). In one study of head and 
neck, breast and prostate carcinoma cell lines and HNSCC tumour biopsies, 
the CD44-high cell population spent an increased time in the G2 phase of the 
cell cycle allowing for DNA repair to take place following UV and cytotoxic 
insults (Harper et al., 2010). In HNSCC, the EGFR signalling pathway has 
been implicated as one of the pathways used by cancer cells to escape the 
effects of radiation through activation of the PI3K and MAPK pathways 
(Thariat et al., 2007). The PI3K pathway was preferentially activated in CSCs 
conferring resistance to radiotherapy in medulloblastomas (Visvader and 
Lindeman, 2008). CSCs also express high levels of drug transporters which 
enable the cells to expel noxious substances effectively and rapidly (Costea et 
al., 2006, Visvader and Lindeman, 2008). Lastly, solid tumours often contain 
hypoxic areas which contribute to resistance to cytotoxic drugs and 
irradiation (Wheeler et al., 2010b). It is thought that hypoxia may promote 
CSC maintenance and augment the CSC populations in solid tumours 
(Visvader and Lindeman, 2008).  
Recent studies have linked the mechanism of EMT and cancer stem 
cell-like subpopulation of cells. For example, in nasopharyngeal carcinomas 
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EMT was reported to induce stem cell-like traits in the epithelial cells, 
including increasing the CD133-positive cell fraction, sphere formation 
ability and in vivo tumourigenicity (Xia et al., 2010). Similar changes were 
seen in breast cancer cells undergoing EMT, with an increase in the stem 
cell-like CD44-positive, CD24-low population (Santisteban et al., 2009).  
In this study we investigated if the morphological changes observed in 
the SCCF1 cell line during chronic gefitinib exposure were associated with 
an EMT by comparing the molecular signatures of the parent and resistant 
cell lines. The presence of CD133-positive subpopulations in the cell lines 
was also explored, and the response of the two cell lines to different 
therapies was further elucidated.  
6.3 Materials and methods 
6.3.1 Cell culture 
Both the parent cell line SCCF1 and the gefitinib resistant sub-line 
SCCF1G were cultured as previously described in chapter 2.3. During 
development of the SCCF1G cell line (chapter 2.3.9), the cells were 
monitored for cell death and morphological changes by light microscopy and 
photographed at regular intervals. Initially, the cells were treated with both 5 
and 10 µM gefitinib.  
Sphere assays were set up from both cell lines and passaged after 7-14 
days (chapter 2.3.6). Cells were monitored by light microscopy and 
photographed at regular intervals.  
6.3.2 Western blot analysis of EMT markers  
The SCCF1 and SCCF1G cell lines were harvested as described in 
chapter 2.3.10. Cell lysates were prepared and their protein content was 
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determined according to protocols described in chapter 2.13.2 and 2.13.3 
respectively. Aliquots of cell lysates containing 20 µg of protein were 
prepared and SDS-polyacrylamide gel electrophoresis and immunoblotting 
were performed on the cell lysates as described in chapter 2.13.4 and 2.13.5 
respectively. The primary antibodies used were mouse monoclonal 
E-cadherin at 1:5,000 dilution, mouse monoclonal β-catenin  at 1:1,000 
dilution, and mouse monoclonal fibronectin at 1:1,000 dilution (all from 
Becton Dickinson Biosciences Ltd., UK), mouse monoclonal vimentin at 
1:1,000 dilution and Slug at 1:500 dilution (both from Abcam, UK), and 
finally rabbit polyclonal Twist at 1:100 dilution (Santa Cruz Biotechnology 
Inc., USA). For loading control, mouse monoclonal β-actin at 1:4,000 dilution 
(Abcam, UK) was used. All primary antibodies were incubated in PBST/5% 
Milk at 4°C overnight, and the protocols described in chapter 2.13.5 were 
followed for secondary antibody incubations, development and visualisation 
of the blot. 
6.3.3 MACS sorting 
The SCCF1 cell line was MACS sorted for CD133 as described in 
chapter 2.18. The two different cell fractions were counted (chapter 2.3.5) and 
the overall percentage of CD133 positive cells was determined. Following 
MACS sorting, the cell fractions were then assayed for sphere forming ability 
and sensitivity to gefitinib, mitoxantrone, doxirubicin and irradiation. In 
addition, both cell fractions were expanded and MACS sorted again for 
CD133. The SCCF1G cell line was similarly MACS sorted for CD133 and the 
two cell fractions were counted and assayed for radiation sensitivity.  
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6.3.3.1 Sphere formation ability assay 
Following MACS sorting of the SCCF1 cell line, both cell fractions were 
seeded into low adherence 24 well plates in N2 medium. Each cell fraction 
was seeded at 2, 1, 0.5 and 0.2 x104 cells per well into six wells for each cell 
density, giving a total of 24 wells for each cell fraction at four different cell 
densities. Cells were incubated at 37°C/5%CO2, and fed with 500 µg per ml 
EGF and bFGF every 48 hours as described in chapter 2.3.6.1. After one 
week, all spheres seen in ten high power fields (x20 objective) were counted 
for each well and the total numbers of spheres per well were calculated. Each 
sample (i.e. each cell density for each cell fraction) was then averaged 
between six wells, and statistical analysis was performed as described in 
chapter 2.19.  In addition, spheres were trypsinized and harvested and the 
total number of cells from each cell fraction was determined as previously 
described (chapters 2.3.6.2 and 2.3.5 respectively). 
6.3.3.2 Gefitinib sensitivity assay 
Following MACS sorting and counting, cells from each fraction were 
seeded at 3x103 cells per well into three 96 well plates in 50 µl normal 
medium. Media aliquots containing gefitinib at twice the final concentrations 
were prepared, and 50 µl were added to each well to produce gefitinib 
concentrations in the wells of 1,3,5,7 and 10 µM respectively. Six wells on 
each 96 well plate were used per drug concentration. Controls included on 
each 96 well plate were DMSO control (cells treated with a DMSO dose 
equivalent to the DMSO concentration present in the wells with the highest 
gefitinib dose) and untreated cells. Medium-only containing wells were 
included on each plate to subtract assay background absorbance. The plates 
were incubated at 37°C/5%CO2, and cell proliferation assays were performed 
as described in chapter 2.14 at 24, 48, 72 and 96 hours following treatment.  
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6.3.3.3 Chemosensitivity assays 
Cells were MACs sorted (chapter 2.18)  and the two cell fractions were 
resuspended at 1x104 cells per ml and seeded at 500 cells per well (50µl) into 
96 well plates and incubated overnight at 37°C/5%CO2. The following day 
the cells were treated by addition of media containing the drugs (etoposide, 
doxirubicin and mitoxantrone) at a range of concentrations from 1 nM to 
100 µM. Each drug concentration was performed in triplicate for each cell 
fraction. Controls included on each plate were one medium-only control for 
each drug concentration and four untreated cells controls for each cell 
fraction. Cells were incubated for 72 hours before cell viability was assessed 
with CellTiter-Glo® Luminescent Cell Viability Assay (Chapter 2.11.2). An 
ATP standard curve was performed to confirm the kit was working 
correctly.  
6.3.3.4 Radiation sensitivity assay 
Both cell lines were maintained in their respective media as described 
in chapter 2.3.2 and 2.3.9. The SCCF1G cell line was maintained in 5 µM of 
gefitinib during the entire assay.  
Following MACS sorting, the negative and the positive cell fractions 
were counted and 300 cells were added to 10 ml media in 10 cm plates in 
triplicate for each cell line, each cell fraction and each radiation dose (36 
plates in total). The cells were then irradiated in suspension at 0, 1, and 4 Gy 
prior to performing CFAs. After 10 days the cells were fixed, stained and 
counted as described in chapter 2.15.  
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6.3.3.5 Evaluation of CD133 positive and negative cells ability to 
generate CD133 positive cells 
Both cell fractions were seeded at 4x105 cells into T75 flasks and 
expanded for two weeks to produce three near confluent T150 flasks. The 
cells were trypsinated and counted as described in chapters 2.3.4 and 2.3.5 
before MACS sorted as previously described (chapter 2.18). Each cell fraction 
was counted, and the overall percentage of CD133 positive cells present was 
determined.    
6.4 Results 
6.4.1 Chronic gefitinib treatment induces morphological changes 
suggestive of an epithelial to mesenchymal transition  
During gefitinib treatment of the SCCF1 cell line marked morphological 
changes were observed in the cell line. These changes were apparent after 
one day of gefitinib treatment. Cells became much larger with spindle 
shaped morphology, abundant cytoplasm, loss of polarity and with 
increased pseudopodia formation (Figure 6.1). After first passage, two 
distinct morphologies were present in the cells treated with 5 µM of 
gefitinib. All cells treated with 10 µM gefitinib died when passaged, so no 
further analyses were performed of these cells. In the 5 µM gefitinib treated 
wells some cells reverted to their epithelial morphology with tightly packed 
colonies of cells with a small amount of cytoplasm producing a cobblestone 
effect, while others retained their mesenchymal morphology (Figure 6.2). 
Clear demarcations between the two morphologies were seen in culture 
where two colonies of different cell morphologies had coalesced. After ten or 
more passages the SCCF1G cell line became more homogenous and two 
distinct populations were no longer so clearly visible. The morphology 
became more epithelial-like with more tightly packed cells forming 
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cobblestone-like monolayers containing cells with a smaller amount of 
cytoplasm, although the cells were still larger and more loosely packed when 
compared to the parent cell line. The relative difference in cell size was 
illustrated by the relative difference in cell numbers obtained from confluent 
flasks from both cell lines (Figure 6.2 and Table 6.2). A comparison between 
the two cell lines’ proliferation rates and colony formation ability is 
summarised in Table 6.2.   
The parent cell line, SCCF1, exhibited a typical epithelial morphology 
when grown as an adherent monolayer, except for occasional colonies 
consisting of cells with a larger amount of cytoplasm and increased 
pseudopodia formation. Larger cells were also found at the edge of colonies, 
or when confluence was reached, occasional cells with a large amount of 
cytoplasm and scatter morphology were present throughout the monolayer 




Figure 6.1: The morphology changes observed in the SCCF1 cell line during the first week of 
gefitinib treatment. The untreated cells became confluent during the first six days with 
densely packed cells creating the typical cobblestone appearance typical of epithelial cells 
(left column). The wells treated with 5 µM gefitinib (middle column) had marked cell death in 
the well, and did not reach confluence in the six days. However, large colonies of much 
larger spindle shaped cells with extensive cytoplasm were formed in the wells. These cells 
exhibited loss of polarity and increased pseudopodia formation. In the wells treated with 
10 µM gefitinib massive cell death occurred, but some sparse colonies of spindle shaped 





Figure 6.2: The cells from Figure 6.1 were all passaged and monitored while being 
expanded in gefitinib containing medium. This figure shows cells treated with 5 µM gefitinib 
as all cells treated with 10 µM died following passage. 
a) During expansion following the first passage two distinct morphologies were observed. 
Some cells reverted to their epithelial type morphology while other retained their 
spindle-shaped morphology. Distinct colonies of the two cell types formed, and as the cells 
reached confluence, cells from the two distinct groups merged forming clear demarcations 
between the two cell types.  
b) High power view of the demarcation line between the two cell types.  
c) High power view of spindle shaped cells.  
d) High power view showing the cells that had reverted to a typical epithelial-like morphology 





Figure 6.3: Normal untreated SCCF1 cell line showing the presence of occasional cells in 
the monolayer with a larger amount of cytoplasm (a). Similar cells with pseudopodia 




Table 6.2: Comparison between SCCF1 and SCCF1G cell lines comparing average number 
of cells in a confluent flask for each cell line, relative proliferation rates and colony formation 
abilities .The passage number P shows total passages of cell line with passages of cell line 
in gefitinib containing media in parenthesis. 
 
6.4.2 Chronic gefitinib treatment causes upregulation of 
mesenchymal markers  
Western blot analysis of cell lysates from both cell lines showed no 
change in the epithelial markers E-cadherin and β-catenin, while 
mesenchymal markers fibronectin and vimentin were increased in the 
SCCF1G cell line when compared to the parent cell line SCCF1 (Figure 6.4). 
E-cadherin and β-catenin were present in relatively high levels in both cell 
lines, while fibronectin and vimentin were not detectable in the parent cell 
line and had become upregulated in the gefitinib treated cells.  
The transcriptional regulators of E-cadherin, Slug and Twist, showed a 
mixed picture; Twist protein levels remained unchanged while Slug was 
upregulated. Their basal levels in the SCCF1 cell line differed, with Twist 
being expressed in the parent cell line while Slug protein levels were not 




SCCF1 SCCF1G Passage 
Average total cell numbers per 
confluent flask 
   
A confluent 
flask of the 
SCCF1 cell line 
yielded ~3-5 
fold more cells  
T150 flasks ~8 x 10
7
 1.2-1.9 x 10
7
 P64 (3) 
T75 flasks ~4 x 10
7
 1.4 x 10
7
 P73(13) 
Relative proliferation rate of cell 
lines measured by proliferation 
assays 
1                    
1                
1 
0.34        













Relative colony formation ability 
1                
1 





6.4.3 The SCCF1 and SCCF1G cell lines forms spheres which 
senesce in early passages 
Both the SCCF1 and SCCF1G cell lines grew in non-adherent sphere 
assay conditions for up to two passages. The first week following transfer 
into non-adherent media the cells grew rapidly and formed large tight cell 
clusters (Figure 6.5). After one week the spheres were passaged, and they 
continued to grow for a further week forming tighter spheres where 
individual cells were difficult to visualise (Figure 6.6). At the end of this two 
week period, the cells would then senesce, and no further growth would 





Figure 6.4: Western blot analysis of protein levels comparing the gefitinib resistant cell line 
(SCCF1G, right) to the parent cell line (SCCF1, left). E-cadherin, β-catenin and Twist protein 
levels remained unchanged as assessed by western blot analysis between the two cells 
lines. Fibronectin, vimentin and Slug were upregulated in the resistant cell line. Results 





Figure 6.5: First week of SCCF1 cell line in non-adherent medium. Cells were seeded at low 
density into N2 medium. Individual cells were easily distinguished. After 2 days spheres 
could be seen forming in the medium which rapidly grew over the next five days. 
 
 
Figure 6.6: SCCF1 cell lines after first passage. Spheres of different sizes formed following 
passage, and grew rapidly for seven days following passage. Cells then became senescent 
and no further growth occurred regardless of whether the cells were passaged or left in the 
media. All images taken five days following first passage. 
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6.4.4 MACS sorting the SCCF1 cell line for CD133 produces a 
small population of labelled cells 
MACS sorting the SCCF1 cell line for CD133 expression produced a 
small population of on average 1% (+/-0.7% standard deviation) of the total 
cell population (Table 6.3). Both CD133 positive and negative cell fractions 
gave rise to both cell populations when expanded for 10 days before being 
MACS sorted again, but on average the CD133 positive cell fractions gave 
rise to almost twice as many CD133 positive cells as the CD133 negative 
population (Table 6.3). The SCCF1G cell line gave rise to a much larger 
CD133 positive population of 7%.  
Table 6.3: Average cell fractions positive for CD133 labelling when MACS sorting the 
SCCF1 and SCCF1G cell lines. The CD133 –ve and +ve cells were MACS sorted, 
expanded for approximately 10 days and then re-sorted to see if the different fractions could 
give rise to both cell fractions.  
 
6.4.5 CD133 positive SCCF1 cells show increased sphere forming 
ability and increased resistance to drug and radiation therapies 
The CD133 positive cells formed on average more spheres than the 
CD133 negative cell fraction at all four cell densities (Figure 6.7). The assay 
was repeated on two separate occasions with similar results. The difference 
in sphere numbers was statistically significant for all four cell densities by 
two sample t-test or Mann Whitney U test. 
 
Cells Average CD133+ve fraction SD Number of counts 
SCCF1 1.0 % +/- 0.7 % 9 







+/- 0.7 % 








Figure 6.7: Sphere forming ability one week after seeding into non-adherent media at four 
different cell densities, all showing statistically significant difference in sphere-forming ability. 
** p=0.01 by Mann Whitney U test, *p=0.002, p<0.001, p=0.009 by two sample t-test left to 
right respectively, bars show +/- standard deviations. Top right insert shows actual live cell 
count following trypsin treatment of spheres and counting using Trypan blue exclusion and a 
haemocytometer chamber.   
 
The spheres were then harvested from all wells, trypsinated and 
counted. The total numbers of viable cells from all wells from each cell 
fraction were determined, and there were 20-fold more viable cells in the 
CD133 positive fraction (Figure 6.7). However, when CD133 positive cells 
only were seeded in non-adherent media, they became senescent after the 




Figure 6.8: The SCCF1 cell line was MACS sorted for CD133 and the two cell fractions were 
seeded into 96 well plates and treated with different concentrations of gefitinib. At 24, 48, 72 
and 96 hours (a, b, c & d) following gefitinib treatment cell proliferation assays were 
performed to assess level of viable cells present in each well. The CD133 positive cell 
fraction was consistently more resistant to gefitinib treatment over the drug concentration 
range after 48 hours (* p<0.05 by two sample t-test, bars show +/- standard deviations). 
 
The CD133 positive cells were more resistant to gefitinib treatment than 
the unlabelled fraction at 48, 72 and 96 hours following treatment (Figure 
6.8). There were relatively more viable CD133 positive cells left at gefitinib 
concentrations of 1, 3, 5 and 7 µM when compared to the CD133 negative cell 
fraction at 48 and 72 hours following treatment. At the 10 µM dose there 
were no differences between the two cell fractions as the dose was 
sufficiently high to kill the majority of the cells in all culture wells. At 96 
hours, total cell death was also observed in the wells treated with 7 µM 
gefitinib. The experiment was performed on three different occasions with 
similar results. The CD133 positive fraction was also more resistant to the 
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chemotherapeutic agents etoposide, mitoxantrone and doxirubicin when 
compared to CD133 negative cells over a wide range of concentrations 
(Figure 6.9). 
 
Figure 6.9: The SCCF1 cell line CD133 positive cell fractions were more resistant to 
chemotherapeutic agents over a wide range of concentrations. Top panel shows etoposide, 
middle panel shows doxirubicin and lower panel shows mitoxantrone treated cells. Bars 
show +/- standard deviation, each point is an average of three wells, * denotes p<0.05 by 




Table 6.4: Summary of data and statistical analysis performed on radiosensitivity assay of 
SCCF1 and SCCF1G cell lines, p values refers to the stars shown in Figures 6.10 and 6.11. 
Statistically significant p values from two sample t-tests marked in bold. Analyses were 
performed on non-normalised and *normalised data respectively.  
 
The radiosensitivity of both cell fractions were analysed by colony 
formation assays following radiation in both cell lines. The basal colony 
formation ability of the SCCF1G cell line was significantly slower than that 
of the parent cell line (p<0.001, by two sample t-test) at approximately a 
quarter of colonies formed per 300 cells seeded for both cell fractions (Table 
6.2).  
Overall, the untreated CD133 negative cell fractions from both cell lines 
formed on average significantly more colonies than the untreated CD133 
Parameter SCCF1 SCCF1G 
CD133 +ve CD133 –ve CD133 +ve CD133 –ve 











Radiosensitivity of cell 
















radiosensitivity of CD133 
positive vs. negative cell 








radiosensitivity of CD133 
fractions between cell 
lines  
 
CD133 +ve fractions 
1 Gy p=0.1 
4 Gy p=0.18 
CD133 –ve cell fractions 
1 Gy p=0.009 
4 Gy p=0.09 
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positive cell fractions (Table 6.4), (p=0.014 and p=0.009 by two sample t-test 
for SCCF1 and SCCF1G cell lines respectively).  
Both CD133 positive and negative cells from both cell lines were 
sensitive to a radiation dose of 4 Gy, but only the CD133 negative fraction 
from the parent cell line showed statistically significant reduction in colony 
formation at the lower radiation dose of 1 Gy (Table 6.4, Figure 6.10). 
 
Figure 6.10: Colony formation assays following radiation treatment of CD133 sorted SCCF1 
(a) and SCCF1G (b) cell lines shown as percentage of untreated control. The parent cell line 
(a) exhibited a dose dependent statistically significant reduction in colony formation ability in 
response to radiation. The CD133 negative cell fraction was significantly more sensitive to 
both radiation doses. The resistant cell line (b) required the higher radiation dose of 4 Gy 
before reduction in colony formation ability was observed. There were no difference in 
sensitivity to radiation between the CD133 positive and negative fractions in this cell line (* p 
values <0.05 by two sample t-test, bars show +/- standard deviations). All data courtesy of 
Dr. Lisa Pang, statistical analysis and graphical representation of data performed by GTB.  
 
In the SCCF1 cell line the CD133 positive cells were consistently more 
resistant to radiation compared to the unlabelled fraction at both radiation 
doses, but in the gefitinib resistant sub-line SCCF1G there were no difference 
in radiosensitivity between the two cell fractions (Table 6.4, Figure 6.10). The 
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relative colony formation ability of the CD133 positive SCCF1G cells was 
similar to that of the CD133 positive SCCF1 cells at both radiation doses, 
while the CD133 negative fraction of the SCCF1G cell line was markedly 
more resistant to the lower radiation dose than its negative counterpart from 
the parent cell line (Figure 6.11, Table 6.4).  
 
Figure 6.11: Comparison of radiation response of the two cell lines according to CD133 
status shown as percentage of untreated control. a) Histograms compare the CD133 
negative cell fractions from both cell lines. The SCCF1G cell line was statistically 
significantly more resistant at the lower dose of 1 Gy, while the difference was less 
pronounced at the higher radiation dose. b) Histograms comparing the CD133 positive cell 
fractions from both cell lines. There were no significant differences between the CD133 
positive fractions of the two cell lines (* p<0.05 two sample t-test, bars show +/- standard 
deviations). All data courtesy of Dr. Lisa Pang, statistical analysis and graphical 
representation of data performed by GTB  
 
6.5 Discussion 
When cells undergo an EMT marked phenotypic changes occur, and 
these changes are accompanied by specific changes in molecular markers. 
The mesenchymal phenotype is associated with the downregulation of 
E-cadherin and β-catenin (Barr et al., 2008) and the upregulation of 
fibronectin, vimentin, Twist, Slug, Snail and Zeb1 among others (Barr et al., 
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2008, Eyzaguirre et al., 2008, Thiery et al., 2009). In contrast, epithelial cells 
express high levels of E-cadherin and cytokeratins, and relatively low levels 
of vimentin and fibronectin (Barr et al., 2008, Thiery et al., 2009).  
The SCCF1 cell line exhibited the typical morphology observed in 
cultured epithelial cells with cuboidal cells arranged in clusters during the 
exponential growth phase, and in a cobblestone pattern after confluence was 
reached (Oda and Watson, 1990, Barr et al., 2008). This was in contrast to the 
morphology observed in the cell line after chronic exposure to gefitinib, 
which was of a mesenchymal-like scattering or migratory morphology (Barr 
et al., 2008). Similar changes were described in a NSCLC cell line in response 
to chronic gefitinib exposure to produce a gefitinib resistant cell line (Rho et 
al., 2009). The NSCLC cell line showed cross-resistance against other TKIs 
including the new generation irreversible TKIs, while resistance to other 
conventional anti-cancer drugs such as cisplatin and paclitaxel developed to 
a lesser degree (Rho et al., 2009). The authors compared the relative 
expression of markers of EMT in the resistant and the parent NSCLC cell 
lines by western blot analysis and immunohistochemistry, and they found 
reduced levels of E-cadherin and cytokeratins and increased vimentin levels 
consistent with a mesenchymal phenotype supporting the development of 
an EMT in the resistant cell line (Rho et al., 2009).  
In this study the rate of proliferation of the SCCF1G cell line was 
reduced compared to the parent cell line. It is possible that the doubling time 
of the two cell lines would have equalised with prolonged exposure of 
increasing concentrations of gefitinib as was the case in the NSCLC cell line 
used in the Rho et al. (2009) study. However, in a recent study by Basu and 
colleagues (2010) which investigated if the heterogeneity observed within ten 
SCC cell lines could be used as a basis for selection of drug resistant 
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subpopulations, all cell lines were reported to contain different proportions 
of E-cadherin-low, vimentin-high mesenchymal-like subpopulations. The 
two cell populations were isolated by flow cytometry, and the mesenchymal-
like population had a lower proliferation rate than their epithelial-like 
counterparts (Basu et al., 2010). The mesenchymal subtype contained a 
greater proportion of cells in the G0 phase of the cell cycle as determined by 
Ki67 labelling (Basu et al., 2010). In addition, the SCC cell line turnover was 
assessed using dilution of the fluorescent membrane label, PKH-67 with 
ongoing cell division, and they reported that the E-cadherin low population 
had the highest label retention indicating a slower turnover of cells (Basu et 
al., 2010). Other studies have reported that cells that have undergone EMT 
were chemoresistant because of their slower proliferation rate (Nagane et al., 
2001, Valcourt et al., 2005). It is possible that the differing proliferation rates 
observed in the cell lines in this study played a part in the apparent 
resistance to radiotherapy observed in the gefitinib resistant cell line. Further 
studies should investigate whether the increased resistance to radiotherapy 
observed here in the SCCF1G cell line would be lost if an increased 
proliferation rate could be achieved following longer exposure to gefitinib.  
The parent cell line in this study may harbour a population of 
mesenchymal-like cells. During the original development of the cell line, 
positive vimentin labelling was observed in different proportions of the cells 
at different passages, and the authors believed this was due to epithelial to 
mesenchymal transdifferentiation occurring in the cell line consistent with 
their observations in feline SCCs (Tannehill-Gregg et al., 2001). During this 
study, however, the parent cell line was negative for vimentin and vimentin 
was only upregulated after chronic gefitinib exposure in the SCCF1G cell 
line.  In contrast to the upregulation of vimentin observed that would 
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support an EMT in the SCCF1G cell line, E-cadherin and β-catenin levels 
seemed unchanged between the two cell lines contrary to what might be 
predicted with an EMT event. A possible explanation for the failure to 
demonstrate changes in E-cadherin and β-catenin levels could be the 
presence of a mixed population in the SCCF1G cell line with some cells 
having undergone EMT whilst others had not. Assessment of the cell 
morphologies present in the cell lines supports this explanation. If there were 
epithelial-like cells present in the cell line expressing high levels of 
E-cadherin and β-catenin, protein from these cells may mask a reduction of 
protein in EMT cells when the whole cell population was assessed by 
western blot analysis. The proteins which were expected to be low or absent 
in the parent cell line but upregulated in a cell line undergoing EMT (with 
the exception of Twist) were all increased in the SCCF1G cell line. In a truly 
mixed population of cells, these results would be expected. If a protein that 
was absent in the parent cell line became upregulated (even if it was only in 
a proportion of the cells), western blot analyses would reveal an 
upregulation of protein levels. Comparatively subtle reductions in 
expression of a heavily expressed protein could be masked due to the semi-
quantitative nature of western blot analysis. These predications are in 
agreement with Basu and colleagues (2010) who stated that analysing cell 
lines as a total population for overall levels of markers may not reflect the 
levels within particular subsets of the tumour cell population. Studies using 
immunofluorescence labelling and flow cytometry to identify distinct 
subpopulations in the cell lines to determine if these subpopulations differ 




There is an additional possible explanation of why β-catenin was not 
downregulated in the SCCF1G cell line as might be expected in cells 
undergoing EMT. In epithelial tissues cells form strong cell to cell adhesions, 
a crucial mechanism for the barrier function of epithelial cells (Wirtz-Peitz 
and Zallen, 2009, Harris and Tepass, 2010). The primary protein involved in 
these adhesions is E-cadherin which dimerizes in the intercellular space 
between adjacent cells at junctional complexes (Harris and Tepass, 2010). The 
intracellular domain of E-cadherin interacts with β-catenin, which in turn 
anchors the protein complex to the microtubules and the actin skeleton of the 
cell, providing stability and structure to the epithelial sheet (Harris and 
Tepass, 2010). In the SCCF1G cell line, β-catenin was predicted to be 
downregulated as it has been reported to be during EMT in other studies 
(Sahlgren et al., 2008). Despite this, overall levels of β-catenin did not appear 
reduced on western blot analysis following transdifferentiation of the cell 
line. This may be due to the presence of different subpopulations as 
discussed above. Alternatively, breakdown of adherens junction which 
occurs during EMT with loss of E-cadherin can lead to an increase in 
cytoplasmic β-catenin and translocation of β-catenin to the nucleus (Barr et 
al., 2008, Thiery et al., 2009). Translocation of β-catenin to the nucleus is a 
hallmark of active Wnt/β-catenin signalling, and has been shown to be 
involved in cutaneous cancer stem cell maintenance (Malanchi et al., 2008). 
In such an event, western blot analysis performed on whole cell lysates may 
not demonstrate reduction in β-catenin levels even though β-catenin had 
dissociated from E-cadherin and was undergoing different intracellular 
processing.  
Based on the morphological change and increase in vimentin 
expression, the SCCF1G cell line did appear to undergo an epithelial to 
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mesenchymal transition upon chronic exposure to gefitinib despite the 
discordant results on western blot analysis. The role of EGFR and EGF in 
promoting EMT is well established (Barr et al., 2008, Thiery et al., 2009, Gan 
et al., 2010), so EGFR targeting might be expected to inhibit EMT, not induce 
it. However, there is an abundance of initiators of EMT reported in 
numerous cellular contexts (Thiery et al., 2009, Xia et al., 2010). It is possible 
that by blocking EGFR, we were selecting for or inducing an alternative 
pathway which drove the transition. 
EGFR targeting has been shown to decrease migration and invasion of 
tumour cells through decreased STAT3 phosphorylation (Wheeler et al., 
2010b) and Akt phosphorylation (Gan et al., 2010). We found decreased 
migration in response to EGFR blockade in the parent cell line as well as 
decreased levels of phosphorylated STAT3 supporting the hypothesis that 
this mechanism occurs in the SCCF1G cell line (Chapter 5.3.1). In one recent 
study hepatocytes that had undergone EMT were found to have increased 
levels of phosphorylated STAT3 and Akt (Wheeler et al., 2010a), both of 
which are downstream targets of EGFR (Yarden and Sliwkowski, 2001). The 
authors reported that the pathways were not, however, activated through 
EGFR, but by an alternative integrin-linked kinase (ILK) (Wheeler et al., 
2010a). This again highlights the abundant receptor crosstalk present in 
cancer cells (Jorissen et al., 2003) which can come into play when one 
pathway is targeted. In this study, the gefitinib resistant cell line had an 
increased migration rate compared to the parent cell line. This was not due 
to increased proliferation, as the SCCF1G cell line proliferated at a lower rate 
than the parent cell line. EMT has been reported to induce a more invasive 
and migratory phenotype (Barr et al., 2008, Xia et al., 2010), and the resistant 
sub-line exhibited such increased migratory abilities. Further studies should 
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compare the phosphorylated STAT3 and Akt levels between the two cell 
lines to further elucidate the possible mechanisms behind the enhanced 
migratory ability of the SCCF1G cell line.  
Whether the cells in this study actively underwent an EMT (Rho et al., 
2009) or whether a more mesenchymal-like subpopulation already present in 
the cell line was selected for (Basu et al., 2010) by treating them with gefitinib 
is unknown. In HNSCC cell lines the presence of different morphological 
subpopulations (holoclones, paraclones and meroclones) with different 
proliferating abilities is well documented (Locke et al., 2005, Harper et al., 
2007). Holoclones contain smaller, epithelial cuboidal shaped cells of a more 
proliferative nature which label strongly for E-cadherin and β-catenin (Locke 
et al., 2005, Harper et al., 2007). Paraclones consist of larger, flattened cells 
with a more scattered morphology, and have a much slower turnover by 5-
bromo-2-deoxyuridine (BrdUrd) incorporation when compared to 
holoclones (Locke et al., 2005). They have also been reported to express 
vimentin (Harper et al., 2007). The third colony pattern described, the 
meroclones exhibit an intermediate phenotype. Similar features were 
observed in the SCCF1 cell line; although the dominant cell type observed by 
far were the small cuboidal, tightly packed cells so typical of epithelial 
monolayers, the morphology is suggestive of the presence of different cell 
populations . In one study comparing gene expression levels between 
holoclone and paraclone colonies of five different HNSCC cell lines by 
Real-Time PCR, it was reported that holoclones had relatively higher 
E-cadherin as well as ErbB3 gene expression when compared to paraclones 
(Locke et al., 2005). This indicates that E-cadherin-high, more epithelial-like 
cells express higher levels of EGFR family members, possibly indicating that 
the mesenchymal-like phenotype is less dependent on EGFR signalling, 
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providing an explanation why EGFR inhibition may be associated with the 
acquisition of an EMT phenotype. The presence of a mixed population 
containing mesenchymal-like cells that are less dependent on EGFR would 
result in selection for or induction of this cell type during chronic gefitinib 
treatment. In a recent study, EGFR expression levels were indeed seen to be 
reduced in the E-cadherin low subset of cells from HNSCC cell lines, and 
reduced levels corresponded with a decreased phosphorylation of the MAPK 
and PI3K pathways in response to EGF (Basu et al., 2010). Further studies 
investigating the potential existence of mesenchymal-like subpopulations in 
the SCCF1 and SCCF1G cell lines and their gene expression profiles are 
therefore warranted.  
Non-adherent sphere assays are extensively used to evaluate the 
presence of putative CSC in cancer cell lines (Visvader and Lindeman, 2008). 
The assay can demonstrate extensive self-renewal if performed over more 
than five passages, but does not quantify CSC frequency (Visvader and 
Lindeman, 2008). The assay maintains CSCs in an undifferentiated state in 
serum-free medium, and then by the addition of growth factors the cells are 
stimulated to proliferate and form cell aggregates described as tumour 
spheres (Monroe et al., 2010). In addition, following serial passage in 
serum-free non-adherent medium these cells are able to recapitulate the 
original cellular morphologies (holoclones, paraclones and meroclones) 
observed in the parent cell line when returned to adherent conditions 
(Costea et al., 2006). It is these abilities of the cells selected for by sphere 
assays that have led to the use of this assay as a means to enrich for putative 
CSC (Costea et al., 2006, Visvader and Lindeman, 2008). Four studies have 
reported sphere formation in HNSCC cell lines (Harper et al., 2007, Okamoto 
et al., 2009, Harper et al., 2010, Xia et al., 2010), but none of the studies report 
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sphere formation beyond the second passage. This was consistent with our 
experience in this study, where the cells readily formed spheres in culture 
but they could not be cultured beyond the second passage. As spheres could 
not be passaged indefinitely they did not meet the criteria to be considered 
as CSC origin so this was not pursued further. Instead, the cell line was 
screened for markers of cells with stem-like traits as an alternative. 
Magnetic cell sorting for the putative stem cell marker CD133 produced 
a subpopulation consisting of approximately 1% of the total cell population. 
This is similar to CD133 positive subpopulations reported in HNSCC cell 
lines of 0.1-0.2% (Harper et al., 2007) and 0.75% (Xia et al., 2010). Other 
markers used in human oral squamous cell carcinoma cell lines to enrich for 
CSCs produced highly variable and often much larger populations with 
CD44 positive cells constituting 10% (Prince et al., 2007), 3-12% (Harper et 
al., 2007), 3-5% or 2% (Okamoto et al., 2009) of the total cells, and podoplanin 
positive cells making up 38% of the total cell population (Atsumi et al., 2008). 
In one study, co-expression of CD44 and CD133 in HNSCC cell lines was 
evaluated by flow cytometry and was positive for 0.1% of the cells (Harper et 
al., 2007). The frequency of CSCs appears to be highly variable between 
tumours, and is often higher in solid tumours compared to haematological 
malignancies (Visvader and Lindeman, 2008). A definitive stem cell marker 
for oral SCC has not yet been determined (Costea et al., 2006). However, in 
human nasopharyngeal carcinomas, CD133 expression was associated with 
increased tumour sphere formation, increased tumourigenicity in mice 
xenografts as well as co-expression with stem cell markers Oct-4 and ALDH 
1 (Xia et al., 2010). In our study, CD133 consistently selected a small but 
consistent population of cells. The CD133 positive population formed 
spheres more readily and was more resistant to gefitinib therapy, different 
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chemotherapeutic agents and irradiation. Two previous studies on oral 
squamous cell carcinomas investigated potential drug resistance in putative 
CSC enriched populations, and they both found a CD44 positive population 
to be more resistant to chemotherapeutic agents (Okamoto et al., 2009, 
Harper et al., 2010) and to UVB and tumour necrosis factor (TNF) (Harper et 
al., 2010). 
Recently, it was reported that carcinoma cells can undergo a reversible 
process termed the epithelial-mesenchymal to stem-like transition (EMST) in 
which cells undergo an EMT and acquire stem cell-like properties 
concurrently (Xia et al., 2010). This was mediated through downregulation of 
microRNAs (miRNAs) belonging to the miR-200 family of miRNA tumour 
suppressors (Xia et al., 2010). Suppression of miR-200a was shown to induce 
Zeb2 and hence E-cadherin downregulation and promotion to a 
mesenchymal phenotype, as well as inducing a larger CD133 positive 
population (Xia et al., 2010). In this study two mechanisms were utilised to 
enrich for more treatment resistant cells in the SCCF1 cell line. The CD133 
positive subpopulation was more resistant to the effects of irradiation as well 
as to cytotoxic drugs and EGFR targeting drugs. In addition, when a more 
mesenchymal-like signature was produced in the cell line, the end result was 
a cell line with an increased proportion of CD133 positive cells supporting 
EMST in the cell line following gefitinib treatment. However, radiation 
resistance in the gefitinib resistant cell line was acquired through a separate 
mechanism, as the CD133 positive and negative SCCF1G cells were equally 
resistant to irradiation.   
6.6 Summary 
This study has shown that through an EGFR-dependant mechanism a 
mesenchymal-like phenotype can be selected for or induced in the SCCF1 
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cell line. These cells were not only more resistant to EGFR targeted therapy, 
but also to irradiation. In addition, the study demonstrated that the SCCF1 
cell line harbours a small CD133 positive population which showed 
increased sphere formation ability and increased resistance to cytotoxic 
drugs, EGFR targeted therapy and irradiation. Through induction of EMT, 
the CD133 positive population in the cell line increased, supporting the 
occurrence of EMST in the cell line. The radiation resistance observed in 
these two cell lines were probably achieved through distinct mechanisms, 
which support the theory that stem-like cancer cells use multiple 






The central aims of this study were to investigate the role of EGFR in 
feline oral SCCs and its potential as a therapeutic target.  The first step in this 
investigation was to establish whether feline oral SCCs expressed EGFR. An 
immunohistochemical study labelling 67 feline oral SCC biopsy samples for 
EGFR and Ki67 was performed, and it showed that EGFR expression was 
widely present in these tumours. The tumours exhibited two commonly 
reported labelling patterns (cytoplasmic and membranous), while no nuclear 
labelling was observed in any of the samples. Translocation of EGFR to the 
nucleus has been reported as a mechanism of resistance to therapy by cancer 
cells following treatment with the EGFR specific monoclonal antibody 
cetuximab (Li et al., 2009). Nuclear EGFR was first observed in hepatocytes 
during liver degeneration, but has now been reported to be involved in cell 
proliferation, transcriptional regulation, DNA replication, DNA repair and 
chemo- and radiotherapy resistance (Wang et al., 2010). All the samples used 
in this study were pre-treatment biopsy samples. Further studies 
investigating the pattern of EGFR labelling in tumours following therapy, in 
particular with EGFR targeting drugs if they became available, could reveal 
if EGFR nuclear translocation plays a role in acquired resistance in FOSCC. 
In addition, immunofluorescent labelling of EGFR of the gefitinib resistant 
SCCF1G cell line would reveal if this cell line exhibited any translocation of 
EGFR to the nucleus. This study also reported a trend towards a better 
survival in the high scoring EGFR group although statistical significance was 
231 
 
not reached. In HNSCC, patients with high EGFR scores responded 
favourably to an overall shortened treatment time with radiotherapy 
(Bentzen et al., 2005, Eriksen et al., 2004). The use of an accelerated 
radiotherapy protocol has been reported in FOSCCs (Fidel et al., 2007), and a 
future study investigating any relationship between response to this form of 
therapy and EGFR expression would further elucidate whether the feline 
tumour responds in a similar manner to HNSCC in man. If this was the case, 
EGFR labelling of pre-treatment biopsies could be a useful tool for patient 
selection for radiotherapy.  
After establishing that a subset of FOSCCs expressed high levels of 
EGFR, the next aims of the study were to clone the tyrosine kinase domain of 
the feline Egfr and using this sequence as a basis, design and construct 
siRNAs against the receptor. The tyrosine kinase domain was found to be 
highly conserved between species, and crucially, the ATP binding pocket 
shared 100% homology with the human EGFR sequence.    
The most efficient siRNA against the feline Egfr was selected following 
extensive vector based screening, and the effective knockdown of feline Egfr 
in the SCCF1 cell line was verified by Real-Time PCR and western blot 
analysis following both naked and hairpin expression vector transfections. In 
parallel, gefitinib treatment of the cell line was evaluated. The results of these 
studies demonstrated that targeting of the feline EGFR in the cell line 
produced marked effects on cellular proliferation, colony formation ability 
and migration, providing evidence that targeting EGFR in the feline tumour 
may be a viable therapeutic target.  
According to published reports, the most effective siRNA in this study 
would be classified as a functional siRNA rather than a highly effective 
siRNA (Khvorova et al., 2003, Reynolds et al., 2004). To investigate this 
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further and improve on knockdown efficiency several more siRNAs could be 
designed against the feline Egfr using the entire sequence instead of the 500 
base pairs sequence used as the basis for the siRNA design in this study. 
These could quickly and efficiently be screened against the evaluated 
siRNA8 for comparison using cell proliferation assays. If pursuing using 
siRNAs as a therapeutic strategy, the use of more than one highly effective 
sequence simultaneously would be beneficial. These siRNAs could target 
separate areas of the Egfr sequence producing an increased knockdown 
efficiency. Using such a cocktail of siRNAs together would mimic the effect 
achieved when using endoribonuclease-prepared siRNA (esiRNA) molecules 
where a long complementary dsRNA is digested by Escherichia coli RNase III 
producing several esiRNAs (Yang et al., 2002).  This method produces highly 
effective gene knockdown, as any reduction of efficiency due to mRNA 
secondary structure is minimised as different areas of the mRNA are 
targeted. In addition, for long term therapeutic use, the potential for 
resistance developing through point mutations is highly unlikely to occur if 
more than one sequence is used simultaneously. 
The results of this study suggest that TKIs designed to target the 
human EGFR may be effective in feline cells, however, the in vitro dose 
required to obtain an effect on the cell line was relatively high. If comparing 
the in vitro dose to clinical doses used in man for the treatment of NSCLC, 
cell lines requiring more than 2 µM gefitinib are classed as insensitive to the 
drug (Sharma et al., 2007). HNSCC has been reported to require higher dose 
rates of gefitinib than NSCLC. A British clinical trial investigating the use of 
gefitinib as monotherapy in recurrent HNSCC doubled the current dose 
used in NSCLC with little detrimental effects (Kirby et al., 2006). Although 
the siRNA produced superior effects compared to the TKI in the cell line 
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used in this study, further studies should investigate the potential use of 
EGFR specific TKIs in cats as the therapeutic use of siRNAs are still in its 
infancy. This study was based on one cell line; ideally a panel of feline SCC 
cell lines should be screened. It seems reasonable to hypothesise that a range 
of TKI sensitivities would be discovered in feline tumour cell lines similarly 
to what has been reported in HNSCC cell lines (Erjala et al., 2007). In 
conjunction with such further studies, this study provides evidence in 
support of a trial of a small molecule TKI to be performed in cats. EGFR 
targeted therapy has produced superior results in HNSCC when used in 
combination with radiotherapy (Bernier and Schneider, 2007). In the feline 
cell line an additive effect was observed when EGFR targeting and 
radiotherapy were combined, suggesting that this treatment combination 
may offer improved outcomes compared to currently available treatments.  
Further work is required in the field of tumour resistance to EGFR 
targeted therapy. The final part of this study investigated potential 
mechanisms of resistance to EGFR targeting therapies and conventional 
treatments, focusing on two potential mechanisms of resistance: cells 
undergoing an epithelial to mesenchymal transition and the presence of a 
putative cancer stem cell population within the cell line. In response to 
chronic gefitinib treatment, morphological changes consistent with an EMT 
were observed in the cell line, but western blot analysis for markers of EMT 
produced a mixed picture suggestive of the presence of two cell populations. 
In order to investigate this, future studies using flow cytometry and 
immunofluorescence to establish whether the SCCF1 and SCCF1G cell lines 
indeed do harbour two such populations should be performed. If two such 
populations exist, isolation by flow cytometry using for example E-cadherin 
antibodies, or alternatively purely based on their size, is possible. The two 
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populations could then be fully characterised to further elucidate the 
mechanisms underlying their resistance to therapy. A microarray analysis to 
establish the expression patterns of genes known to be involved in EMT like 
E-cadherin, β-catenin, fibronectin, vimentin, Twist, Slug, Snail and Zeb1 
would further elucidate which cellular markers are differentially expressed 
in the more resistant cell fraction. Identifying the mechanisms used by this 
cell line to acquire resistance to these therapies would reveal important 
information about resistance pathways utilised by cancer cells.  
Non-adherent sphere assays were used in an effort to demonstrate 
putative cancer stem cells in these cell lines, but serial passaging of the 
spheres was unsuccessful. The use of non-adherent sphere assays to 
demonstrate the presence of a cancer stem cell population is controversial, 
and results from these assays have been criticised for being over-interpreted 
(Visvader and Lindeman, 2008). To date, convincing data demonstrating the 
successful in vitro serial passaging of spheres of HNSCC origin have not been 
reported (Prince and Ailles, 2008). Other methods that have been used to 
identify CSCs in HNSCCs include the use of specific surface antigens as stem 
cell markers and the presence of a side population (SP) based on excretion of 
Hoechst dye (Monroe et al., 2010). However, the gold standard for 
evaluating the presence of CSC is serial orthotopic transplantation studies of 
sorted tumour cell subpopulations into immunocompromised mice 
(Visvader and Lindeman, 2008, Monroe et al., 2010). This has been 
performed using CD44-positive (Prince et al., 2007) and CD133-high 
(Monroe et al., 2010) flow cytometer sorted HNSCC cells as well as after 
injection of a Hoechst-excreting SP from three HNSCC cell lines (Song et al., 
2010). In order to further investigate the presence of a CSC population in the 
feline cell line a xenotransplantation study would have to be performed 
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using cell populations produced preferably by double sorting for a stem cell 
marker using both flow cytometry and MACS sorting. Initial results from 
this study suggest that CD133 could be used as a possible stem cell marker in 
feline oral SCCs, but further studies would have to be performed to confirm 
this.  
The results from this study suggest that EGFR targeting in feline oral 
SCCs may be a feasible therapeutic option. The study supports the future 
investigation of EGFR targeting in combination with current treatment 
modalities like radiotherapy. Using RNA interference techniques, the crucial 
role of EGFR as an oncogenic driver in this tumour cell line was 
demonstrated. Targeted therapies rely on tumour addiction to an oncogene, 
and EGFR has been shown to be such an oncogene in a range of solid 
tumours in man. The therapeutics developed so far to block EGFR have 
proven less successful as monotherapies than was initially anticipated (Lai et 
al., 2009). Recent efforts have been directed towards understanding the 
relationships between the different pathways, their potential overlap and 
mechanisms of intrinsic and acquired resistance to therapy (Wheeler et al., 
2010a). This study demonstrated superior activity and efficiency using 
siRNA when compared to the more conventional TKI used to target the 
receptor in man, in particular after some resistance to therapy had been 
allowed to build up over time. If the major obstacle to wider clinical use of 
reliable in vivo delivery of RNAi-based drugs could be overcome, results 
from this study indicate that these may have superior action compared to 
conventional drugs.  Until such time, FOSCC is a tumour-type that 
potentially could be amenable to local delivery of siRNAs by injection of the 




In summary, this study has demonstrated that feline EGFR has 
potential as a therapeutic target in oral SCCs by reporting widespread EGFR 
expression in feline SCC tumour biopsy samples and demonstrating the 
effect of EGFR targeting in a feline SCC cell line. Future work should 
investigate the different therapeutic approaches available to establish the 
most efficient way of targeting the receptor. 
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 Appendix A: N2 media 
Appendix A: N2 media 
 
Component Quantity added End concentration 
DMEM/F12 -  Makes 10L (1X) 
Sodium Bicarbonate 1.2 g  
Progesterone 156.25 µl 10 nM 
Putrescine dihydrochloride  50 µl 50 µM 
Sodium selenite  141.8 µl 15 nM 
Apo-Transferrin (human)  25 ml 12.5 µg/ml 
Insulin (bovine pancreas)  1 ml 10 µg/ml 
EGF (recombinant human) 50 µl 5 ng/ml 
bFGF (recombinant human) 50 µl 5 ng/ml 
Methylcellulose 1.6 g/100ml 1.6% 
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Appendix B: Solutions and buffers 
 
Agarose gels: 1-1.2% small (35 ml) and large gels (100-120 ml) were made by 
adding 1-1.2g of agarose per 100 ml distilled water and microwaving until 
dissolved. The solution was allowed to cool, and nucleic acid labelling 
solutions were added before gel was poured into moulds and allowed to set.  
 
Freezing media: 10% DMSO in FBS 
 
Giemsa stain 10%: Add 5ml Giemsa stain to 45 ml distilled water and mix 
well. 
 
imMedia™ Amp Blue sachets: Add content of one sachet to 200 ml distilled 
water and heat in microwave until dissolved. Allow to cool before pouring 
into plastic 10 cm dishes, makes 8-10 agar plates. 
 
Laemmli Sample Buffer (2x): 120 mM Tris-HCl pH 6.8, 4% (w/v) sodium 
dodecyl sulphate (SDS), 20% (v/v) glycerol, 200mM DTT, 0.04% (w/v) 
bromophenol blue.  
 
Luria broth base (Miller’s LB broth base®, Invitrogen):  powdered form, 
dissolve 25 g per litre of distilled water. Autoclave and allow to cool. Add 
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250 µl Ampicillin at a concentration of 100mg per ml to each 250 ml of LB 
broth. Typical formula per litre: 10 g Peptone 140,  5g Yeast Extract, 10 g 
sodium chloride.  
 
Phosphate-buffered saline (PBS) (10x): purchased as 10x concentrate, made 
up with 100 ml 10x solution in 900 ml distilled water. Typical formula (g/l) 
sodium chloride (8g), potassium chloride (0.2g), di-sodium hydrogen 
orthophosphate (1.44g), potassium di-hydrogen orthophosphate (0.24g).  
 
PBS/BSA 0.5% solution: Dissolve 100 mg BSA in 20 ml PBS and filter 
sterilise. Store at 2-8°C.  
 
PBS Tween-20 (PBST): 0.01 M Phosphate, 0.154 M NaCl, and 0.1 % Tween-
20, pH 7.4.  
 
PBST blocking buffer: 5% Skimmed Milk in PBST.  
 
Propidium Iodide: Frozen stock at 10mg/ml in water, kept in 20µl aliquots at 
minus 20°C. Working stock at 200µg/ml, make up by adding 980µl PBS, 
cover in foil and store in fridge. 
 
Resolving gel: 8-10% acrylamide, 375 mM Tris-HCl pH 8.8, 0.1% SDS, 0.1% 





SDS-PAGE running buffer (1x): 25 mM Tris, 190 mM glycine, 0.1% (v/w) 
SDS 
 
Separation buffer for MACS sorting: PBS at pH 7.2, 0.5% BSA and 2mM 
EDTA. Filter sterilised and stored at 2-8°C.  
 
Stacking gel: 5% acrylamide, 126 mM Tris-HCl pH 6.8, 0.1% SDS, 0.1% 
ammonium persulphate and polymerisation was initiated by adding 0.1% 
TEMED 
 
TAE electrophoresis buffer (10x): Tris-HCl (0.4M, pH 8.0), sodium acetate 
(0.2M), EDTA (0.02M, pH 8.0).   
 
TE buffer: 10mM Tris (pH 8.0), 1mM EDTA 
 
Transfer buffer (1x): 25 mM Tris, 190 mM glycine, 20% (v/v) methanol 
 
Tris-buffered saline Tween-20 (TBST): 20mM Tris-HCl, 0.15M NaCl, and 
0.1% Tween-20.  
 




Urea lysis buffer: 7M Urea, 0.1 % DTT, 0.05% v/w Triton X-100, 25 mM 

















Our records show that you have submitted a sample to the Diagnostic Services Department, 
at the Animal Health Trust in the past three years, for a case of feline, oral squamous cell 
carcinomas (SCC). 
 
As I am sure you are aware, squamous cell carcinoma is a devastating disease of the oral 
cavity in older cats, for which there is seldom a satisfactory treatment once the tumour has 
progressed to a stage where definitive surgery is not an option. All too often, cats present 
with advanced cancer and despite best supportive care, euthanasia is often required within a 
matter of weeks.  
 
In order to gather more background information on this group of cats, we would be very 
grateful if you could spare the time to look back into your practice case notes and complete 
the enclosed questionnaire. Although most of these cats will have died, we hope access to 
their medical records will still be possible. The information that you provide will form the 
basis of a study involving further pathological analysis of your submitted samples.  
 
You may not be able to answer all of the questions from your records. However, any 
information that you are able to provide will be useful to us, so please still return the form. I 
have enclosed a pre-paid envelope. Alternatively, you can fax the questionnaire back to 
Alison Hayes, at the Small Animal Centre. However you choose to reply, your prompt 
attention would be very much appreciated.  
 
In helping to gather this information, you are contributing to an ongoing, multidisciplinary, 
research project. The information that we gain may provide a better understanding of the 
biology of this common cancer and may ultimately lead to new therapeutic options. We hope 
to conclude the study in the next 6 months and look forward to being able to share our 
findings directly with you. 
 
Once again, thank you for taking the time to complete the enclosed questionnaire. All 
information will remain confidential and no cat owners will be contacted. If you have any 





Alison Hayes (Mrs) BVMS CertVR MRCVS 
Clinician in Oncology
CENTRE FOR SMALL ANIMAL 
STUDIES 
Direct telephone: 08700 502540 Fax: 08700 502541 
Oncology Unit 
S Murphy BVM&S MSc (Clin Onc) MRCVS 
Markus Clinician in Veterinary Oncology 
Alison Hayes (Mrs) BVMS CertVR MRCVS 
Clinician in Oncology 
Prue NeathBSc(Hons), BVetMed,DACVS, MRCVS 




FELINE ORAL SQUAMOUS CELL CARCINOMA QUESTIONNAIRE 
 
Re:       Re: Lab No:  
 
 
Where boxes are provided, please tick the relevant box .  
If a date is required, please enter the day/month/year format e.g for 26
th
 October 
2002 would be 26/OCT/2002. 
 
  
THII S   SECTII ON   II S   ABOUT   THE   AGE   OF   THE   CAT  
1. Was the date of the cat’s birth known?  Yes If yes please state date of birth 
 --/---/---- 
1. Please go to question 3 
 
No   Please go to question 2 
2. If date of birth was unknown, please give age in years at diagnosis ……….   
      Is this approximate?   Yes    
No       
THIS QUESTION IS ABOUT THE BREED/TYPE Please tick only one box  
   
3. What breed was the cat? 
Domestic Short haired (DSH)  
Domestic Long haired (DLH)  
Unknown     
Pedigree     Please specify 
………………………………………………… 
 
4. Colour:   
Please state colour ……………………………………………………………………………    
Colour unknown              
 
THIS QUESTION RELATES TO GENDER Please tick only one box  
 
5. What was the sex? 
Male     
Male neutered       
Female     
Female neutered       




THIS SECTION ASKS ABOUT THE DISEASE PRESENTATION 
 
This disease may have presented before a definitive diagnosis was possible. Please answer 
the following questions. 
 
6. What was the date of first presentation?   --/---/----  
7. What was the date of biopsy    --/---/---- 
 
8. Was this problem discovered as part of a regular, routine or general health examination 
e.g. pre-vaccination examination?   Yes         
       No    
 
9. Was the owner concerned about the general health of their cat?   
       Yes         
       No   
 
10. Was the owner concerned about the oral health of their cat?  
       Yes         
       No      
       




12.  Was there a history of stomatitis/dental disease?   
Yes  Please go to question 13 
 No   Please go to question 14 




THIS SECTION IS ABOUT THE DISEASE PROGRESSION 




15.  Did the cat die or was euthanasia performed? 
 
Yes   
No   
Don’t know   
Died   
Euthanasia  
 




16.  Date of death if known --/---/---- 





Please add any further information about the cause of death or euthanasia.  
…………………………………………………………………………………………………
….……………………………………………….…………………………………………… 
MORE SPECIFICALLY ABOUT THE TUMOUR 
As the disease progresses, large amounts of the mouth can become involved, and it is not 
always possible to say where the tumour originated.  
 
18.  When thinking about the site of the tumour within the oral cavity, please tick one of the 
following that best describes the tumour.  
Sublingual    
Tongue, other than sublingual  
Mandible   go to question 19 
Maxilla   go to question 19 
Hard palate   
Soft palate  
Cheek (i.e. buccal mucosa)  
Unknown site in the oral cavity  
No tumour in the oral cavity  
 
19.  Within the mandible or maxilla please indicate the position. Please tick one box. 
             Rostral (i.e. incisors or canine teeth)     
Cheek teeth (i.e. premolar and molar)   
Exact location uncertain    
  
THIS QUESTION IS ABOUT THE SPREAD OF TUMOUR BEYOND THE ORAL 
CAVITY 
 
The regional lymph nodes are in the retropharyngeal and submandibular areas. 
When considering these regions, were the nodes 

















 go to question 22 
 go to question 23 
 go to question 23 
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22.  Were samples sent to a pathologist? 
  
 
















THIS SECTION RELATES TO TREATMENT  
These questions relate to three treatment periods before, during and after a diagnosis was 
made. 
 
Before a histological diagnosis was made   
 












Please describe this and any other medication given prior to biopsy 
……………………………………………………………………………………………
……………………………………………… 
Relating to treatment at the time of biopsy 
 


















 go to question 26 
 go to question 27 
 go to question 27 
 go to question 28 
 go to question 29 






 go to question 24 
 go to question 25 





 please describe below 
 go to question 25 
 go to question 25 
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Relating to treatment after a histological diagnosis was made 
 











Please describe this and any other medication given after biopsy 
……………………………..………………………………………………………………… 
……………………………….………………………………………………………………. 
31.  If any definitive treatment attempted, e.g. surgery, chemotherapy, radiotherapy, please  












 Don’t know 
Yes  
No 
 Don’t know 
Yes  
No 
    Don’t know  
 go to question 30 
 go to question 31 












Signature ……………………………………….  
 




Please return completed questionnaire to Alison Hayes in the envelope provided to 
 
Alison Hayes 
Animal Health Trust,  
Lanwades Park,  
Kentford,  
Newmarket, Suffolk CB8 7UU 
Fax: 08700 502541 
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Appendix D: Feline EGFR sequence 
and alignment with the feline 
genome 
Appendix D: Feline EGFR sequence and alignment 
with the feline genome 
 
BLAST search against feline whole genome shotgun sequences 
Program: BLASTN 2.2.24+  
Reference:  
Zheng Zhang, Scott Schwartz, Lukas Wagner, and Webb Miller 
(2000), "A greedy algorithm for aligning DNA sequences", 
Journal of Computational Biology 
2000; 7(1-2):203-14. 
 
SCCF1 full tyrosine kinase region sequence 

























Feline amino acid sequence 













Sequences producing significant alignments: 
Accession Description 
ACBE01065685.1 Felis catus c497001689.Contig1, whole genome shotgun sequence 
AANG01387714.1 Felis catus cont1.387713, whole genome shotgun sequence 
ACBE01065687.1 Felis catus c435901305.Contig1, whole genome shotgun sequence 
AANG01738232.1 Felis catus cont1.738231, whole genome shotgun sequence 
ACBE01065683.1 Felis catus c505502232.Contig1, whole genome shotgun sequence 
AANG01387712.1 Felis catus cont1.387711, whole genome shotgun sequence 
AANG01738233.1 Felis catus cont1.738232, whole genome shotgun sequence 
ACBE01065684.1 Felis catus c490401688.Contig1, whole genome shotgun sequence 
AANG01387767.1 Felis catus cont1.387766, whole genome shotgun sequence 
AANG01738234.1 Felis catus cont1.738233, whole genome shotgun sequence 
 
Query: our TK sequencing 
Sbjct: feline genome shotgun sequence 
 
 
Query  14    GGACCAGACAGCTGCGTGCAGTGTGCACACTACATCGACGGCCCTCACTGCGTCAAGACC  73 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 4489   GGACCAGACAGCTGCGTGCAGTGTGCACACTACATCGACGGCCCTCACTGCGTCAAGACC  4430 
 
Query  74    TGCCCGGCTGGCATCATGGGAGAAAACAACACCCTGGTCTGGAAGTTTGCGGACGCCAAT  133 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  4429  TGCCCGGCTGGCATCATGGGAGAAAACAACACCCTGGTCTGGAAGTTTGCGGACGCCAAT  4370 
 
Query  134   CGCATGTGTCACCTGTGCCATTCAAACTGTACCTACGG  171 
             |||||||||||||||||||||||||||||||||||||| 




Query  171   GCTGTTCTGGGCCAGGTCTTGAAGGCTGTGCTACAGATGGG  211 
             |||| || ||||||||||||||||||||||||||||||||| 
Sbjct  2271  GCTGTTCTGGGCCAGGTCTTGAAGGCTGTGCTACAGATGGG  2215 
 
 
Query  210   GGCCCAAGATCCCATCCATCGCCACTGGGATTGTTGGGGGCCTCCTCTTGGTGGTGGTGG  269 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  4953  GGCCCAAGATCCCATCCATCGCCACTGGGATTGTTGGGGGCCTCCTCTTGGTGGTGGTGG  4894 
 
Query  270   TGGCCCTTGGGGTGGGCCTCTTTCTGCGCCGACGCCACATCGTCCGCAAGCGCACACTTC  329 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  4893  TGGCCCTTGGGGTGGGCCTCTTTCTGCGCCGACGCCACATCGTCCGCAAGCGCACACTTC  4834 
 
Query  330   GCAGACTGCTGCAGGAAAGAGAG  352 
             ||||||||||||||||||||||| 
Sbjct  4833  GCAGACTGCTGCAGGAAAGAGAG  4811 
 
 
Query  351   AGCTTGTTGAGCCTCTTACGCCCAGCGGAGAAGCTCCCAACCAAGCTCTCTTGAGGATCT  410 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3941  AGCTTGTTGAGCCTCTTACGCCCAGCGGAGAAGCTCCCAACCAAGCTCTCTTGAGGATCT  3882 
 
Query  411   TAAAGGAAACAGAATTCAAAAAGATCAAGGTGCTGGGCTCTGGAGCATTTGGCACAGTGT  470 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  471   ACAAGG  476 
             |||||| 
Sbjct  3821  ACAAGG  3816 
 
 
Query  474   AGGGACTCTGGATCCCAGAAGGTGAGAAGGTTAAAATTCCTGTGGCCATCAAGGAGTTAC  533 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2302  AGGGACTCTGGATCCCAGAAGGTGAGAAGGTTAAAATTCCTGTGGCCATCAAGGAGTTAC  2361 
 
Query  534   GAGAAGCCACATCTCCAAAAGCCAACAAGGAAATCCTTGATG  575 
             |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2362  GAGAAGCCACATCTCCAAAAGCCAACAAGGAAATCCTTGATG  2403 
 
 
Query  575   GAAGCTTACGTGATGGCCAGTGTGGACAATCCCCACGTGTGCCGCCTCCTGGGCATCTGC  634 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3864  GAAGCTTACGTGATGGCCAGTGTGGACAATCCCCACGTGTGCCGCCTCCTGGGCATCTGC  3923 
 
Query  635   CTGACGTCCACGGTCCAGCTCATCACACAGCTCATGCCCTTCGGCTGCCTCCTGGACTAT  694 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3924  CTGACGTCCACGGTCCAGCTCATCACACAGCTCATGCCCTTCGGCTGCCTCCTGGACTAT  3983 
 
Query  695   GTCCGCGAGCACAAGGACAACATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAGATT  754 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3984  GTCCGCGAGCACAAGGACAACATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAGATT  4043 
 
Query  755   GCGAAGG  761 
             ||||||| 
Sbjct  4044  GCGAAGG  4050 
 
 
Query  759    AGGGCATGAACTACCTGGAAGACCGGCGCTTGGTGCACCGTGACCTGGCAGCCAGGAATG  818 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  18063  AGGGCATGAACTACCTGGAAGACCGGCGCTTGGTGCACCGTGACCTGGCAGCCAGGAATG  18004 
 
Query  819    TCCTGGTGAAGACGCCACAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAACTGCTTG  878 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  18003  TCCTGGTGAAGACGCCACAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAACTGCTTG  17944 
 
Query  879    GTGCCGAGGAGAAAGAATACCACGCGGAAGGAGGCAAAGT  918 
              |||||||||||||||||||||||||||||||||||||||| 
Sbjct  17943  GTGCCGAGGAGAAAGAATACCACGCGGAAGGAGGCAAAGT  17904 
 
 
Query  917   GTGCCTATCAAGTGGATGGCTTTGGAATCAATTTTACACCGAATTTACACCCACCA  972 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  6313  GTGCCTATCAAGTGGATGGCTTTGGAATCAATTTTACACCGAATTTACACCCACCA  6368 
 
Query  973   AAGTGACGTCTGGAGCTATGG  993 
             ||||||||||||||||||||| 
Sbjct  6369  AAGTGACGTCTGGAGCTATGG  6389 
 
 
Query  992    GGAGTCACCGTTTGGGAGTTGATGACCTTTGGGTCTAAACCTTACGACGGAATCCCCGCA  1051 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Query  1052   AGTGAGATCTCGACCATCCTGGAGAAAGGAGAGCGCCTCCCGCAGCCACCCATATGCACC  1111 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  13664  AGTGAGATCTCGACCATCCTGGAGAAAGGAGAGCGCCTCCCGCAGCCACCCATATGCACC  13605 
 
Query  1112   ATCGATGTCTACATGATCATGGTCAAGTG  1140 
              ||||||||||||||||||||||||||||| 
Sbjct  13604  ATCGATGTCTACATGATCATGGTCAAGTG  13576 
 
Query  1140  GCTGGATGATAGATGCAGACAGTCGCCCGAAATTCCGTGAGTTGATCATTGAATTCTCCA  1199 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  198   GCTGGATGATAGATGCAGACAGTCGCCCGAAATTCCGTGAGTTGATCATTGAATTCTCCA  257 
 
Query  1200  AAATGGCCCGAGACCCCCAGCGCTACCTTGTCATCCAGG  1238 
             ||||||||||||||||||||||||||||||||||||||| 
Sbjct  258   AAATGGCCCGAGACCCCCAGCGCTACCTTGTCATCCAGG  296 
 
 
Query  1234  CCAGGGAGATGAGAGAATGCATCTGCCAAGCCCTACAGACTCCAATTTTTACCGCGCCCT  1293 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1703  CCAGGGAGATGAGAGAATGCATCTGCCAAGCCCTACAGACTCCAATTTTTACCGCGCCCT  1762 
 
Query  1294  GATGGACGAAGAAGACATGGAAGACGTCGTAGATGCC  1330 
             |||||||||||||||||||||||||||||||||||||  
Sbjct  1763  GATGGACGAAGAAGACATGGAAGACGTCGTAGATGCC  1798 
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